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NOVEL DOSIMETRY VERIFICATION SOLUTIONS FOR ADVANCED
RADIATION THERAPY
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ABSTRACT
Improved optimisation of radiation dose delivery to tumours with improved sparing of nor-
mal tissues is an ongoing goal of radiotherapy practice. Advanced radiotherapy techniques
are constantly improving to achieve this goal. However, these techniques are more complex
to deliver. Hence verifying the source of dose errors is increasingly challenging. Accurate
verification of treatment delivery for advanced radiotherapy becomes increasingly important
in mitigating dose delivery errors which may compromise clinical outcome. This disserta-
tion investigated treatment dosimetry verification for two different radiotherapy delivery
systems i) Open gantry linear accelerator and ii) Helical TomoTherapy HI-ART ® (HT).
Part (i) Open gantry linear accelerator - novel prototype hybrid EPID based dosimeters were
developed for treatment verification to combine geometric and dosimetric verification in a
single system. Initial work on dose response for standard EPIDs provided a more consistent
understanding of EPID under-dose response for small monitor units (MUs).
The dose response linearity of a standard a-Si EPID was evaluated for different combi-
nations of linac, image acquisition settings and imaging data processing methods. EPID
nonlinear response was demonstrated to be primarily due to gain ghosting affects in the a-Si
photodiodes. This work has resolved some of the inconsistencies in the literature regarding
EPID dose response and proposes a simple yet robust pixel-to-dose calibration method for
EPID-based IMRT dosimetry.
Standard EPID detectors are optimized for imaging but are suboptimal for dosimetry. Two
novel prototype hybrid EPID based dosimeters also referred to as dual detector configura-
tion were developed and characterised. First, dual detector configuration combines a con-
ventional EPID (imager) and 2D array dosimeter ionisation chamber array (ICA) while the
other dual detector combines a conventional EPID (imager) and prototype 2D silicon detec-
tor array. Excellent agreement in measured dose response (<1.5%) and global gamma pass
rate with 3%/3mm criteria (> 94%) for all clinical modulated fields was achieved for each of
the prototype detectors compared to reference dosimeters in the transit geometry. The water
equivalent dose response achieved overcomes a major limitation of implementing in vivo
dosimetry with current EPIDs. The imaging performance of both dual detector designs was
approximately the same as the standard EPID. The dual detector configuration was operated
simultaneously as both imager and dosimeter without significant compromise in the perfor-
mance of either device. Dual detector design decouples the imaging and dosimetry functions
so that each can be optimized without compromising the other, providing more flexibility
for future improvements in radiotherapy treatment verification systems. The improvement
to existing standard EPID design would facilitate a superior system for simultaneous geo-
metric and dosimetric treatment verification.
A simple model for comparing transit dosimetry with a conventional treatment planning
system (TPS) was proposed and implemented. Excellent agreement was achieved in mea-
sured dose response when compared with TPS-calculated portal dose images. No additional
EPID modelling was required, thereby removing the uncertainty in modelling the complex
dose response of standard EPIDs. The water equivalence of the hybrid dosimeter approach
provides a means of direct comparison of the plan specific treatment planning system (TPS)
dose calculation and measurement.
Part (ii) Helical TomoTherapy HI-ART ®- Potential HT delivery errors associated to the me-
chanical system were introduced by simulation in order to understand the potential impact
of these errors on patient dosimetry. Commercial dosimetry systems sensitivity to detect
delivery errors were then tested. An exit detector DQA (delivery quality assurance) tool for
HT pre-treatment verification was also developed to overcome some of the limitations of
phantom based verification systems.
Several potential HT delivery errors associated to the mechanical system were simulated
for ten nasopharynx radiotherapy treatment plans. Plans with intentionally introduced er-
rors were compared with the equivalent ‘no error’. Results demonstrated that most of the
clinically relevant errors are prevented by machine interlocks. Exceptions to this were dose
differences due to couch position and the secondary interlock for jaw position. The investi-
gation suggested that interlock thresholds for jaw position (secondary interlock) and couch
speed should be monitored more precisely than monitored currently to avoid clinically rel-
evant delivery errors. This work has established a framework to characterize HT machine
delivery errors and their clinical significance. This framework could be applied to any pa-
tient dataset to determine a given institutions plan specific delivery error threshold as well as
validate plan robustness for a given machine QA tolerance or determine clinically relevant
HT QA tolerances.
All the error plans that were determined as clinically relevant for jaw width, couch speed
and MLC errors were measured with two commercial dosimetry systems (MatriXXEvolution
and ArcCheck).The Wilcoxon signed rank test indicated that no statistically significant dif-
ferences were found in detecting the simulated delivery errors between these two dosimetry
systems (p>0.05, 95% confidence level). Both dosimeters were able to pick up clinically
relevant delivery errors except the ArcCHECK with couch speed up to 2.5% and jaw width
up to -1 mm. This work provides understanding of a widely used commercial dosimetry
system’s sensitivity to detect clinically relevant delivery errors as well as their inherent lim-
itations.
An in-house exit detector DQA tool was developed and validated. Excellent agreement in
global gamma pass rate with 2%/2mm criteria (> 95%) between planned and reconstructed
dose was achieved using this tool. The close agreement of measured ion chamber (<1.5%)
to reconstructed dose computed by exit detector DQA tool on the ‘cheese’ phantom vali-
dated the accuracy of dose reconstruction inside the patient. The mean time for performing
DQA on the 112 clinical plans was 24.7 ± 3.5 minutes using the proposed tool compared
to 39.5 ± 4.5 minutes for phantom based verification system demonstrating the efficiency
of exit detector DQA tool. The sensitivity to detect MLC errors was demonstrated. The exit
detector DQA tool offers a direct and comprehensive solution with the opportunity to visu-
alize the clinical significance of MLC delivery errors. This tool offers powerful advantages
for supplementing existing patient specific DQA with specific utility for patient cases where
field delivery geometry exceeds the size of commercial dosimetry measurement systems.
KEYWORDS: Dual detector, Waterequivalent EPID, Transit dosimetry, On board exit
detector
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Chapter 1
Introduction
The main objective of effective radiotherapy treatment is to deliver high radiation doses to
kill cancer cells, whilst limiting dose and hence toxicity to normal tissues (NT). Inaccurate
radiotherapy can result in ineffective treatment or serious harm to the patient. Recent in-
troduction of technology advances such as intensity modulation radiotherapy (IMRT), vol-
umetric modulated arc therapy (VMAT) and Helical TomoTherapy HI-ART® (HT) have
increased the achievement of these objectives [2–4]. Due to superior dosimetric conformity
of these techniques, their role has further extended to hypo-fractionated treatments. These
complex treatments are rapidly becoming the standard of care worldwide [1] because: i)
tumour control can be increased by dose escalation, using dose distributions much more
closely conformed to complex tumour shapes [5, 6]; ii) patient quality of life (QOL) is
enhanced by reduced risk of treatment-related toxicities by improving normal tissue NT
sparing [7, 8]; and iii) safe re-irradiation is becoming increasingly possible due to increased
dose conformity of the techniques [9–11].
Many methods of achieving dose modulation have been proposed and applied to clinical
practice. The IMRT technique holds the beam direction constant during irradiation and
indexes the collimator shape to a fraction of the total prescribed monitors unit (MU) for that
direction. In another implementation called VMAT the gantry moves during the irradiation,
indexing the collimator shape and gantry angle to the delivered dose. The radiation source
of the HT system is a linear accelerator (linac) mounted on a rotating gantry similar to a CT
scanner (Figure 1.1 b). Radiation is delivered to the patient using helical delivery, obtained
by concurrent gantry rotation and couch/patient travel. The IMRT and VMAT techniques




Figure 1.1: Radiation therapy treatment machines a) C-arm conventional linear accelerator
and b) Helical TomoTherapy
Advanced radiotherapy technologies and methods are complex. In addition to their com-
plexity, each of them has its own unique features that require different considerations for
their clinical implementations. Misadministration of advanced radiotherapy delivery tech-
niques are more difficult to detect and can possibly lead to poor outcomes for some patients.
In response to increasing treatment complexity, quality assurance (QA) bodies through-
out the world acknowledge that patient treatment verification, especially through in vivo
dosimetry, is highly desirable for optimal patient safety during radiation treatment [12–15].
Recent growing interest in hypo-fractionated treatments, with steeper effective dose-response
curves [16] may imply stricter dose and geometry requirements. Tumour motion during ra-
diotherapy poses an additional challenge for accurate dose delivery [17, 18]. Development
of novel techniques to compensate motion by MLC tracking [19] and couch tracking [20]
are underway. Motion compensation using tracking occurs during treatment with the ra-
diation beam on. These and other similar advances will continue to increase demands for
robust dosimetric and geometrical treatment verification to ensure patient safety and treat-
ment accuracy.
The widespread availability of integrated image guided radiotherapy (IGRT) systems has
resulted in reduced geometric uncertainties prior to treatment. The kilovoltage (kV) imaging
devices attached to linacs and providing superior soft tissue contrast have improved patient
and target position verification prior to treatment. They do not utilise the treatment beam
and therefore do not directly verify the treatment delivery in real-time. By utilising the
kV imaging device, monitoring of soft tissue by tracking the implanted fiducials during
treatment has been demonstrated by a few studies [21, 22]. The applicability of this tool is
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currently limited to those anatomical sites where fiducial markers can be implanted safely.
Electronic portal imaging devices (EPIDs) are capable of recording an x-ray image of the
patient with the treatment beam, and therefore the device that can directly verify treatment
delivery. This unique capability of megavoltage (MV) EPIDs recording both the patient
image (i.e. geometry) and beam intensity transiting from patient (i.e. dose) during treatment
has the potential to play an important role in the future development of treatment verification
QA devices for linacs.
A review by van Elmpt et al [23] gives an excellent overview of the diverse applications
for EPIDs in clinical dosimetry and their clinical implementations up to 2008. Despite the
potential, the clinical implementation of EPIDs for dosimetry has been slow. EPID design
has been optimised for imaging applications and therefore has severely limited their routine
clinical use as dosimeters. This is due to mainly the energy dependent response of EPIDs
[24–27]. The problem becomes worse when measurements are conducted in vivo due to
the additional scatter from the patient recorded by the EPID [28]. A large body of reported
research from several groups on EPID dosimetry is focused on development of methods to
account for energy response either with complex algorithms or Monte Carlo computations
[25, 28–34]. Current research in EPID technology is focused on developing more efficient
detectors [35, 36] for imaging using very high density scintillators which are likely to be
even more problematic for dosimetry.
A small body of research was focused on developing a novel EPID design. The goal of this
EPID design is for the EPID to act directly as a dosimeter rather than an imager [27, 37–40].
The former scenario (i.e. dosimetry with standard EPID) typically necessitates a complex
detector characterisation and calibration scheme along with custom software to convert por-
tal images into dose images. The latter scenario has seen detector prototypes that, while
capable of performing accurate patient dosimetry, suffer from decreased x-ray detection ef-
ficiency thus inhibiting their use for imaging. In both cases, proposed detectors have not
been suitable for applications in both imaging and dosimetry. Therefore the focus of devel-
opment work for the next generation treatment verification device should be to provide the
capability to simultaneously verify both location and quantity of the dose delivered during
treatment to address the demand and challenges in modern radiotherapy technique verifica-
tion. Such treatment verification tools can provide a record of delivered dose that could be
used to assess the effectiveness of the new techniques.
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HT (Figure 1.1 b) uses a dynamic delivery in which the gantry, treatment couch, and mul-
tileaf collimator leaves are all in motion during treatment. The dosimetric impact due to
variation in delivery parameters has been well studied and reported [41–46] for IMRT and
VMAT delivery. However, the clinical impact due to variation of HT delivery parameters in-
cluding the effect on the resulting patient dose distributions has not yet been studied. Most
of the recommended HT QA procedures and tolerances in AAPM Task Group 148 [47]
were adopted from the collective experience of the task group members; vendor designed
QA tests and from previously published reports [48–50]. It is unclear that the recommended
HT QA tolerances had any clinical relevance.
The HT clinical implementation and treatment verification is performed using either two
dimensional (2D) or quasi three dimensional (3D) dosimetry systems. Most clinics per-
form phantom-based measurement (pre-treatment verification) as an ongoing QA with the
aim to detect errors before treatment delivery and correct them at the earliest opportunity.
Serveral studies evaluated sensitivity of commercially available dosimetry system to detect
intentionally introduced potential delivery errors for IMRT and VMAT delivery [46, 51–58].
Different dosimetry systems demonstrated varying ability to reliably identify errors [58]. All
of the above detector sensitivity studies focused on the MLC positional accuracy, collimator
or gantry rotation and dose errors for C-arm linac based treatment and may therefore not be
relevant to the different delivery mechanism of HT machines. The only study on detector
sensitivity to detect HT delivery error using the ArcCHECK dosimeter was reported by Tem-
pleton et al [59]. No comprehensive comparison of different detectors for HT treatments has
been undertaken. Therefore, a comprehensive error detection framework for HT includes: a
systematic simulation of potential delivery errors, modeling of their clinical impact to deter-
mine clinically relevant errors, and comparison to current commercial dosimeter’s ability to
identify them. This will produce clear guidelines on a robust treatment verification system
for clinical implementation and for the choice of the most appropriate dosimetry system for
individual clinical situations.
The phantom-based verification systems are very laborious and time consuming. Clearly,
there is need for a means of overcoming the increased demands on physics resources due to
the additional patient specific QA typically performed using commercial phantoms [60, 61].
Another limitations of phantom-based verification systems is that they do not provide a link
between QA results and its impact on patient dose. Few commercial dosimetry systems
now facilitate the dose reconstruction based on dose measured in phantom to evaluate the
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impact on patient dose. These algorithms contain significant approximations and their limi-
tations have been demonstrated by recent studies [62, 63]. The unique HT delivery is often
tasked with treating long or otherwise large fields such as cranio-spinal irradiation and to-
tal marrow irradiation. This large field delivery geometry exceeds the size of commercial
dosimetry measurement systems. Some researchers [64, 65] proposed a QA procedure us-
ing an on board exit detector on HT. This involves applying a simple method to verify the
MLC performance as a pre-treatment verification tool and demonstrated efficiency. Further
development is warranted to improve the on board exit detector approach by supplement-
ing with dose reconstruction which would overcome the current limitation of the phantom
measurement based QA approach.
Testing each sub-component for sources of errors in the patient treatment pathway is be-
coming extremely difficult. Accurate verification of treatment delivery becomes increas-
ingly important and challenging. Despite the rapid evolution in our ability to deliver highly
conformal x-ray beams, and guide treatment using modern imaging technologies, there are
still short comings arising in the radiotherapy process that limit the ability to predict patient
outcomes. Arguably one of the largest uncertainties is the current inability to quantify the
actual dose delivered to the patient. Dose verification is also a critical component of adaptive
radiotherapy, as it provides a measure of delivery success.
This dissertation investigated treatment verification for two different radiotherapy delivery
systems. The first part developed and characterised novel prototypes for treatment veri-
fication on a conventional linear accelerator (linac). Novel prototypes were developed to
combine geometric and dosimetric verification in a single system. Also, the underlying
causes of under dose response at small MU for standard EPID were investigated.
The second part investigated clinical HT treatment verification. Specifically, simulate po-
tential HT delivery errors associated with the mechanical system to understand the impact
of these errors on patient dosimetry, and understanding commercial dosimetry systems sen-
sitivity to detect clinically relevant delivery errors as well as their inherent limitations. Also,
the development and clinical implementation of an exit detector DQA (delivery quality
assurance) tool for HT pre-treatment verification to overcome some of the limitations of
phantom-based QA systems was investigated.
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1.1 Aims and Objectives
This project aims to investigate two different components of treatment verification the first
for a conventional linac and the second for HT based treatment delivery as outlined below:
1. Dose characterisation and development of novel prototype hybrid EPID based dosime-
ters for treatment verification for a conventional linac system
Research questions:
(i) What are the underlying causes for EPID dose under-response at smaller
monitor units?
(ii) Can the EPID design be improved to provide a superior system for simul-
taneous geometric and dosimetric treatment verification?
(iii) Can an EPID based hybrid novel prototype configuration overcome the
current limitations of implementing a-Si EPID based dosimetry in the clinic?
In Chapter 3, EPID dose under-response at small monitor units and its underlying causes
under various combinations of linac, EPID design, image acquisition settings and differ-
ent treatment delivery modes (static open and segmented beam) were investigated. This
work resolved some of the inconsistencies in the literature regarding EPID dose response
and also improved the understanding about consideration of the dose non-linearity effect
in pixel-to-dose calibration methods for EPID-based IMRT dosimetry.
Chapters 4 and 5 outlined the development and characterisation of novel prototypes that
can perform simultaneous geometric and dosimetric treatment verification. The approach
of novel prototype design is based on optimisation of EPID detectors for radiotherapy
applications to overcome the current challenges of the energy dependent response (prob-
lematic for dosimetry) without compromising imaging performance.
Chapters 6 discussed a simple model for implementing comprehensive transit dosime-
try as a means of in vivo dose verification utilising a novel prototype (water-equivalent
dosimeter) and a conventional treatment planning system (TPS). This approach removes
the additional uncertainty introduced by modelling the complex dose response of stan-
dard EPIDs and the requirement of development of an additional software tool to calcu-
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late the predicted dose at EPID plane which resolves current limitations of implementing
a-Si EPID based dosimetry.
2. Assessment of current detector systems and development of an on board exit detec-
tor dosimetry tool for efficient pre-treatment verification for HT
Research questions:
(i) What magnitude of changes to delivery parameters will have clinical im-
pact on the resulting dose distributions?
(ii) Are the available commercial dosimeters sensitive to clinically relevant
delivery errors for HT?
(iii) Can an on board exit detector system achieve equivalent or improved
sensitivity, robustness and efficiency compared to the current standard phantom-
based measurement for pre-treatment verification?
Chapter 7 outlined a framework to characterize HT machine delivery errors and their
clinical significance. This framework could be applied to any patient dataset to deter-
mine a given institutions plan specific delivery error threshold as well as validate plan
robustness for a given machine QA tolerance or determine clinically relevant HT QA
tolerances.
Chapter 8 assessed the sensitivity of commercially available dosimeters to intentionally
introduced delivery errors that may occur based on machine malfunction or calibration
errors. This improves the understanding of a widely used commercial dosimetry system’s
sensitivity to detect HT delivery errors.
Chapter 9 outlined the development and clinical validation of an in-house HT on board
exit detector based tool supplemented with dose reconstruction. This tool has potential to
overcome the limitations of phantom-based measurement QA. A comprehensive clinical
evaluation is presented to assess this tool’s accuracy, robustness and efficiency.
Chapter 2
Literature Review
2.1 Cancer and the role of radiotherapy
"Nothing in life is to be feared, it is only to be understood. Now is the time to understand
more, so that we may fear less" Marie Curie
Cancer is a major public health problem worldwide as it accounts for a quarter of all deaths
and surpasses heart disease as the leading cause of death for people under the age of 85 [66].
In Australia, it is the second most frequent cause of death in 2009, causing 29% of all deaths
[67]. It is estimated that half of all cancer patients should receive radiotherapy at some
point during the course of the disease if evidence-based guideline recommendations were
applied to the population [68–70]. Moreover, management of cancer is a rising concern in
an ageing population and is increasingly important in developing countries. The increasing
rate of cancer occurrence in Australia and the need to improve the ratio of actual to optimal
utilization of radiotherapy, suggests that the utilization of radiotherapy is likely to increase
in the future.
2.2 History of external beam radiotherapy
The late 19th century was a prestigious period when three Nobel prizes were awarded for
discoveries related to ionizing radiation. In December 1895, Röntgen discovered X rays
(Figure 2.1) quickly followed, in June 1896, by Becquerel who discovered natural radioac-
tivity and in 1898, by Curie who isolated radium [71]. These three fundamental scientific
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discoveries paved the way for the two main techniques of radiotherapy: teletherapy, using
long source to surface distance (SSD), and later called external beam radiotherapy (EBRT);
and brachytherapy, based on a short SSD, initially delivered with radium and later with 50
kV X rays [72]. This era was also successful when considering the rapid transfer from bench
to bedside. The first patients with cancer were treated with radiation in 1896, six months
after Röntgen’s discovery, for gastric cancer and basal-cell carcinoma in France, America
and Sweden [73, 74]. The harmful effects of radiation also became apparent very quickly
[75], and were taken into account to optimize the therapeutic ratio and stimulate radiation
protection. By 1913, manufactured radium tubes or needles and Coolidge tubes were de-
signed to allow the routine use of radiotherapy in the fight against cancer [76]. Since that
time, the aim of radiotherapy has always been, from a physical point of view, to deliver as
close as possible to 100% of the dose in the gross tumour volume (GTV) and close to no
radiation to the organs at risk (OAR). A major achievement made during that period was the
capacity to measure the radiation dose using ionizing chambers [77] with the first accurate
dose unit (the Röntgen unit) in 1932. First, the different patterns of intrinsic radiosensitiv-
ity among cells and tissues were demonstrated by Bergoniė and Tribondeau in 1906 [78].
Second, the role of fractionation to create a beneficial differential effect between cancer and
normal cells was discovered [79]. In 1934, Coutard proposed a fractionation scheme of 200
Röntgen per fraction, five times per week, which was converted into the standard contempo-
rary 2 Gy/fraction scheme and, more recently, was well fitted with the α/β model to describe
its biological effect [80]. In 1928, the international Commission on Radiological Protection
(ICRP) was created to address the question of radiation protection [81].
Following the discovery of artificial radioactivity, and further to Johns and Cunningham’s
work [82], cobalt 60 was adopted as an alternative source of high-energy γ rays for telera-
diotherapy, with a higher dose rate than could be achieved with radium. The first telecobalt
unit was installed in 1948 in Hamilton, Canada (Figure 2.1) and subsequently used widely
for 2 - 3 decades [83]. Linacs were developed before and during the second world war and
the first electron accelerator designed for medical use was installed in the Hammersmith
hospital, London in 1953 [84]. The first patient treated in North America with a 6 MV linac
was at Stanford in 1956 [85]. Both telecobalt and linac based mega-voltage (MV) therapies
allowed skin-sparing application of radiation dose to deep tumours in the pelvis and thorax
for the first time. The first computed tomography (CT) image of a patient was acquired in
1971 [86] and in the 1980s was being implemented in radiotherapy departments. This per-
mitted more accurate definition of the tumour and healthy tissues. Dose distributions could
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Figure 2.1: Timeline 1 | Early landmark discoveries in radiotherapy from Thariat et al [1]
now be sculpted in three dimensions (3D) using treatment planning systems (TPS) with
‘beams-eye-view’ and linacs with multileaf collimators (MLC). Three dimensional confor-
mal radiotherapy (3DCRT) saw many tumour sites benefit from higher doses and improved
OAR sparing [87].
2.3 Advanced radiotherapy techniques
Intensity modulated radiation therapy (IMRT) was propsed by Brahme [88] in 1988 and
started entering clinics due to technology advances (e.g. MLC) in the late 1990s [89]. The
IMRT technology provided an ability to precisely shape the dose distribution to the target
while avoiding the healthy tissues [90]. There were a variety of different techniques for
delivering IMRT including; beam compensators [91], and MLCs in both step and shoot [92]
and sliding window mode [93], serial tomotherapy [94] and helical tomotherapy (HT) pro-
posed by Mackie [95]. Volumetric modulated arc therapy (VMAT) first proposed by Yu
[96] in 1995 also named intensity modulated arc therapy (IMAT) , is a form of rotational
IMRT and has become standard of care in many centres. This was later refined by Otto
[97] to improve the optimisation technique required to generate a plan. It is noteworthy
that these techniques also adapted to deliver simultaneous integrated boosts yielding higher
2.3. Advanced radiotherapy techniques 11
doses to the GTV without increasing the overall treatment time. There is growing interest to
utilise these advanced techniques to deliver the radiation dose in a single or few fractions (<
5 fractions) often referred to as stereotactic radiotherapy commonly known as stereotactic
ablative radiotherapy (SABR). SABR has shown superior and promising outcome over sur-
gical procedures or in non-operable patients [98–100]. These complex treatments are rapidly
becoming the standard of care worldwide because: i) tumour control can be increased by
dose escalation, using dose distributions much more closely conformed to complex tumour
shapes [5, 6] ii) patient quality of life (QOL) is enhanced by reduced risk of treatment-
related toxicities by improving normal tissue (NT) sparing [7, 8]; and iii) safe re-irradiation
is becoming increasingly possible due to increased dose conformality of the techniques [9–
11].
Image guided radiotherapy (IGRT) is an umbrella term used to describe advanced EBRT
techniques that integrate various modern imaging technologies with radiotherapy planning
and delivery. Within IGRT, pre-treatment imaging is typically used to monitor patient setup
with the goal of improving the accuracy of treatment delivery [101]. If using image guid-
ance reduces the geometrical uncertainties associated with target localization, then it may be
possible to reduce the margin of healthy tissue being treated around the clinical target vol-
ume [102]. Several radiation-based and non radiation-based imaging systems are currently
used in IGRT [103–106]
Electronic portal imaging devices (EPIDs) are a type of radiation-based imaging system that
may use either the MV therapy beam or a gantry-mounted kV x-ray source to acquire 2D
planar images to verify patient set up prior to treatment. These images may then be used
in real time to guide treatment delivery for a patient or may be reviewed offline at a later
time [101, 102, 107, 108]. Developments in imaging technology coupled with advances in
computer technology have fundamentally changed the processes of tumour targeting and
radiation therapy planning. Radiation oncologists face particular problems in treating parts
of the body where organs and tumours may move during treatment. Movement of the target
due to respiration or for any other reason during treatment increases the risk of missing the
targeted area or under-dosing the area. As the delivery of the radiation dose becomes more
and more precise, movements of organs and tumour have a significant effect on the accuracy
of the dose delivery. This is particularly dramatic for tumours located in the chest, since they
move during breathing. However, movement is not only an issue with tumours located in
the chest; tumours in the larynx, abdomen (liver), prostate and bladder and in the pelvis in
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Figure 2.2: Timeline 2 | Advances in radiotherapy technology from Thariat el al [1].
general also move during and between treatment applications. The introduction of IMRT,
VMAT and SABR procedures brings special physics problems. For example, calibrations
have to be performed in small fields where the dosimetry is challenging, and no harmonized
dosimetry protocol exists. Use of the correct type of dosimeter is critical and errors in mea-
surement can be substantial [109]. Several new treatment machines provide radiation beams
that do not comply with the reference field dimensions given in existing dosimetry proto-
cols, thereby complicating the accurate determination of dose for small and non-standard
beams. The introduction of highly precise collimators (and their use in IMRT), small fields,
robotics, SABR delivery, VMAT and image guidance has brought new challenges for com-
missioning and quality assurance (QA). Existing QA guidelines are often inadequate for
the use of some of these technologies. The new technologies are developing at a histori-
cally high rate (Figure 2.2). New commissioning and QA protocols do not follow that pace.
Increasingly complex QA procedures require additional staff in adequate numbers in the
radiotherapy centres that actually implement the advanced technologies. These advances
do not come without a risk. IMRT, VMAT and SABR techniques are not just an add-on to
the current 3DCRT process; they represent a new paradigm that requires the knowledge of
multimodality imaging, setup uncertainties and internal organ motion, tumour control prob-
abilities (TCP), normal tissue complication probabilities (NTCP), 3D dose calculation and
optimization, and dynamic beam delivery of nonuniform beam intensities.
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Advanced radiotherapy techniques are complex. Misadministration of advanced radiation
delivery techniques is more difficult to detect and may lead to poor outcome. Therefore,
their potential for improved effectiveness requires caution and a safety based approach. A
robust and reliable system for treatment verification is desired to realise the potential clinical
benefit.
2.4 Treatment Verification
Treatment verification has two important roles in radiotherapy: i) to mitigate mistreatments
that result in adverse patient outcomes (patient safety); and ii) to optimise treatment out-
comes by ensuring accuracy (treatment accuracy). Ensuring patient safety and treatment
accuracy requires techniques to control both geometric and dosimetric accuracy.
Patient safety: Serious accidents due to errors do occur in radiotherapy and have resulted in
fatalities [110]. A World Health Organisation (WHO) review of radiotherapy incidents be-
tween 1976 and 2007 [14] reported that the risk of injurious outcome to patients from errors
was about 1500 per million treatment courses. There is considerable public concern about
radiotherapy accidents. The potential dangers of implementing new radiotherapy technolo-
gies without sufficient safeguards have received wide publicity following the occurrence
of several serious accidents [12, 111, 112]. Recent multicentre dosimetry studies in North
America have had very poor results, with about one third of centres failing to meet the very
generous global gamma criteria of 7% dose accuracy and 4 mm geometric accuracy [113].
Dosimetric errors of up to 22% were identified. The main cause of errors was identified as
a combination of positional set-up errors, and incorrect configuration or implementation of
MLC models in treatment planning systems (TPS) and clinical dosimetry.
Treatment accuracy: Accuracy requirements for radiotherapy are decided by compromising
between what is practically achievable and what is necessary to achieve the treatment goals.
There is a general consensus that the overall accuracy of radiation therapy should be within
±5% to the prescribed dose [114–116].
A wide variety of instrumentation and experimental methods are in use, and IMRT QA
protocols continue to develop in an ad hoc manner [61] for both pre-treatment verification
and in vivo dose verification. Often several different measuring devices are used in com-
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bination to overcome the specific limitations of each device. Previous serious accidents
[12, 111, 112], and many others, could have been avoided with accurate dose verification
measurements acquired during treatment (in vivo dosimetry). It is highly likely that many
more mistreatments and near misses go undetected [117–120]. The increased complexity of
advanced techniques and workload may have an impact on treatment discrepancies [121].
The QA program in radiotherapy treatment (RT) diminishes uncertainties and inaccuracies
in dosimetry, treatment planning, equipment performance and treatment delivery improving
both dosimetric and geometric accuracy as well as precision of dose delivery. To address
the increasing demands on geometric accuracy, the use of imaging for treatment verification
has developed rapidly in recent years and provides submillimetre accuracy for daily patient
setup and target localisation [101, 102, 122–127]. Image guided radiotherapy (IGRT) aids
in tracking daily treatment setup to minimize geometric error. Verifying dose accuracy for
modern treatments such as IMRT, VMAT, HT and SABR typically relies on pre-treatment
dose measurements. This verification typically involves exporting the treatment fields from
the patient CT scans on the TPS, and importing them onto a verification phantom CT scan.
A verification phantom is usually an approximately cylindrical or cubic shaped object made
from material that is approximately radiologically equivalent to water and designed to house
various types of dose measuring devices within the phantom. The dose is then re-calculated
for the phantom using the same treatment field. The calculated dose to a point, area, or
volume within the phantom is recorded for comparison with a direct measurement of the
dose obtained in the same phantom [61, 128–132]. The phantom-based verification is also
performed to validate the accuracy of the TPS beam model and clinical implementation.
This commissioning data is used to establish the baseline for QA tolerance and also stream-
line the ongoing pre-treatment verification QA program in the clinic. The pre-treatment QA
process checks the correct transfer of the plan data to the linac and the accuracy of treatment
plan delivery. The aim is to detect and correct errors at the earliest opportunity.
Dosimetry systems used in clinics vary widely and have varying levels of capability, sen-
sitivity and limitations [46, 53, 133]. Moreover, pre-treatment measurements are time con-
suming and do not necessarily identify clinically relevant errors in dose delivery that may
occur during the course of treatment. One of the limitations of phantom-based treatment
verification QA is that it does not provide the connection between measurement results and
how the patient dose distribution might be affected. In vivo dosimetry technique refers to
measuring techniques for recording and verifying the dose actually received by patient dur-
ing treatment. In vivo dosimetry helps to detect the major errors and to assess clinically
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relevant differences between planned and delivered dose for each individual patient. In vivo
dosimetry could help to limit the impact of a problem. In addition, it would identify and re-
move the systematic errors which could impact other patients. If no error is detected, in vivo
dosimetry provides a confirmation record of correctly delivered dose within the expected tol-
erance. These factors are driving a growing demand for effective in vivo dose verification
[118, 119]. Accurate in vivo dose verification will help overcome current concerns about
the safety and accuracy of advanced treatment techniques.
2.5 Dose verification – instrumentation and methodology
The following sections briefly describe applications and limitations of some of the main
dosimeters used for treatment verification.
2.5.1 Point dosimeters
A point detector is a dosimeter that integrates dose and reports a single dose value, often
referred to as a point dose measurement. A point dose measurement has zero dimensions,
but point detectors can often produce a signal as a function of time. The use of the most
common types of point detectors in treatment verification is described below.
Ionisation chambers: Ionisation chambers have long been the gold standard for reference
dosimetry in radiation therapy. Several IMRT guidance documents, text book chapters,
and clinical studies have demonstrated an important role for ionisation chambers in patient
dosimetry [60, 61, 109, 132, 134, 135]. Typically, ionisation chambers are placed in a central
region of a phantom, or in a region corresponding to the uniform high dose area, which is
then irradiated by all of the treatment beams. The ionisation charge reading is converted
to dose with a calibration factor and the dose compared to the TPS calculation. Ionisation
chambers are limited by the fact that they can only report dose to a point, or averaged over
a small area.
TLDs and semiconductors: Thermo-luminescent dosimeters (TLD) and semiconductor diodes
have been used in radiotherapy for many years [117, 136, 137]. The small size and solid
state construction makes them well suited to in vivo dosimetry. The absence of any cables
on TLDs is an added advantage for in vivo use. There is a time delay to obtain the mea-
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surement results with TLDs but diodes can be read in real time. The theoretical principles
and use of TLDs have been described previously [138, 139]. The theoretical principles and
use of diodes for in vivo dosimetry have been described in reports [140, 141]. The use
of semiconductor devices, including p-n junction diodes and Metal Oxide Semiconductor
Field Effect Transistor (MOSFET) devices for dosimetry has been described by Rosenfeld
[142]. MOSFETs can be made extremely small, making them suitable for high resolution
measurements in brachytherapy plan verification in the in vivo setting [67, 143–146]. The
MOSkin, a new MOSFET based detector designed by the Centre for Medical Radiation
Physics (CMRP) has been shown to have promise as a real time in vivo dose monitoring
device in the presence of dose gradients and modulated fields [147]. TLDs and diodes have
been used for IMRT dosimetry, both in phantom measurements, and in vivo. Entrance or
exit dose measurements conducted in vivo with TLDs or diodes can be used to verify indi-
vidual fields but they are subject to large uncertainties due to the presence of dose gradients
and modulated fields [148, 149].
2.5.2 2-dimensional dosimeters
Two dimensional (2D) detectors are able to measure dose or relative beam/fluence intensity
to an entire plane. These types of detectors have become more widely used in radiotherapy
because of the QA requirements of IMRT and dynamic or virtual wedge profile measure-
ment. Some examples of two-dimensional detectors are given below.
Film: Film was one of the first types of dosimeters used in radiotherapy. The very high
spatial resolution of film is an advantage for modulated treatment dosimetry. Various types
of film continue to be widely used for IMRT. The two main types of film are radiographic
and radiochromic. There are many challenges in obtaining accurate dose measurements
with both types of film including, energy response, field size and depth sensitivity, film
batch sensitivity differences, film orientation, processing and scanner variations. The future
of radiographic film dosimetry is uncertain because the increased use of Electronic Portal
Imaging Devices (EPIDs) and computed radiography screens in radiotherapy imaging has
allowed many department to become filmless [150]. The improved coating of radiochromic
films had overcome a number of issues related to dosimetry. Radiochromic films do not
require chemical processing and are widely used for commissioning and for patient specific
IMRT treatment verification [151] and treatment verification of SABR cases [152].
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Detector arrays: Commercially available 2D detector arrays, either diode array [55, 153] or
ionisation chamber arrays have been used for pre-treatment dosimetry of modulated fields
[154–156]. Cilla et al. used an ionisation chamber array for a transit dosimetry phantom
study using IMRT fields [157]. The use of a 2D detector as a transmission dosimetry device
mounted onto the head of the linear accelerator have been demonstrated in previous studies
[158, 159]. The 2D detector arrays tend to have good dose response characteristics for QA
measurements but lack spatial resolution compared to other 2D dosimeters due to larger
distance between detectors and also relatively large individual detector size. For example
the detectors on the currently available arrays are at least 5 mm apart (centre to centre).
Alternative prototype 2D devices have been reported. A small prototype monolithic silicon
segmented sensor has been manufactured and tested for radiotherapy dosimetry [160, 161].
The physical characteristics of plastic scintillating materials and their applications in radio-
therapy have been extensively studied and reported in the literature [162–169]. These scin-
tillators are manufactured using low-Z materials (i.e. low atomic number) and have been
shown to respond in a nearly water-equivalent manner to both x-ray and electron beams in
the energy range relevant for radiotherapy [162, 165, 166, 168, 169]. Prototype plastic scin-
tillator sheets coupled to a Charge Coupled Device (CCD) camera have also been tested for
radiotherapy and IMRT dosimetry [169–171].
The novel prototype named as ‘Magic Plate’ has been developed by Rosenfeld’s group at
CMRP [172]. This prototype is a 2D semiconductor based detector specifically designed for
treatment verification in transmission mode. CMRP are currently working on a miniature
SRS mobile tracking version of this detector.
The potential of 2D chamber array dosimetry devices as a transit dosimeter which are typ-
ically used for pre-treatment QA have been demonstrated by a few researchers [173–175].
Prabhakar et al [126] proposed a novel approach of treatment verification in real time using
a 2D MAPCHECK array attached to the treatment couch. None of the previous work used
the 2D detector in series with EPIDs. In this dissertation, we investigated the novel config-
uration by combining dosimeter (ionisation chamber array or magic plate) and an imager
(EPID) in series and used simultaneously. Chapters 4 and 5 investigated the hypothesis of
dual detector concept where this configuration enabled measurement of the transit dose with
(2D array dosimeter) without affecting the imaging performance of the EPID.
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2.5.3 EPID
Current EPID designs contain a copper layer and a phosphor layer in combination with an
amorphous silicon (a-Si) photodiode array. Optical photons are generated in the phosphor
scintillator layer by incident radiation from the megavoltage photon beam and scatter from
the copper plate. The optical photons create a signal in the photodiodes. This is known as
the indirect EPID configuration. In this dissertation, this metal/phosphor EPID design is
referred as a standard EPID.
Indirect EPIDs: EPIDs were introduced for patient position verification [176–178]. The
idea of using EPIDs for dosimetry was realised in the 1980s [179]. Little was published on
the topic until the mid 1990’s. Since then the interest in EPIDs for dosimetry has increased
rapidly [23]. The increasing research on EPID dosimetry coincided with the introduction
of IMRT. EPIDs are well suited to IMRT dosimetry because they are high resolution, 2D
digital detectors. EPIDs are available on most modern linear accelerators [23]. Different
types of EPIDs have been clinically implemented, and these have been described in several
review papers [177, 178, 180].
Dose response characteristics for a-Si EPIDs was studied and reported by a number of re-
searchers [28, 181–185]. All these studies reported that EPIDs exhibit under response to
dose at small monitor units (MU). The key studies of EPID dose response highlighted the
inconsistent interpretation of EPID dose response characteristics. An under dose response
correction was suggested using an empirical approach [181, 183] and applied on a pixel-
by-pixel basis. These corrections are complex to implement accurately on a pixel-by-pixel
basis due to the variations in time between segments and variation in dose per segment.
The EPIDs under dose response is widely reported based on static open beam exposures,
with little or no consideration for how accurately this behaviour translates to segmented
IMRT. Chapter 3 investigates the EPID dose linearity under different combinations of linac,
EPID design and acquisition system to understand the underlying causes of EPID under
dose response at small MU. Also a simple pixel-to-dose calibration methodology for IMRT
verification is described.
The current generation of commercially available EPIDs are indirect detection active matrix
flat panel imagers, also known as amorphous silicon (a-Si) EPIDs [178, 180]. One limitation
of the use of EPIDs for dosimetry purposes is the non water-equivalent response of imaging
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detectors [26]. The non water-equivalent EPID response is associated with over-sensitivity
to the low energy where the signal is influenced by the scatter within the bulk layers of the
imager [24–27], and by patient generated low energy scatter.
A review by van Elmpt [23] gives an excellent overview of the diverse applications for
EPIDs in clinical dosimetry and their clinical implementations up to 2008. Both pre-
treatment and in vivo treatment verification may be performed by comparing the delivered
dose distribution (measured with the EPID) to the planned distribution predicted using the
TPS [29, 30, 118, 119, 186, 187]. Each of these dosimetry methods may be further catego-
rized according to whether the detected fluence was reconstructed to give calculated dose in
2D [29, 186, 187] or 3D [30, 118, 119]
Different approaches were demonstrated to convert EPID signal to dose. The first approach
applies empirical models to convert the measured grey-scale image of the EPID into a portal
dose image [27, 188–192]. The second approach simulates or models the detector response,
usually by Monte Carlo (MC) simulation [25, 33, 34, 193, 194] or by empirical models
[192]. For accurate simulations, a detailed model of the EPID is necessary; however, ac-
curate technical details are not always available, and often assumptions with respect to the
construction and materials of the various layers are made. This requires longer dose cal-
culation times and extra resource for development. One simple EPID dosimetry model
previously demonstrated uses the ‘extended phantom’ concept to calculate a predicted dose
image (PDI) at the EPID plane using the TPS dose to water model [195–199]. When used
with standard EPIDs, this method still requires a separate EPID model to convert the mea-
sured EPID signal into dose to water (i.e. to model the complex dose response of the stan-
dard EPID). The potential of EPIDs for detecting various dose delivery errors has been well
demonstrated in previous studies [119, 200–202]. Despite the large body of research dating
back to the early 1990s and before, the reported use of clinical EPID-based in vivo dosime-
try is still surprisingly limited to a small number of centres. To utilise the standard EPID
as a dosimeter, requires extensive software development to integrate the various steps as
outlined: i) To model dose response characteristics of a-Si EPID, ii) incorporate the dose
response characteristics into a computation of predicted pixel values, or conversion from
pixel values to dose in water with or without a back-projection dose reconstruction model
to compute dose inside the patient, and finally iii) software tools to quantitatively compare
predicted versus measurement based results.
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Further, the changes in EPID technology over recent decades have not been driven by the
technical demands of dosimetry, but by the need for improved imaging standards for patient
positioning, such as enhancement in image quality and faster read-out [160, 161]. These
efficient MV detectors generally consist of higher atomic number materials than current
EPIDs, which is likely to make EPID dosimetry even less water equivalent and still more
difficult to implement.
Direct EPID:
When the protective cover and all other materials covering the photodiode array, including
the copper plate and the phosphor layer are removed the system is referred to as a ‘direct
EPID’. The signal is produced by the interaction of the megavoltage photon beam directly
within the photodiodes.
The modification of the indirect detection configuration is in an attempt to improve upon the
dosimetric response of standard EPID. Several studies by Greer and his group [38, 39, 203–
206] investigated modified forms of the standard indirect-detection EPID where materials
above the photodiode array were replaced with water-equivalent build up material. Their
hypothesis was that by removing the high-Z components and replacing them with water-
equivalent material, the EPID’s response should be closer to water-equivalent, a desirable
characteristic for dosimetry applications. The authors investigated applications using the
modified direct-detection EPID for clinical IMRT dosimetry [39]. In doing so, they first
established which configuration of buildup and backscatter material resulted in a direct-
detection response that best agreed with water-equivalent measured dosimetry data. This
ideal configuration was found to use a thickness of dmax solid water build up without any
additional backscatter. The main conclusion drawn from these studies was that it is possible
to modify the standard EPID to obtain a water-equivalent dose response, however the trade
off in sensitivity results in a drastic reduction in image quality, particularly for low dose
imaging. Due to the absence of the metal/phosphor layer in the modified EPID design, the
signal is now produced by the interaction of the megavoltage photon beam directly within
the photodiodes. This results in the reduction in quantum efficiency and sensitivity. There-
fore, the image quality in modified EPID design particularly for low dose imaging suffers
[38]. These studies primarily focused on demonstrating how the modification of the EPID
structure provides a water-equivalent dose response by comparing the modified EPIDs dose
response with another established water-equivalent detector. None of these studies provided
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any framework for how this configuration can be adopted in routine clinical use i.e. how
the measured EPID dose information can be linked to dose received by patient and the
methodology for how to obtain the predicted dose at the EPID plane for transit dosimetry
verification. Chapter 6 outlines the framework for the clinical implementation of in vivo
dose verification and is presented utilising a water equivalent EPID and a commercial TPS.
With the aim of improving both the quantum efficiency and water-equivalence of current
EPIDs, Teymurazyan and Pang [207] proposed a modified indirect detection EPID that em-
ploys an array of plastic scintillator fibres in place of the metal plate and phosphor screen
in standard EPIDs. Using MC simulations, they predicted that such an EPID could achieve
a theoretical DQE of 37% for a 6 MV beam with fibers 30 cm in length. Other properties
including the detection efficiency and MTF were also quantified. Unfortunately, however,
the use of such thick (and consequently heavy) scintillators poses certain mechanical dif-
ficulties that may complicate their clinical practicality. Another important conclusion was
that using plastic scintillator in place of the standard high-Z x-ray converter materials results
in a water-equivalent dose response, which would potentially render this design suitable for
portal dosimetry. A significant limitation of this study, however, is that the authors did not
report any experimental data against which to validate their model.
The former scenario (standard EPID-based dosimetry) typically necessitates a complex de-
tector characterisation and calibration scheme along with custom software to convert portal
images into water- equivalent dose images. The latter scenario (direct EPID) has seen de-
tector prototypes that, while capable of performing accurate patient dosimetry, suffer from
decreased x-ray detection efficiency thus inhibiting their use for imaging. In both cases, pro-
posed detectors have not been suitable for applications in both imaging and water-equivalent
dosimetry. Chapter 4 and 5 discussed characterisation of novel EPID based prototypes that
are capable of simultaneous imaging and dosimetry.
2.5.4 Quasi 3D dosimeters
Two commercial dosimeters are routinely used specifically for VMAT or other rotational
therapy such as HT treatment dose verification. The Delta4 system (Scandidos, Uppsala,
Sweden) consists of two planar dosimeter arrays mounted orthogonally. Dose reconstruc-
tion software can then generate 3D dose maps [208]. It has 1069 p-type silicon diodes on
two orthogonal planes mounted within a polymethylmethacrylate (PMMA) phantom. The
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diodes are cylindrical in shape with an active area 0.78 mm2. The diode pitch is 6 mm within
the central 6 x 6 cm2 region, and 10 mm for the outer region. An inclinometer is attached to
the linac gantry (providing independent measurement of the gantry rotation) in conjunction
with the Delta4 dosimeter used for VMAT dose verification. The second dosimeter, Arc-
CHECK (Sun Nuclear, Melbourne, FL) consist of a cylindrical structure with 1386 diodes
arranged in a helix with a diameter and length of 21 cm [51]. The device is configured with
a solid PMMA insert.
Phantom-based measurement treatment verification QA process is cumbersome and limited
to verify treatment length < 25-30 cm. Verification of treatments exceeding the dimensions
of the dosimeter is quite challenging. They can’t be used for in vivo dosimetry. One of
the limitations of phantom-based measurement treatment verification QA is that it does not
provide the connection between measurement results and how the patient dose distribution
might be affected. Software for these these systems allows time dependent dose verification
for VMAT delivery and calculates the delivered dose distributions in patients by perturbing
the calculated dose using errors detected in fluence or planar dose measurements to corre-
late the gamma passing rate and the composite dose predicted with patient dose distribution.
These algorithms contain significant approximations and their limitations have been demon-
strated by recent studies [62, 63].
Advanced radiotherapy technologies and methods are complex; much more so than previous
approaches and their treatment delivery uncertainties are not yet well studied or understood.
The aim of phantom-based measurement QA is to detect and correct errors at the earliest
opportunity. Therefore, the sensitivity of each dosimetry system to detect clinically relevant
error must be studied and understood.
Various studies have previously been performed to assess the sensitivity to IMRT and/or
VMAT simulated errors for the Delta4 [51, 52], ArcCHECK [51, 53, 54], MapCHECK
[46, 55], MatriXX [56] and PTW 2D array [52, 57]. These studies mainly focus on C-arm
linac based treatment. The general conclusion drawn from the above mentioned studies was
that different dosimetry systems were able to detect particular errors. Masi et al [52] mea-
sured using four different dosimetry systems the clinical VMAT plans optimised using two
TPS. Authors reported slightly lower gamma pass-rate for plans from one of the considered
TPS which was attributed to a higher level of complexity of the optimised plans. The de-
tector sensitivity to intention 3 mm translation shifts and to gantry angle offset was shown
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to be strongly plan and partially detector dependent. Yet no comprehensive comparison of
different detectors for key clinical sites for helical tomotherapy treatments has been under-
taken. Also, no systematic study has been undertaken to determine the delivery errors that
are clinically relevant.
2.5.5 3-dimensional dosimeters (Gel dosimetry)
Point detectors or 2D detectors may be used to obtain 3D measurements by combining a
series of exposures. However, gel dosimetry is the only class of true 3D detectors available
for radiation dose measurements. Several types of gels have been used in radiotherapy
over many years. Gel dosimetry is founded mainly on the work of Gore et al [209] who
demonstrated that changes due to ionising radiation in Fricke dosimetry solutions, developed
in the 1920’s, could be measured using nuclear magnetic resonance (NMR). Several studies
have demonstrated the use of polymer gels for dose verification of IMRT treatments [210–
213]. There is no consensus on the optimal formulations of gel dosimeters or the optimal
evaluation techniques to be used [214]. This is a barrier to the broader implementation of
gel dosimetry techniques in radiotherapy clinics.
2.5.6 On board exit detector
Helical tomotherapy (HT) was developed as an integrated system for delivering complex
intensity-modulated radiation therapy (IMRT) treatments combined with mega-voltage com-
puted tomography (MVCT) capabilities [95]. The on board exit detector is an arc-shaped
CT xenon detector array located opposite the linear accelerator on a rotating slip-ring gantry.
The detector array consists of cells which are small xenon gas cavities separated by thin
tungsten septal plates. The detector array is designed to collect radiation exiting the patient
for MVCT reconstruction. It also measures exit fluence during treatment delivery which can
be used for delivery verification. The detector collects data from 640 channels and at each
linear accelerator pulse (300 Hz).
The reconstruction of three-dimensional doses on HT using exit dose measurement via the
in-line CT detector array is feasible. Dose verification on HT was first studied by Kapa-
toes [215, 216]. Methods for the verification of multi leaf collimator leaf open time (MLC
LOT) have been investigated by many authors, some of whom used independent devices
[217] whereas others used the MVCT detector to allow for in vivo dose calculation based on
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dose reconstruction in the presence of the patient [215, 216, 218], Some researchers [64, 65]
proposed a QA procedure that involves applying a simple method to verify the MLC perfor-
mance as a pre-treatment verification tool. Previously reported work on on board detector
(OBD) pre-treatment verification tools has not utilised a dose reconstruction approach.
Despite the rapid evolution in our ability to deliver highly conformal x-ray beams, limita-
tions with current detectors hinder our ability to measure dose delivery to the patient for
QA and treatment plan optimization. The availability of such a detector would be extremely
beneficial both to verify that the actual dose delivered matches the planned dose distribution
and for identifying those patients that would benefit from treatment adaptations, thus making
radiotherapy safer and more effective. The overall goal of this dissertation investigated treat-
ment dosimetry verification for two different radiotherapy delivery systems. The first part
develops and characterises a novel prototype hybrid EPID based dosimeter as a proposed
solution for evaluating complex treatment techniques on a conventional linear accelerator
which aims to combine both geometric and dosimetric verification in a single system. Intial
work investigates the underlying causes of under dose response for standard EPIDs. The
second part investigates clinical HT treatment verification. Specifically, the impact of treat-
ment delivery parameters on clinical HT plans, sensitivity of commercially available devices
to detect delivery errors and development and clinical implementation of an in-house exit
detector-based dose reconstruction tool to verify dose delivery of HT treatment plans.
The proposed EPID based novel prototype configuration would improve treatment verifi-
cation. Understanding the sensitivity of dosimetry systems provides information to inform
support the decision of the most appropriate dosimetry system for each individual clinical
situations and clinical implementations. The developed solution of exit-dosimetry would
improve the efficiency of pre-treatment verification. This will facilitate a safer and more
efficient implementation of other developing technologies in radiotherapy treatment deliv-
ery than is currently possible. Thus improving patient access to state-of-the-art radiotherapy
will be achieved.
Chapter 3
Dose calibration of EPIDs for segmented
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All medical linear accelerator (linac) vendors currently provide a-Si EPID as a standard op-
tion. EPIDs are used routinely in radiotherapy for image verification of patient position.
However, it has been demonstrated previously that a-Si EPIDs also have great potential
for dosimetry applications [23]. Despite many studies demonstrating the potential of a-Si
EPIDs for dosimetry, there remain some technical challenges to be overcome in order to re-
alize their full potential in routine clinical practice. There are issues related to the non-water
equivalence of the EPID [31, 38, 204, 219] and the detector’s image acquisition process
[185, 220, 221]. Previous studies of the dose response characteristics of a-Si EPIDs have re-
ported an underresponse at small MU exposures relative to longer exposures [28, 181–184].
The resulting nonlinear EPID dose response, referred to here as gain ghosting, has been
attributed to trapped charge effects [27, 181, 184, 222]. Gain ghosting is associated with
variations in the quantity of trapped charge with exposure to radiation. The electric field
characteristics change as the level of trapped charge increases, resulting in a change in pixel
sensitivity with exposure to radiation. Image lag, defined as residual signal registered with a
time delay from the original radiation induced electron-hole pair, is also attributed to trapped
charge [27]. Image lag measured from the relative residual signal in image frames acquired
immediately after an exposure has been reported as 2%-10%, depending upon incident ex-
posure and EPID model [28, 181–183]. McDermott et al. [181] measured both image lag
versus time elapsed (post-irradiation) and linearity of dose response (gain ghosting) for an
Elekta iViewGT a-Si EPID. They proposed a correction for ‘combined ghosting effects’ to
account for both image lag and gain ghosting using a triple exponential fitted as a function
of time based on measurements with open beams. The same group quantified the nonlinear
response of six EPIDs from three different vendors: Elekta iViewGT (Elekta Oncology Sys-
tems, Crawley, UK), Varian aS500 (Varian Medical Systems, Palo Alto, CA), and Siemens
OptiVue (Siemens Medical Solutions, Concord, CA) [182]. The underresponse was in the
order of 4%–6% at 5 MUs relative to 1000 MU for Siemens and Elekta EPIDs. Nijsten et al.
[28] also reported an underresponse of up to 6% at 5 MU exposures relative to 1000 MU for
a Siemens EPID, and implemented the ghosting correction factor into their EPID dosimetry
calibration algorithm as proposed by McDermott et al. [181]. Similar nonlinear characteris-
tics were measured on an Elekta EPID by Winkler et al. [183]. They proposed that the EPID
dose response be a logarithmic function of dose, rather than time as proposed by McDer-
mott et al. [181]. This research group accounted for an additional dose rate response effect
during linac beam startup and demonstrated that image lag increases with the ratio of MUs
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between the first and second exposure, and with reduced time interval between two subse-
quent exposures for IMRT fields. Recently, Warkentin et al. [223] proposed a pixel-by-pixel
correction model that incorporates both image lag and nonlinearity correction for dynamic
delivery with a Varian aS500 system. In the same study, they highlighted the importance of
these corrections to reduce ambiguities and uncertainties in EPID-based dose verification.
Van Esch et al. [192] reported a forgoing irradiation of 500 MU resulted in image lag of
only 1% in the following image acquired after approximately 10 s for Varian aS500 EPIDs.
They also attributed the underresponse of up to 6% at 2 MU mainly to rounding error of
signal count from the acquisition software. Another factor in EPID dose response, which
has not been addressed in most studies, is the importance of different image acquisition soft-
ware controls and frame readout schemes. Chang and Ling [220] identified potential errors
in the Varian synchronous, frame-averaging acquisition mode due to missing data between
the start of irradiation and imaging, and from the last (incomplete) frame. Kavuma et al
[185] also observed significant artifact in in-plane profiles at low MU exposures on Varian
EPIDs with IAS2/IDU-II acquisition software, and suggested the IAS2/IDU-II acquisition
system would not be suitable for step and shoot IMRT verification with low MU segments.
Both of these issues were resolved in following vendor upgrades. Budgell et al. [224]
investigated the intersegment EPID response reproducibility at low dose measured over a
series of 20 successive segments delivered with 1 and 2 MUs. The measured inter segment
variability was within 1% and consistent with ion chamber data. They also reported the
acceptable reproducibility of off-axis profiles measured for 20 successive segments with 4
MU. A comprehensive investigation about the influence of the readout scheme on the dose
response for all three linac vendors at small MU was carried out by Podesta et al. [221].
This research group modelled the discrepancies in dose response at low MU of up to 37%
using only the incomplete integration of EPID frames acquired during irradiation. They re-
ported no underresponse for Elekta and Varian TrueBeam systems (post-software upgrade),
but reported large underresponse for Siemens, Varian TrueBeam (pre-software upgrade) and
Varian Clinac systems. While difficult to compare directly, these results do not appear con-
sistent with previous EPID dose response studies. The above review summarizes some of
the key studies of EPID dose response, highlighting the inconsistent interpretation of EPID
dose response characteristics. Despite the apparent successful and increasingly widespread
clinical implementation of EPID dosimetry, fundamental dose response issues remain unre-
solved. These issues came to light during the development of an EPID dosimetry program
in our department and were the motivation for this work. The specific issues we aim to
address in this work include: i) the inconsistencies in the literature about the underlying
3.2. Methods and Materials 28
causes of nonlinear dose response of EPIDs; ii) the EPIDs nonlinear behavior is widely
reported based on static open beam exposures, with little or no consideration for how ac-
curately this behavior translates to segmented IMRT; iii) the management of these effects
on a multivendor EPID dosimetry program, with particular regard to the relative importance
of the EPID detector design, the linac, and the image acquisition and processing methods
implemented across different systems; and iv) unexpected EPID dose response behavior ob-
served on Siemens EPIDs. This work will contribute to a more consistent understanding and
implementation of pixel-to-dose calibration methods for EPID-based IMRT dosimetry.
3.2 Methods and Materials
3.2.1 Equipment
Different combinations of linacs, EPIDs, and acquisition software were investigated in an
attempt to isolate the source and relative contributions to EPID dose response behavior. Each
experimental setup is described in Table 3.1. The bottom row provides a code used to refer to
each experimental setup throughout this paper. In each case the standard gain (flood field)
and offset (dark field) corrections were applied to EPID measurements. All IMRT fields
were delivered using the segmented (step and shoot) technique with gantry angle fixed at 00
with 6 MV photons only.
3.2.1.1 Siemens EPID system
Details of EPID construction, acquisition software, and image processing implemented on
the Siemens equipment (Siemens Medical Solutions, Concord, CA) can be found in a previ-
ous study [28]. The EPID images for step and shoot IMRT delivery were acquired with the
multi-frame acquisition mode (experimental setup 1 and 2a from Table 3.1). This mode of
acquisition saves a frame average image for each IMRT segment. According to the Siemens
documentation#, the number of frames (Nframes ) acquired per segment or beam is determined
by the following relation:
#Linear Accelerator System Manual, Siemens Medical Solutions
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(3.1)
The integrated pixel value (IPV) for IMRT fields with n segments is given by equation 3.2:
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where, Ri denotes the EPID frame average pixel value for the ith segment (i.e., EPID frame
average response per segment), and Ni denotes the number of frames (Nframes ) for the ith
segment.
(Nframes) is reported in the DICOM file header. All images were exported in DICOM format
and analyzed with in-house code using MATLAB (MathWorks Inc version 7.12.0.635(R2011a);
MathWorks, Natick, MA). The ‘Port during’ imaging option used for IMRT operates in ‘free
running mode’. Based on personal communications†, with other research groups and the
vendor, the image acquisition is thought to be triggered by a beam-on and beam-off signal
from secondary Siemens software. There is no beam pulse synchronization in ‘free running
mode’.
3.2.1.2 Elekta EPID system
Details of EPID construction, acquisition software, and image processing implemented on
the Elekta equipment (Elekta Oncology Systems, Crawley, UK) can be found in previous
studies [181, 183]. Measurements with the Elekta EPID (experimental setup 3a and 3b
from Table 3.1) were conducted using two image acquisition software systems available on
the iViewGT workstation: i) iViewGT Elekta software in standard clinical mode (version
3.4b 162-SP2), and ii) XIS PerkinElmer software (version 3.2.0.7 ). IMRT images acquired
with the iViewGT software use the ‘Single’ exposure option. This mode of acquisition
saves a frame average image for each segment. The individual frame average image for
each segment was exported. The integrated pixel value (IPV) for each segment or field is
obtained using equation 3.3:
Integrated pixel value =
65535−Raw Pixel V alue
PSF
(3.3)
where the 65535 is the 16-bit offset and PSF is the pixel scaling factor. The PSF for each
segment of an IMRT field is reported by the iViewGT software. The integrated EPID im-
age was obtained by manually adding the IPV of each segment determined using equation
3.3. The PSF includes scaling factors for the number of frames acquired and a configurable
renormalization used to ensure gray-scale values are optimal for visualization of clinical
images. When this renormalization is set as 0 in the iViewGT initialization file (sri.ini), the
†Mark Podesta, personal communication, January 23, 2013.
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PSF is numerically equal to the inverse of the number of frames acquired during the im-
age, analogous to 1/Nframes from equation 3.1. The number of frames acquired PostBeamOff
(an image acquisition setting) is also configurable in the initialization file. To investigate
the impact of this setting on pixel-to-dose calibration, the EPID images were collected with
zero, three, and ten PostBeamOff frames with renormalization settings of 40,000 (the default
clinical setting) and zero. The images and associated log files (containing the image header
information) were exported using the standard export option from the iViewGT worksta-
tion for further analysis. The image data controller uses the gun pulses from the linac to
synchronize the reading of the data from the panel, so that image data is read when the ra-
diation pulse is not present. As soon as the complete frame is read from the panel, a frame
synchronization pulse is sent to the data controller‡. The measurements with the XIS appli-
cation (experimental setup 3b from Table 3.1) were conducted in continuous ‘free running
mode’ with no external trigger mechanism. The acquisition was manually started immedi-
ately prior to beam-on and stopped at an arbitrary time after beam-off (at least 10 frames
after beam-off). The XIS software stores the individual frames. The integrated image was
obtained by summing each frame in MATLAB. The frame signal amplitude was used to in-
dicate the start and stop of each beam and hence control the number of PostBeamOff frames
used in the analysis (Figure 3.1). The two different acquisition systems (iViewGT and XIS)
on the same linac enabled us to investigate the impact of software based acquisition settings
on the reported dose response of the EPID.
3.2.1.3 Standalone research EPID system
A standalone PerkinElmer detector was also used in this study. This EPID was similar to
the Elekta and Siemens EPIDs, with the advantage of being mobile so it could be used
across the different linacs. The research EPID measurements (experimental set-up 2b and
3c from Table 3.1) were conducted on both Siemens and Elekta linacs in continuous ‘free
running’ mode using XIS acquisition software. The acquisition settings were set to match
the clinical acquisition settings as described Table 3.1. The integrated image was obtained
by summing each frame in MATLAB as described above for the Elekta images acquired
with XIS software. The beam off trigger was estimated as the frame where the signal had
dropped to approximately 50% or less of the beam-on value. Figure 3.1 describes the image
acquisition and triggering process. Using one EPID across different linacs provided more
information on the impact of the linac on the reported dose response of the EPID. For seg-
‡Elekta iViewGT Corrective Maintenance Manual, Elekta, Stockholm, Sweden
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Figure 3.1: Schematic illustration of three different frame integration methods: i) No frame
PostBeamOff; ii) 3 frames PostBeamOff; and iii) 10 frames PostBeamOff, where 0, 3, and
10 frames after the beam has stopped are included in integrated images, respectively. The
beam-off trigger was estimated as the frame where the signal had fropped to approximately
50% or less of the beam-on value.
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Figure 3.2: Experimental set-up for simultaneous EPID and ionisation chamber array mea-
surements.
mented delivery, the ‘10 frames post beam off’ integrated image was obtained by summing
the maximum number of post beam off frames available between two consecutive IMRT
segments not strictly 10 frames. In order to isolate EPID dose response behaviour from
beam characteristics, such as dose per MU linearity, each experiment was conducted with
the ICA positioned beneath the EPID to acquire simultaneous reference measurements. This
ICA has been previously shown to display linear dose response behaviour in both ‘movie’
mode and integrating mode [155, 225]. The ICA was operated in ‘movie’ mode at ap-
proximately the same integration time as the EPID in each experiment. The ICA software
restricts integration times to multiples of ten milliseconds, therefore the ICA integration
time was set to the EPID integration time rounded to the nearest 10 milliseconds (see table
3.1). The set-up for the simultaneous EPID and ICA measurements is shown in figure 3.2.
Previous work verified this set-up had no effect on the EPID dose response characteristics
under investigation [226].
All the measurements discussed below in sections 3.2.2 and 3.2.3 were conducted with all
three equipment combinations summarised Table 3.1. All measurements were conducted
with three minute intervals between each measurement unless stated otherwise to minimize
image lag.
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3.2.2 Dose linearity for segmented fields
The linearity of EPID response with dose was measured with static open fields for varying
MU exposures (1- 100 MUs). The open beam experiment provided a baseline for compar-
ison with EPID dose response linearity with IMRT delivery. Six IMRT fields were created
specifically for this experiment. The segments of each IMRT field were fixed at 10 × 10
cm2 field size, each field having a total of 20 MU. Field 1 consisted of 20 segments at 1
MU per segment, field 2 consisted of 10 segments at 2 MU per segment, and fields 3, 4, 5,
and 6 consisted of 5, 4, 2, and 1 segments of 4, 5, 10, and 20 MU per segment respectively.
The single segment at 20 MU represents a standard static open beam delivery of 20 MU.
The total integrated EPID response for each IMRT field was obtained from the sum of the
average of the central 20 × 20 pixels per frame. The integrated pixel value per segment
and in total for each IMRT field was compared with the corresponding static open beam
case. For the remainder of this study we refer to the IMRT fields used in this experiment as
‘simple’ IMRT fields. The ICA provided a reference of delivered dose. The integrated EPID
response for total 20 MU exposure measured with single static open field and five ‘simple’
IMRT fields was compared to assess whether the under-response seen in static fields persist
with segmented delivery.
3.2.3 Inter-segment reproducibility
To evaluate inter-segment variations in EPID response during segmented delivery the ‘sim-
ple IMRT fields’ described above were delivered five times consecutively. The reproducibil-
ity of EPID response at off-axis positions was also investigated from profiles along the cen-
tral pixel row and column for each segment. The ICA provided a reference of delivered dose
profiles.
3.2.4 Clinical IMRT fields
Four sets of ‘clinical IMRT fields’ with constant MU per segment of 2, 4, 5, and 10 MUs
were created by editing the RTP file. The percentage deviation in the integrated detector
response at each pixel was determined from 10 repeat measurements. This experiment was
conducted on both linacs.
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3.2.5 EPID pixel-Dose calibration
The integrated EPID dose for the clinical IMRT fields described in section 3.2.3 was deter-
mined using three different methods as described by Eqs. (3.4) , (3.5) and (3.6) below. The
results were compared to assess the impact of calibration methodology:
Calibration method 1 (ghosting correction method):







· (CF (100MU)) (3.4)
Calibration method 2 (no ghosting correction):






· (CF (100MU)) (3.5)
Calibration method 3 (small MU calibration method):






· (CF (20MU)) (3.6)
where (IPV)n is the integrated pixel value for the nth segment, CF(100MU) and CF(20MU)
is a pixel-to-dose calibration factor determined at 100 MU and 20 MU respectively, trad is
radiation beam-on time, G(trad) is a ghosting correction factor determined from the function
of EPID dose response linearity measured with open static fields for Linac1 and Linac3
(experimental setup 1 and 3c from Table 3.1). The value of trad is determined from the
product of the number of frames and frame acquisition rate for the Siemens linac and from
an inverse of the product of PSF and frame acquisition rate for the Elekta linac. There is no
correction for any specific ghosting or non-linearity in calibration methods 2 and 3. Method
3 uses a calibration factor determined at a MU level more closely matched to IMRT segment
MU, with the aim of reducing the impact of non-linear dose response (gain-ghosting) on
clinical dosimetry. A gamma evaluation, with 2% and 3% difference (global maximum)
and 2 and 3 mm distance-to-agreement criterion with 10% dose threshold, is performed to
quantify the difference between the integrated EPID dose map calculated from calibration
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methods 1, 2 and 3 using the same EPID data. Field size correction factors and other detector
scatter corrections were ignored for the EPID dose computation since they remain constant
irrespective of calibration methods being investigated here.
3.3 Results
3.3.1 Dose linearity for segmented fields
The EPID dose response as a function of MU for static and ‘simple’ IMRT fields for all
EPIDs are shown in figures 3.3 (a) and (b) for the Siemens Linac and figures 3.3 (c) and
(d) for the Elekta linac (experimental setup 1, 2a and 3a from Table 3.1). In the case of the
Elekta EPID, dose response for ‘simple’ IMRT fields versus static fields agreed to within
2.5% for MU≥2. However, for Siemens EPID, the agreement in dose response for ‘simple’
IMRT fields versus static fields was difficult to interpret due to the poor reproducibility
for segmented delivery, particularly at MU ≤ 5. Both Siemens and Elekta clinical EPIDs
under responded by 9% and 8% respectively relative to ICA for 1 MU per segment (or
field). At 2 MU and above the agreement between Elekta clinical EPID and ICA was within
2.5%. No significant difference was observed in dose response for the Elekta clinical EPID
when measured under a different acquisition setting as described in section 3.2.1, and agreed
within 1%. The renormalization for each of the three different PostBeamOff frame Elekta
datasets was set to 40,000 (Figure 3.3 (c) and (d)). At 2 MU and above, the agreement
between Siemens clinical EPID and ICA was within 3.5%. The reproducibility at 1 MU for
clinical Siemens EPIDs was poor (7.8% and 12.7% SD for linac 1 and linac 2, respectively;
3.3 (a) and (b)), while for clinical Elekta reproducibility was clinically acceptable (<3.0%
SD for all acquisition setting). The reproducibility of the ICA data remained within 0.3% in
all cases.
The EPID dose response as a function of MU for static and ‘simple’ IMRT fields for the
research EPID are shown in figures 3.4 (a) and (b) for the Siemens Linac and figures 3.4 (c)
and (d) for the Elekta linac (experimental setup 2b and 3c from Table 3.1). In both cases
the EPID dose response for ‘simple’ IMRT fields versus static fields agreed to within 1.3%
for MU ≥2. The research EPID under-responded by 6% and 5% relative to ICA for 1 MU
per segment for Siemens and Elekta linacs respectively. At 4 MU and above the agree-
ment between research EPID and ICA response was within 3% for both Linacs. The dose
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Figure 3.3: Relative EPID response versus MU for open static and ‘simple’ IMRT fields with
fixed field size 10 × 10 cm2 for Siemens and Elekta clinical EPID systems (experimental
set up 1, 2a and 3a from Table 3.1). Data points are the ratio of EPID and ICA response for
both static and ‘simple’ IMRT fields. Error bars show the standard deviation from 5 repeat
measurements.
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Figure 3.4: Relative EPID response versus MU for open static and ‘simple’ IMRT fields
with fixed field size 10 × 10 cm2 for research EPID measured on Siemens and Elekta linacs
(experimental setup 2b and 3c from Table 3.1). Relative EPID response for clinical Elekta
EPID using XIS software (experimental set up 3b from Table 3.1). Data points are the ratio
of EPID and ICA response for both static and ‘simple’ IMRT fields. Error bars show the
standard deviation from 5 repeat measurements.
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response measured with the clinical Siemens EPID agreed closest with the dose response
measured with the research EPID with no PostBeamOff frame setting for static open fields.
The research EPID did not show the poor reproducibility seen at small MU with the Siemens
EPID (figure 3.3), confirming this was not related to the beam. The dose response measured
with the clinical Elekta EPID agrees with dose response measured with the research EPID
to within 1% for both static and ‘simple’ IMRT fields. The reproducibility of the ICA data
remained within 0.3% in all cases. Figure 3.6 depicts the EPID pixel signal collected frame
by frame at the central axis. Table 3.2 compares the integrated EPID response for single
20 MU exposure with total integrated EPID response for ‘simple’ IMRT fields for 1 MU,
2 MU, 4 MU, 5 MU and 10 MU per segments on Linac 2 and Linac 3. Table 3.2 shows
the under response persists for segmental delivery with 1 MU (≤4-6%) and 2 MU (≤2-3%)
per segment similar to static open. The under response was seen for all three post beam off
frame settings.
3.3.2 Inter-segment reproducibility
a) Central axis: Figure 3.6 depicts the integrated dose response per segment at the central
axis of the Siemens EPID and ICA for the ‘simple’ IMRT field with 5 MU per segment. The
large variations in EPID response reflect the large errors bars in figure 3.3(b). The variation
in EPID response per segment was up to ±20%. The simultaneously measured ICA did not
indicate any variation in beam delivery. Further investigation for the Siemens EPID images
found inconsistencies in the value of Nframes. The frequency of this EPID dose response
phenomenon varied depending on the MU per segment. Inter-segment reproducibility was
worst at MU per segment ≤ 5 MU, at 10 MU per segment and above the phenomena was
not observed at all and reproducibility was within 1%. The same variation in Nframes was not
present for the measurements taken with the same linac, EPID and software for open static
beam (non-segmented) delivery at any MU settings.
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Table 3.2: The integrated research EPID response at CAX for both static and ‘simple’ IMRT
fields with total of 20MU exposure. The captured frames were summed as no PostBeamOff,
three PostBeamOff, and ten post-beam-off frames for the same EPID image to demonstrate
the effect from different acquisition protocols. The percentage values in brackets indicate
the relative difference in the integrated pixel values for each simple IMRT field compared to
















































































b) Off-axis: The off–axis profiles for each IMRT segment (frame average image) along
the central row (cross-plane) and central column (in-plane) of the Siemens EPID panel and
ICA were compared for the ‘simple’ IMRT fields (figure 3.7). Some EPID cross-plane
profiles were tapered at the field edge while the in-plane profiles did not display this effect.
By comparison the profiles in both planes (experimental set-up 1 and 2a from Table 3.1)
measured simultaneously with the ICA did not show any tapering of profile shape or any
variation in amplitude acquired within segments. No such artifacts in profiles were observed
on the clinical Elekta EPIDs.
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Figure 3.5: The EPID response at CAX per frame for ‘simple’ IMRT fields (a and b) for1
MU and 5 MU per segment respectively (c) static open field (20 MU).
Figure 3.6: Relative response per segment for 5 repeats of the ‘simple’ IMRT field for EPID
(Triangle with cross-hair) and ICA (square with cross-hair) with 5 MU/segment. All the
data points are normalised to non-segmented single exposure 20 MU.
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Figure 3.7: The off–axis profiles of individual IMRT segment (frame average image) for the
‘simple’ IMRT field (4MU x 5 segments) along a) the central row (cross-plane), b) central
column (in-plane) acquired with the Siemens EPID panel and c) ICA simultaneously as
shown in figure 3.1
3.3.3 Clinical IMRT field
Figure 3.8 shows a 2D map representing the percentage standard deviation at each pixel for
both clinical EPIDs (Siemens and Elekta) and the ICA for the same ‘clinical IMRT field’
from ten sequential measurements acquired simultaneously on the two detectors (experi-
mental setup 1 and 3a from Table 3.1). The figures have been scaled and cropped to show
the same spatial extent of the IMRT field. The average percentage standard deviation of
the entire region of data shown in Figs. 3.8(a) and (b) was 3.98%(0.90%), 2.94%(0.95%),
2.34%(0.68%), and 1.55%0.17%) for the EPID (ICA) measurements with 2, 4, 5, and 10
MU per segment cases, respectively, for Siemens EPID. The average percentage standard
deviation of the entire region of data shown in Figs. 3.8(c) and (d) was 1.6%(0.90%),
1.4%(0.85%), 1.3% (0.70%), and 1.05%(0.18%) for the EPID (ICA) measurements with 2,
4, 5, and 10 MU per segment cases, respectively, for Elekta EPID. The maximum percentage
standard deviation of the entire region of data was 9.2%(3.5%), 8.1%(2.7%), 7.5%(2.2%),
and 1.9%(1.4%) for Siemens (Elekta) EPID measurements with 2, 4, 5, and 10 MU per
segment cases, respectively. The gray scale image provides a visualization of the poorer
reproducibility of the Siemens EPID measurements compared to the ICA.
3.3.4 EPID pixel-Dose calibration
To determine the ghosting correction factor, G(trad), described in the Materials and Methods
Section 3.2.5 and implemented in calibration method 1 (Eq.3.4), a curve (polynomial func-
tion) was fitted to both the Siemens and Elekta clinical EPIDs static beam exposure dose
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Figure 3.8: 2D maps of the percentage standard deviation at each pixel/detector position
within the field from ten repeats for a ‘clinical’ IMRT field with 5 MU per segment (a)
clinical Siemens EPID (c) clinical Elekta EPID and (b) and (d) for ICA detector measured
with Siemens and Elekta linac simultaneously.
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response (Fig.3.3(a) and 3.3(c)) as a function of beam-on time. The polynomial fit curve
for Siemens EPID was 4th polynomial order G(trad) = -1.02· 10-15·t4 + 1.16· 10-11·t3 - 4.97·
10-8·t2 + 9.71· 10-5·t + 0.910 where, ‘G(trad)’ is ghosting correction and ‘t’ is beam on time
in miliseconds.
The polynomial curve fitted to the Elekta EPID dose response as a function of beam-on
time with renormalization setting 0 and 4000 agreed within 1% and, therefore, the ghosting
correction G(trad) for Elekta EPID was used based on EPID dose response data acquired with
the renormalization value set to 0. The function fit was accurate within 0.5% to measured
data for beam-on time (down to 2 MU) and given by polynomial fit equation G(trad)= -1.06
x 10-12.t4 + 1.46 x 10-9.t3-6.77 x 10-5.t2 + 1.7410-3.t + 0.91.
Table 3.3: The percentage gamma pass rate determined using three different calibration
methods for both Siemens and Elekta EPIDs for the same integrated image of an IMRT
field. The IMRT fields were modified to have a fixed number of MU per segment. The
Elekta EPID images were acquired with clinical setting (i.e., renormalization set to 40,000)
and for two different PostBeamoff acquisition settings
Calibration Clinical Percentage Gamma pass rate
Methods IMRT Siemens Elekta
(MU/Segment) 2%/2 mm 3%/3 mm 2%/2 mm 3%/3 mm
















a Three PostBeamOff frames
b zero PostBeamOff frames
Table 3.3 depicts the percentage gamma pass rate for the ‘clinical’ IMRT (experimental
setup 1 and 3a from Table 3.1) when the EPID dose calculated using the method 1 (Eq.3.4)
against the EPID dose calculated using method 2 and 3 (Eq.3.5) and (Eq.3.6).
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3.4 Discussion
The dose response linearity experiments conducted in this work confirm that the nonlinear
dose response measured with static open beams at small MU persists in segmented IMRT
delivery based on the MU per segment. This validates the pixel-to-dose calibration methods
incorporating a ghosting correction on a segment-by-segment basis for IMRT dosimetry us-
ing corrections determined from open static beam exposures. The existence of gain ghosting
was confirmed as being present and consistent across different EPIDs and linear accelera-
tors at small MU exposure. Gain ghosting is associated with variations in the quantity of
trapped charge with exposure to radiation. The rate of the accumulation of trapped charge
and the rate of signal from the discharge of trapped charge slowly approaches equilibrium
with increasing dose. The close agreement between segmental IMRT and static open beam
delivery, and the fact that the static open beam fields had substantially longer time peri-
ods between subsequent exposures, supports the finding that gain ghosting affects dominate
over image lag signal from previous exposures in terms of the EPIDs nonlinear response be-
havior at small MU. The nonlinearity at small MUs was relatively insensitive to acquisition
settings. We have not investigated the impact of pulse repetition frequency (PRF). A method
of simultaneous measurements with an ICA and EPID was demonstrated to reliably separate
out the EPID dose response from beam delivery characteristics. This methodology demon-
strated an irregularity in the Siemens implementation, which resulted in poor measurement
reproducibility of IMRT fields at small MU per segment. It was also demonstrated that the
ghosting correction is not required if the EPID is calibrated at an appropriately small MU
exposure. The magnitude of underdose response reported in the present work is smaller than
some previously reported studies. This may be partly due to the fact we normalized the dose
response relative to 100 MU rather than 1000 MU used in other studies [28, 182]. In previ-
ous work [227] on Siemens linacs, we normalized to 800 MU and achieved larger underdose
response in closer agreement with other studies [28]. At 2 MU and above, the agreement
between EPID and ICA response was within 2.5% (for Elekta) and 3.5% (for Siemens). The
dose response measured with clinical EPID and the default clinical software setting shown
in figure 3.3 agreed with the research EPID dose response shown in figure 3.4. No signifi-
cant difference (≤ 1%) was observed in dose response for both the static and ‘simple’ IMRT
fields measured with the clinical Elekta EPID under different PostBeamOff frame acquisi-
tion settings. This demonstrates that nonlinearity at small MUs was relatively insensitive
to acquisition settings and across different EPID detectors. The poor reproducibility for the
Siemens EPID in the case of ‘simple’ IMRT fields was not observed either with simulta-
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neous measurement conducted with ICA or with the standalone research EPID (Fig. 3.4).
There were particularly large variations in the integrated Siemens EPID response between
successive segments having 2, 4, and 5 MU per segment, as shown in Fig.3.6. Intersegment
reproducibility was worst at MU per segment ≤ 5MU for Siemens EPIDs and occurs in a
nondeterministic manner. This was attributed to an inconsistent number of frames per seg-
ment being recorded in the image header file. The vendor documentation indicates that the
frame number is derived using Eq.3.1. This equation appears to be independent of actual
delivery parameters that may affect the real number of frames acquired, such as real dose
rate variations, and should therefore not vary for a given MU per segment. The variation
in integrated EPID response was not seen for static beam (non-IMRT) exposures on the
same linac. We also observed the tapered shape or variation in amplitude acquired within
segments for ‘simple’ IMRT fields in case of Siemens EPID only. This variation in ampli-
tude may be due to the synchronization between linac trigger pulse (beam-on and beam-off)
and detector control board incorporating the real-time dose-rate variation, particularly for
segment IMRT delivery. The experiment performed on both Siemens EPIDs (experimental
setup 1 and 2a from Table 3.1) shows inconsistent reporting of frame number in the header
file, suggesting that it is an issue with Siemens image acquisition systems for segmented
delivery. Moreover, Podesta et al. [221] modeled the discrepancies in Siemens clinical
EPID dose response up to 37% at 1 MU and 20% at 2 MU. The author validated that these
variations are associated with acquisition readout scheme (i.e., missing frames). We have
not addressed the additional scatter or spectral corrections that can be applied to account for
patient transit or MLC transmission effects [28, 228]. Dynamic MLC and VMAT were not
available for this study, and further work is required to determine how these results apply
to that setting. The dose linearity response reported in this study is only at 6 MV. The dose
linearity at 18 MV in our previous study [227] for Siemens EPID was within 2% compared
to 6 MV beam at ≥ 1MU. Winkler et. al. [183] also reported the EPID dose response for 6,
10, and 25 MV photons with an Elekta system and confirmed the dose linearity of the EPID
did not depend on energy. The ghosting correction suggested by McDermott et al.[181] and
Nijsten et al. [28] was designed to keep the EPID measured dose accuracy at lower MUs
within approximately 1%. The ghosting correction factor was determined as a function fit
to a dose-response curve that ranged from 5 MU to 1000 MU, normalized to 1000 MU. This
range of MU does not reflect clinical step and shoot IMRT technique which may be deliv-
ered with fewer than 5 MU per segment and is rarely delivered with more than 30 MU per
segment for conventional dose fractionation as demonstrated by previous work [229]. We
selected 20 MU for calibration in our study for two reasons: i) the mode value for maximum
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MU per segment in most of IMRT fields is nominally 20 MU [229]; and ii) linac output is
relatively more stable after 20 MU is delivered. However based on the dose-response curve
in 3.3(a) and 3.3(c), in principle, calibration value at 4 or 5 MU can be used, provided the
linac output is stable. Ghosting and image lag corrections are complex to implement accu-
rately on a pixel-by-pixel basis due to the variations in time between segments and variation
in dose per segment. For step and shoot delivery, based on our results, we can conclude that
adding a ghosting or image lag correction is an unnecessary complication for accurate EPID
based IMRT dosimetry.
3.5 Conclusion
The EPID dose response behavior for step and shoot IMRT fields delivered by Siemens and
Elekta linacs was investigated. The nonlinear EPID dose response as a function of MU
measured for single open beam exposures was found to be consistent with dose response for
segmented IMRT delivery. The nonlinear dose response was consistent across both clinical
EPIDs and the standalone research EPID, with the exception of the poor reproducibility
seen with Siemens EPID images of IMRT fields. The nonlinear dose response was relatively
insensitive to acquisition settings and appears to be primarily due to gain ghosting affects
in the a-Si photodiodes. When the pixel-to-dose calibration factor was determined at 20
MU, no additional ghosting correction factor was necessary for the accurate determination
of dose for clinical IMRT fields.
Chapter 4
Feasibility study of a dual detector
configuration concept for simultaneous
megavoltage imaging and dose
verification in radiotherapy
Statement of joint authorship
S. Deshpande: Develop experimental design, performed experiments, analysed results,
wrote manuscript
L. McNamara: Matlab scripting and analysed results
L. Holloway: Assisted with strategic implementations of the experiments and with publica-
tion submission.
P. Metcalfe: Assisted in interpreting results and writing, as supervisor he endorses the as-
sessment
P. Vial: Render advice on the experiment, interpreting results and write up
‡Part of this chapter has been published:
S. Deshpande, L. McNamara, L Holloway P Metcalfe, P Vial. Feasibility study of a dual detector configu-





Treatment verification has two important roles in radiotherapy: (i) to mitigate mistreatments
that result in adverse patient outcomes (patient safety); and (ii) to optimize treatment out-
comes by ensuring accuracy (treatment accuracy). Ensuring patient safety and treatment
accuracy requires techniques to verify both patient and target location (geometry) and the
dose delivered. Current and emerging technologies in radiotherapy are increasingly sensitive
to geometric errors, and verifying the delivered dose is increasingly challenging. To address
the increasing demands on geometric accuracy, the use of imaging for treatment verifica-
tion has developed rapidly in recent years [102]. Image guided radiotherapy (IGRT) aids
in tracking daily treatment setup to minimize geometric error. Verifying dose accuracy for
modern treatments such as intensity-modulated radiation therapy (IMRT) typically relies on
pretreatment dose measurements. However, pretreatment measurements are time consum-
ing and do not necessarily identify clinically relevant errors in dose delivery that may occur
during the course of treatment. These factors are driving a growing demand for effective in
vivo dose verification [118, 119]. All medical linear accelerator (Linac) vendors currently
provide amorphous silicon (a-Si) electronic portal imaging devices (EPIDs) as a standard
IGRT option [180]. Although previous studies [23, 28, 30, 118, 198] have demonstrated
the EPID’s potential as an in vivo dosimeter, the routine use of EPIDs for in vivo dosime-
try remains generally limited to a few centers who have invested significant resources into
developing in-house systems [28–30, 32, 198, 230]. The nonwater-equivalent response of
EPID (optimised for imaging purpose) remains one of the limiting factor for implementing
EPID as a dosimeter in routine clinical practice [26, 38]. Previous studies reported that
with modifications the current commercial EPID design can be a water-equivalent dosime-
ter, [38–40, 206] albeit with a significant reduction in imaging performance [38]. Recently,
our group introduced a new prototype EPID design that has the potential for simultaneous
imaging and dose verification with a single detector [40]. More efficient detector designs
have also been proposed for improved megavoltage (MV) imaging performance [36, 231].
These efficient MV detectors generally consist of higher atomic number materials than cur-
rent EPIDs, which is likely to make EPID dosimetry even less water- equivalent and still
more difficult to implement. Another consideration is that the increasing utilization of in-
room kV imaging systems for IGRT may reduce the imaging role of MV EPIDs. Other
possible approaches to in vivo dose verification include (i) the use of transmission dosime-
try devices mounted onto the head of the linear accelerator [154, 159] (ii) the use of 2D
dosimetry devices which are typically used for pretreatment QA [174, 175], and (iii) the
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analysis of the delivery system computer log files [232, 233] of machine states. The linac
log files do provide measured MLC positions and not the measured estimate of fluence. Pre-
vious study [234] demonstrated the discrepancy between the reported MLC position by log
files and image based measured actual MLC position. This highlighted the limitations of
using linac log file to reconstruct delivered dose. Point detectors that are placed onto the
patient during treatment have some special applications but may be inadequate as a general
solution for in vivo dosimetry in modern radiotherapy [118, 235]. In this study, we propose
a new dual detector design to address the limitations in radiotherapy treatment verification
described above. To the best of our knowledge, this dual detector concept has not been pre-
viously reported. The proposed dual detector combines imaging and dose detectors in series
at the EPID position. The clinical application of this system requires that performance of
both the dosimeter and imager is not significantly degraded in the dual detector configu-
ration. Preliminary work indicated that a commercially available ionization chamber array
(ICA) maintains accurate water-equivalent dose response when positioned directly under an
EPID [226]. However, it is known that EPID response and image quality is influenced by
backscatter which is dependent on the configuration of materials immediately behind the
detector [236, 237]. In this study, we investigate the clinical feasibility of a dual detector
configuration with a comprehensive experimental assessment. The imaging performance of
the EPID and the dose response characteristics of the ICA in the dual detector configuration
are compared against their respective standalone (reference) configurations.
4.2 Methods and Materials
4.2.1 Equipment
The dosimetry equipment used in this study consisted of a commercial ICA, called the
I’mRT MatriXX (IBA dosimetry, Schwarzenbruck, Germany). The MatriXX ICA is a 2D ar-
ray of ionization chambers with accompanying OmniPro-I’mRT software (version 1.6, IBA
dosimetric, Schwarzenbruck, Germany). This device has an array of 1020 air-vented plane
parallel ionization chambers (with a volume of 0.08 cm3 each) arranged in a 32 × 32 grid
providing a maximum field of view of 24× 24 cm2. The ionization chambers are 4.5 mm in
diameter and are spaced at 7.62 mm center-to-center. All measured ICA data were interpo-
lated down to 1 mm resolution by applying the user selectable ‘Cubic Spline’ interpolation
algorithm option available in the OmniPro I’mRT software. Previous work [39] validated
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the accuracy of cubic spine interpolation implemented in OmniPro I’mRT software. The
detector has 3.3 mm water equivalent inherent buildup. A solid water slab was used as
an additional water equivalent buildup and backscatter material (Gammex RMI, Middleton,
WI). The imaging detector used was an a-Si EPID (XRD 1640 AN CS PerkinElmer, Santa
Clara, CA), and the imaging data were collected using XIS software V3.3.1.1 (PerkinElmer,
Santa Clara, CA) using a 399 ms frame period. The EPID consists of a 40 × 40 cm2 a-Si
photodiode array and comprises 1024 × 1024 pixels, giving a pixel pitch of approximately
0.4 mm. A QC-3V image quality phantom and Pips-Pro software (version 3.2.3a, Stan-
dard imaging, Inc., Middleton, WI) were used to assess image quality. A purpose built line
spread function (LSF) apparatus was also used to determine the EPIDs modulation transfer
function (MTF). All experiments were conducted on an Elekta Synergy linear accelerator
(Elekta Oncology Systems, Crawley, UK) with 6 MV photons at gantry 900. All the clinical
IMRT fields were planned as step and shoot IMRT fields on the Pinnacle treatment planning
system (Philips Radiation Oncology Systems, Fitchburg, WI Version 9.0).
4.2.2 Dosimetry experimental setup
The dose measurements were performed in both nontransit and transit geometries. The non
transit dose measurements were performed with the detector plane at the isocenter (100 cm
source-to-detector distance) with no object in the beam ( Figs. 4.1(a) and 4.1(b)). The tran-
sit dose measurements were performed at an extended 145 cm source-to-detector distance
with sheets of solid water or an anthropomorphic phantom (ATOM® Dosimetry Verifica-
tion phantoms, CIRS) positioned on the treatment couch and centered at the isocenter ( see
Figs.4.1(c) and 4.1(d)). The ICA was calibrated to dose as per the manufacturer guidelines
in the reference dosimetry configuration (nontransit geometry). We assessed if a common
calibration could be used for both transit and nontransit dosimetries by comparing mea-
surements against reference ion chamber measurement (Roos® Plane-Parallel Ion chamber,
PTW Freiburg, Germany). All the dose measurements were performed with the ICA in both
reference dosimetry configuration and dual detector configuration as described below.
4.2.2.1 Reference dosimetry configuration
The reference dosimetry configuration comprised of the solid water slab equal to water
equivalent reference depth (Deff) as buildup placed on the ICA (Figs.4.1(b) and 4.1(d)). An
additional 5 cm solid water backscatter material was added to ensure full scatter conditions.
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Figure 4.1: Schematic illustration for dosimetry measurement setups (a) dual detector con-
figuration (nontransit) (b) reference dosimetry configuration (nontransit) (c) dual detector
configuration (transit) (d) reference dosimetry configuration (transit). For transit geometry
measurements, either the solid water slab or anthropomorphic phantom (interchangeable)
was used. For visualization purpose, only the anthropomorphic phantom image is shown
((c) and (d)) placed at isocenter.
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Deff was determined as described in section 4.2.3.1. Measurements with the ICA in the refer-
ence dosimetry configuration were used in both the transit (Fig. 4.1(d)) and non-transit (Fig.
4.1(b)) geometries as the reference for dose response to which the dual detector configura-
tion was compared. The water-equivalence of the ICA dose response has been extensively
validated in both transit and nontransit geometries [155, 206, 238]
4.2.2.2 Dual detector configuration
The dual detector configuration consisted of an EPID (closest to the source), 2 cm solid
water, the ICA, and 5 cm solid water backscatter material. The 2 cm of solid water between
the EPID and ICA was necessary to fill the air gap between the two devices ( see Fig.4.1(a)
and 4.1(c)). Section 4.2.3 describes the experiments used to compare the dose response
of the ICA in the dual detector configuration with the reference dosimetry configuration
(described above).
4.2.3 Dose response evaluation
4.2.3.1 Estimation of water equivalent reference depth (Deff)
The water equivalent reference depth, (Deff) was defined as the depth at which the measured
central axis (CAX) dose and dose profiles showed the closest agreement between the refer-
ence dosimetry configuration and dual detector configuration (at the same source-to-detector
distance). In other words, Deff is the water equivalent thickness of the buildup material on
top of the ICA in the dual detector (Fig. 4.1) configuration. The CAX dose and dose pro-
files were measured with 10 × 10 cm2 open fields measured with different thicknesses of
solid water placed on the ICA (in 1 cm increments) in the nontransit reference dosimetry
configuration (as defined in Sec. 4.2.2.1). To further validate Deff, field size output factors
and transmission factors were measured with varying thickness of solid water buildup in the
reference dosimetry configuration and compared with dual detector configuration measure-
ments. The value of Deff was determined in the nontransit geometry and validated in the
transit geometry to confirm agreement. Finally, Deff was also calculated using the effective




(∆di) · (ρi) (4.1)
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where Deff is the water equivalent reference depth (Deff) and ∆di and ρi are the thickness
and relative electron densities of each different layer of buildup material (EPID layers plus
2 cm solid water slab), respectively, in dual detector configuration. Detailed dimensions
and material compositions of the EPID were obtained from the manufacturer (PerkinElmer,
Santa Clara, CA).
Subsequent clinical IMRT fields dose measurements (Sections 4.2.4.2, 4.2.4 and 4.2.4.1)
undertaken using the dual detector configurations were compared to reference measurements
conducted at Deff. The Deff depth used in reference configuration for clinical IMRT field dose
verification was arrived at through basic dose response measurements (Sections 4.2.3.2 and
4.2.3.3).
4.2.3.2 Field size output factor and off-axis response
The field size output factor for square field sizes varying from 3 × 3 to 20 × 20 cm2 was
determined from the ratio of the ICA response at CAX relative to a 10 × 10 cm2 field for
nontransit and transit geometries. The dose profile and off-axis response were measured for
a 5 × 5 cm2 and the maximum available field size with both dual detector configuration and
reference dosimetry configuration in nontransit and transit geometries. The maximum field
size of 20 × 20 cm2 in nontransit and 15 × 15 cm2 in transit geometries was used to avoid
unnecessary exposure of electronics to the x-ray beam.
4.2.3.3 Transmission factors
Transmission factors measured in the transit geometry were calculated using static fields
of 15 × 15 cm2 (defined at the isocenter). Sheets of solid water were positioned on the
treatment couch to create a homogeneous transit object with thicknesses ranging from 0 to
25 cm in 5 cm increments and centered about the isocenter. Transmission factors were then
calculated by dividing the CAX response measured with ICA to the value obtained with
no solid water in the beam (for same the MUs). The transmission factors measured in the
reference dosimetry configuration and dual detector configuration were compared.
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4.2.4 IMRT fields
The following clinical dosimetry measurements were performed using the ICA. In-house
developed MATLAB code (version: 7.10.0.499 (R2010a), Mathworks, Inc., MA) was used
for data processing and comparison. The gamma evaluation technique [240] was applied
to quantitatively compare the 2D dose maps measured with the calibrated ICA. Gamma
criteria used was 2% dose difference (relative to the maximum dose) and 2 mm distance-to-
agreement, with doses below10% of the maximum dose excluded from the evaluation.
4.2.4.1 Nontransit geometry
A total of five step and shoot IMRT fields including, three test patterns (two wedge-shaped
and one pyramid-shaped pattern) and two complex head and neck IMRT beams were mea-
sured in the nontransit geometry.
4.2.4.2 Transit geometry
Seven prostate step and shoot IMRT fields and three IMRT test patterns (as above for the
nontransit geometry) were measured with a 20 cm thick solid water slabs in the beam. The
20 cm of solid water was centered symmetrically about the isocenter. In addition, seven
head and neck, five brain, four lung, and seven prostate IMRT fields were measured with an
anthropomorphic phantom placed in the beam at isocenter (see figs.4.1(c) and 4.1(d)).
4.2.5 Imaging experimental setup
The impact that backscatter material present in the dual detector configuration has on the
imaging performance of the EPID was evaluated quantitatively and qualitatively. Similar to
the dosimetry evaluation, the EPID’s imaging performance was experimentally evaluated by
comparison of the image quality in a reference imaging configuration and the dual detector
configuration as described below. All the image quality measurements discussed in section
4.2.6 for both configurations were performed with a source to detector (imager) distance of
144 cm as shown in Fig.4.2
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4.2.5.1 Reference imaging configuration
The reference imaging configuration represents the EPID in standalone mode as routinely
used (i.e. without the presence of any additional buildup or backscatter material Fig 4.2(c)
and 4.2(d) ) .
4.2.5.2 Dual detector configuration
The dual detector configuration is as described in section 4.2.2.2.
4.2.6 Image quality evaluation
4.2.6.1 QC-3V image quality phantom
The PipsPro QC-3V image quality phantom and software were used to compare the EPID
spatial resolution and contrast to noise ratio (CNR) in the dual detector configuration and
reference imaging configuration. The phantom was placed on its side on the treatment couch
and positioned using the external alignment marks at the isocenter. EPID images of the
phantom were acquired using 1 frame (4 MU, or a dose of approximately 0.6 cGy at a
detector plane) in the reference imaging configuration and dual detector configurations. The
low dose levels used here are similar to those typically used for pre-treatment portal imaging.
Details on the algorithms used to calculate CNR, MTF and noise using PipsPro software can
be found in the literature [241].
4.2.6.2 LSF and MTF
The MTF was also determined using an angled slit technique. A purpose built LSF ap-
paratus with slit angle set to 40 was used for MV image quality experiments. Technical
considerations for this method can be found in previous studies [242, 243]. The LSF ap-
paratus employs two machine-surfaced tungsten blocks, each block having a thickness of
17.5 cm, height of 11.5 cm, and length of 8 cm, determined from previous investigations to
be suitable for achieving accurate results at MV energies [242–244]. The tungsten blocks
were mounted on a stage that allowed the blocks to be translated and rotated (Fig. 4.3) for
alignment of the slit (approximately 80 µm wide) with the radiation beam. The tungsten
blocks were positioned as close as possible to the EPID as shown in Figs. 4.2(b),4.2(d), and
4.3.
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Figure 4.2: Schematic of the experimental setup for image quality evaluation. Anthropo-
morphic phantom images were acquired for the (a) dual detector configuration and (c) ref-
erence imaging configuration. MTF measurements were performed for the (b) dual detector
configuration and (d) reference imaging configuration.
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Figure 4.3: Experimental setup for measurement of LSF. The tungsten blocks are mounted
on a translating and rotating stage as close to EPID as possible.
The EPID images acquired were frame averaged, each consisting of 50 frames (170 MU).
The composite oversampled LSF was obtained as follows: a region of interest over the slit
image was selected spanning approximately 20–30 rows. Due to the angle of the slit, each
row profile is progressively shifted by a small spatial increment with respect to the previous
row. Each row was shifted by the subsampling distance determined by the angle of slit, and
summed over each column. For further details, the reader is referred to Fujita et al.[245].
The MTF was then calculated from the modulus of the Fourier transform of the normalized
LSF, where the normalization was to the unit area under the LSF. EPID images of the slit
for both reference imaging configuration and dual detector configuration were acquired.
4.2.6.3 Anthropomorphic phantom
Images of an anthropomorphic head phantom were acquired to qualitatively evaluate the
performance of the EPID in the dual detector configuration and reference imaging config-
uration when imaging an object representative of human anatomy. With the gantry angle
at 900, the head phantom was positioned facing the source on the treatment couch and was
centered at the isocenter (see Figs. 4.2(a) and 4.2(c)). For each EPID configuration, an an-
terior posterior (AP) image of the phantom was acquired by one frame (4MU or a dose of
approximately 0.6 cGy at the detector plane).
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4.3 Results and Discussion
4.3.1 Dose response evaluation
4.3.1.1 Estimation of water equivalent reference depth (Deff)
The calculated Deff using (Eq. 4.1) was 6.05 cm. The measured 10 × 10 cm2 open field
CAX dose and dose profiles with the dual detector configuration showed the best agreement
with the reference dosimetry configuration measurement at solid water buildup depth of 6.0
cm (Fig. 4.4 ). This result was consistent in both the transit and nontransit geometries
and agreed with calculation (Eq. 4.1) to within 0.5 mm. Therefore, Deff was determined
to be 6.0 cm for all configurations. The sensitivity of CAX dose versus depth at Deff was
approximately 0.3%/mm.
4.3.1.2 Field size output factor and off-axis response
Figures 4.5(a) and 4.5(b) show the field size output factor measured with the dual detector
configuration and reference dosimetry configuration at varying buildup depths, in nontran-
sit and transit geometries, respectively. Field size output factors measured with the dual
detector match within 0.8% to those measured with the reference dosimetry configuration
at buildup depth 6 cm (Deff). Consistent with results described in Section 4.3.1.1, the best
agreement with dual detector field size output factors was achieved with 6 cm buildup. The
detector response at positions away from the central axis of the x-ray beam is shown in Fig.
4.6 for the dual detector configuration and reference dosimetry configuration in nontransit
and transit geometries. The maximum percentage difference in beam profiles between the
dual detector configuration and reference dosimetry configuration was ≤2.5% in both non-
transit and transit geometries (inside the radiation field). The noise for field size 5 x 5 cm2
seen in figure 4.6(b) could be associated to slight offset of the detector position from central
axis while changing the setup.
4.3.1.3 Transmission factors
Transmission factors measured with both the dual detector configuration and reference dosime-
try configuration in transit geometry are shown in Fig. 4.7. Transmission factors measured
with the dual detector configuration match within ≤ 0.5% to those measured with the refer-
4.3. Results and Discussion 60
Figure 4.4: Comparison of (a) nontransit geometry and (b) transit geometries, ICA measured
dose profiles in reference dosimetry configuration at buildup depths of 4, 5, 6 cm (Deff), 7
and 8 cm of solid water slab with the dual detector configuration. The relative ratio between
dose profiles measured at varying buildup depths in reference dosimetry configuration to the
dose profile measured with dual detector configuration is also shown for (c) nontransit and
(d) transit geometries, respectively.
4.3. Results and Discussion 61
Figure 4.5: Comparison of (a) nontransit geometry and (b) transit geometries, ICA measured
field size output factors in reference dosimetry configuration at buildup depths of 4, 5, 6 cm
(Deff), and 7 and 8 cm of solid water with the dual detector configuration. The relative
ratio between field size and output factors measured at varying buildup depths in reference
dosimetry configuration to dual detector configuration is also shown for (c) nontransit and
(d) transit geometries, respectively.
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Figure 4.6: Comparison of relative dose profiles in the (a) nontransit and (b) transit ge-
ometries measured with the ICA in the dual detector configuration and reference dosimetry
configuration for 5×5 cm2 and maximum achievable field sizes within the respective mea-
surements geometries. The relative ratio between the two configurations is shown for (c)
nontransit and (d) transit geometries.
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ence dosimetry configuration at 6 cm (Deff).
4.3.2 IMRT
4.3.2.1 Non-transit geometry
The gamma evaluation results for the absolute dose maps of IMRT fields measured with ICA
in the dual detector configuration and reference dosimetry configuration in the nontransit
geometry are presented in Table 4.1. In all cases, the pass rates were greater than 99%,
indicating a very close agreement between detector configurations. Figure 4.8 shows the
almost indistinguishable dose profiles of a wedge IMRT pattern measured with the ICA in
the dual detector configuration and reference dosimetry configuration.
Table 4.1: Gamma evaluation results comparing the absolute dose map with ICA in dual
detector configuration and reference dosimetry configuration for clinical IMRT fields and
standard IMRT test patterns in nontransit geometry








The Gamma evaluation results for the ICA absolute dose map with the dual detector con-
figuration and reference dosimetry configuration in head and neck, brain, lung, and prostate
IMRT fields with anthropomorphic phantoms and solid water slab phantom placed in the
beam are presented in Table 4.2. The mean pass rates, averaged over all fields in the indi-
vidual plans were greater than 98% including IMRT standard test patterns (data not shown),
indicating a very close agreement between detector configurations in the transit geometry.
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Figure 4.7: Comparison of transmission factors measured with the dual detector configura-
tion at buildup depths of 4, 6, 8 cm, and reference dosimetry configurations, respectively.
The measurements were performed with static fields of 15×15 cm2 defined at the isocenter.
The relative ratio of transmission factors for reference dosimetry and dual detector configu-
rations is also shown (b).
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Figure 4.8: Dose profile comparison for wedge IMRT test pattern measured with both refer-
ence dosimetry and dual detector configurations. The ratio of the dose profiles is displayed
in the insert.
Table 4.2: Gamma evaluation results comparing the ICA absolute dose map from the
dual detector configuration and reference dosimetry configuration using anthropomorphic
or solid water slab phantoms, and IMRT fields
Head and Necka Braina Lunga Prostatea Prostateb
Field Percentage gamma pass rate (2% and 2 mm criteria)
1 98.1 97.66 100 97.95 99.5
2 100 100 97.6 100 99.2
3 96.5 99.5 100 100 99.8
4 100 100 100 98.2 100
5 100 100 98.2 99.3
6 100 100 99.1
7 97.6 96.32
Mean 98.8 99.43 99.39 98.59 99.5
a Measurement with anthropomorphic phantom in the beam.
b Measurement with solid water slab phantom in the beam.
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The above dose response evaluation demonstrates that integrating the ICA with the EPID
in the dual detector configuration had no significant impact on dose response over a wide
range of clinically relevant conditions once the equivalent depth is accounted for. The dose
response of the ICA was not sensitive to the non-water equivalent layers of material of the
EPID (e.g., the thin metal screen that sits on top of the phosphor scintillator). The EPID is
known to be materially homogeneous in the direction perpendicular to the beam, and this is
an important requirement for the dosimetry aspect of the dual detector concept. As the ICA
can acquire and report data frame by frame in real-time, it could, in principle, be used for
time resolved dose verification during IMRT or volumetric modulated arc therapy (VMAT)
[201, 246] in the dual detector configuration. The development of a clinical dosimetry model
is beyond the scope of this work. Many models for implementing the transit in vivo dosime-
try with EPIDs have been demonstrated and continue to be developed.It is anticipated that
any of these published EPID based models could be adapted for use with a water equivalent
dosimeter and implemented with more reliable dosimetry based on standard dose in water
models.
4.3.3 Image quality evaluation
4.3.3.1 QC-3V image quality phantom
The spatial resolution (determined by the spatial frequency at half the maximum MTF (f50)),
noise, and CNR measured using the PipsPro QC-3V image quality phantom and software
in the reference imaging configuration and dual detector configuration are shown Table 4.3.
The presence of additional backscatter material decreases CNR in the dual detector con-
figuration. Figure 4.9 shows the images of the QC-3V image quality phantom taken with
the EPID in the reference imaging configuration and dual detector configuration. While the
resolution and CNR reported by the PipsPro software was better for the reference imag-
ing configuration, there is no appreciable difference in the visual perception of high or low
contrast detail between the two configurations.
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Figure 4.9: EPID images of the QC-3V image quality phantom taken with the (a) reference
imaging configuration and (b) dual detector configuration.
Table 4.3: Comparison of resolution, noise, and CNR for the dual detector configuration
and reference imaging configuration. The results are quoted as mean ± standard deviation
from five repeat measurements
EPID configuration Resolution(f50)(lp/mm) Noise CNR
Dual detector
configuration
0.40 ± 1.25×10−3 14.94 ± 3.34 263.23 ± 24.85
Reference configuration 0.41 ± 1.14×10−3 7.81 ± 1.57 324.01 ± 26.65
4.3.3.2 LSF and MTF
Figure 4.10 compares LSFs measured in the dual detector configuration and reference imag-
ing configuration as described in section 4.2.6.2. The FWHM for the reference imaging con-
figuration and dual detector configuration matches very closely (0.075 mm difference). The
LSF for the dual detector configuration becomes increasingly wider compared to the refer-
ence imaging configuration below approximately 10% of the peak signal. This is consistent
with signal blurring from the additional broad angle backscatter, due to the presence of the
solid water and ICA in the dual detector configuration. Figure 4.11 compares the MTFs
derived from the measured LSFs in Fig. 4.10. The measured spatial frequency at half the
maximum MTF (f50) was 0.14 mm-1 and 0.12 mm-1 for the reference imaging configuration
and dual detector configuration, respectively. The kink in MTF curve at approximately 0.8
mm-1 which could be the combination of both analysis approach and slight setup variation
while switching from reference configuration to dual detector configuration measurement.
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Figure 4.10: The measured line spread function (normalized) for the reference imaging
configuration and dual detector configuration.
Figure 4.12 compares the relative pixel sensitivity for an open static 5× 5 cm2 field acquired
in both configurations. The increase in EPID signal with the dual detector configuration is
an approximately uniform 2%–3% across the image due to the contribution of additional
backscatter signal from the solid water and ICA. The characteristics of the backscatter ef-
fect on EPID signal seen here are consistent with that reported previously [204]
4.3.3.3 Anthropomorphic phantom
AP projection images of an anthropomorphic head phantom acquired using the reference
imaging configuration and dual detector configuration are shown in Fig. 4.13. The images
from the two configurations show no discernible difference in the visualization of anatom-
ical details. The qualitative and quantitative imaging results reported above demonstrate
that while the presence of the additional backscatter material had a measurable effect on
EPID imaging performance (see Table 4.3), the effect was not visible in qualitative image
comparisons (see Figs. 4.9 and 4.13) and is considered negligible for clinical purposes. Fur-
ther study is required to assess the dual detector imaging performance comprehensively in a
clinical setting.
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Figure 4.11: The measured modulation transfer function for the reference imaging configu-
ration and dual detector configuration.
Figure 4.12: Illustration of impact of backscatter in dual detector configuration: (a) Rel-
ative line profile of EPID images of an open static field for dual detector configuration
(dashed–dotted line) and reference imaging configuration (solid gray line). (b) 2D pixel
value relative ratio map between reference imaging configuration and dual detector config-
uration for static open 5 × 5 cm2 field.
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Figure 4.13: Portal image of anthropomorphic head phantom acquired with the (a) refer-
ence imaging configuration and (b) dual detector configuration to assess the impact of the
presence of the ICA on portal image visualization.
4.3.4 Optimized dual detector design
In this study, we used readily available equipment to demonstrate the feasibility of the dual
detector concept. The measured dose was offset by 1.3% at CAX and both the field size
and transmission factor by <0.5% when 5 cm backscatter was removed in the dual detector
configuration. This suggests the required backscatter material thickness could be further
optimized for dosimetric purposes. Figures 4.10 and 4.11 compares the measured LSF and
MTF for dual detector configuration (5 cm solid water plus ICA) and reference imaging
configuration (without backscatter material). It is demonstrated that the difference is due
to the presence of backscatter material. These are two extreme scenarios. The backscatter
material thickness optimized for dosimetric purpose will further improve the imaging per-
formance. It is envisaged that a more elegant design could be easily achieved based on the
same concept but with a purpose built configuration to optimize performance. An optimized
dual detector may incorporate different imaging or dosimetry detectors to those used in this
study. For example, a more efficient imager consisting of high atomic number segmented
crystalline scintillators [35, 36, 231, 247] could be incorporated without compromising dose
verification capability as long as the sensitive detector of the overlying EPID is materially
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Figure 4.14: Schematic illustration of conceptual optimized design (RHS) for dual detec-
tor that fits within the existing standard EPID (LHS) panel dimensions.Schematics are not
drawn to scale, and the gaps located between the neighboring layers are for illustrative pur-
poses only.
homogeneous in a direction perpendicular to the beam. A smaller detector spacing on the
dose detector for higher resolution dosimetry with higher signal to noise ratio would also be
desirable for modulated fields and improved characterization of high dose gradient regions.
Figure 4.14 shows a schematic diagram of a possible dual detector design that fits within the
size of existing EPID panels. A water-equivalent depth equal to the depth of dose maximum
for the highest photon energy being used would be adequate for dosimetry with all photon
energies.The dimensions shown in Fig. 4.14 would be suitable for a Linac delivering up
to 18 MV photons. The total dimensions of the dual detector in Fig. 4.14 are compatible
with existing Perkin Elmer EPID panels and should, therefore, be compatible with existing
Linac EPID housings. Additional considerations not investigated in this study include the
engineering requirements of the mechanical support and the configuration of electronics and
data readout schemes required to implement the proposed dual detector configuration.
This study demonstrates proof-of-concept of a novel dual detector for radiotherapy treat-
ment verification. Current EPID detectors are optimized for imaging but are suboptimal for
dosimetry. The proposed dual detector concept decouples the imaging and dosimetry func-
tions so that each can be optimized without significantly compromising the other, providing
more flexibility for future improvements in radiotherapy treatment verification systems.
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4.4 Conclusion
The proposed dual detector configuration, combining a conventional EPID and 2D array
dosimeter, can be operated simultaneously as both imager and dosimeter without significant
compromise in the performance of either device. This study demonstrates the feasibility
of a dual detector configuration device for simultaneous imaging and in vivo dosimetry in
radiation therapy.
4.5 Acknowledgments
The authors report no conflicts of interest in conducting the research. The authors would
like to acknowledge the funding support from the Cancer Institute NSW Australia (Research
Equipment Grant 10/REG/1-20) and Cancer Council NSW (Grant ID RG 1-06).
Chapter 5
Novel dual detector concept for
simultaneous transit dose and image
verification in radiotherapy
Statement of joint authorship
S. Deshpande: Develop experimental design, performed experiments, analysed results,
wrote manuscript
S. Alhujaili and O. Brace: Assisted with experiments
P. Vial and L. Holloway: Render advice on the experiment, interpreting results and write
up
M. Petasecca M.Lerch: Assisted with experiments and interpreting results
A. Rosenfeld and P. Metcalfe: Assisted in interpreting results and writing, as supervisors
both of them endorse the assessment
‡Part of this chapter has been submitted for publication:
S. Deshpande, S. Alhujaili, O Brace, P. Vial, L. Holloway, M, Petasecca, M.Lerch, A. Rosenfeld, P. Met-
calfe, Silicon array dosimeter in situ with electronic portal image device for simultaneous transit dose and




Currently, radiation therapy (RT) is trending toward more precise and accurate dose de-
livery, which employs radiation beam intensity modulation and image guidance for target
positioning either on-line or in real time. Emerging techniques are increasingly sensitive
to geometric errors and verifying the delivered dose is increasingly challenging. Therefore,
a comprehensive treatment verification system should have the capability of verifying both
geometric (i.e. location of target in real time) as well as dosimetric accuracy (i.e. correct
quantity of dose delivered) to ensure the delivered dose matches the prescribed dose. To
address the increasing demands on geometric accuracy the use of imaging for treatment ver-
ification has developed rapidly in recent years [102]. Image-guided radiotherapy (IGRT)
aids in tracking daily treatment setup to minimize geometric error.
The kilovoltage (kV) imaging devices attached to the linac providing a superior soft tissue
contrast have improved patient and target position verification prior to treatment. They do
not utilise the treatment beam and therefore do not directly verify the treatment delivery in
real-time or/and may not be done routinely. Verifying dose accuracy for modern treatments
such as intensity-modulated radiation therapy (IMRT) typically relies on pre-treatment dose
measurements. However, pre-treatment measurements are time consuming and do not nec-
essarily identify clinically relevant errors in dose delivery that may occur during the course
of treatment. These factors are driving a growing demand for effective in- vivo dose verifica-
tion [61, 119]. All medical linear accelerator (linac) vendors currently provide amorphous
silicon (a-Si) electronic portal imaging devices (EPIDs) as a standard IGRT option [23].
These standard EPIDs are optimised for imaging but are suboptimal for dosimetry due non-
linear energy dependence [25–27, 189, 248]. Several groups have developed methods to
account for energy response, either with complex algorithms or Monte Carlo computations
[25, 28–34] to utilise the standard EPID as a dosimeter. Despite the demonstrated potential,
the clinical implementation of EPID dosimetry still limited to a relatively small number of
centres.
Further, the changes in EPID technology over recent decades have not been driven by the
technical demands of dosimetry, but by the need for improved imaging standards for patient
positioning, such as enhancement in image quality and faster read-out. More sensitive detec-
tor designs have also been proposed for improved megavoltage (MV) imaging performance
[35, 36]. These efficient MV detectors generally consist of higher atomic number materi-
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als than current EPIDs, which is likely to make EPID dosimetry even less water equivalent
and still more difficult to implement. A small body of research explores novel EPID design
specifically to act as dosimeters rather than imagers [27, 37–39]. The former scenario i.e.
dosimetry with standard EPID typically necessitates a complex detector characterisation
and calibration scheme along with custom software to convert portal images into water-
equivalent dose images, an approach undertaken in majority of previously reported studies
on EPID dosimetry [23]. The latter scenario has seen detector prototypes that, while capable
of performing accurate patient dosimetry, suffer from decreased x-ray detection efficiency
thus inhibiting their use for imaging [38, 40]. In both cases, proposed detectors have not
been suitable for applications in both imaging and dosimetry.
Our research group is engaged in developing a system which is capable of verifying both de-
livered dose (dosimetry) and geometric (location of target) accuracy without compromising
each other. First approach was to replace the metal/phosphor screen by plastic scintillator
array referred as a novel prototype EPID configuration [40]. Although demonstrated to be
a water equivalent dosimeter, further improvement is required to match the imaging perfor-
mance of this configuration to commercially available a-Si EPIDs. Anther approach was a
dual detector concept [249] that combined the dosimeter (2D ionization array) with imager
(standard EPID), as described in Chapter 4 of this thesis. The configuration utilized a bulky
2D ionization chamber array dosimeter (ICA). This posed engineering challenges to com-
bine both imager and dosimeter into a clinical system. An important requirement for the
dosimetry aspect of the dual detector concept is that the overlying EPID imager structure
should be materially homogeneous in a direction perpendicular to the beam [249]. It is un-
clear whether the next generation of more efficient EPID imager e.g. [247], will meet this
requirement. The initial assessment of imaging performance demonstrated that placing the
ICA either above EPID (Appendix A) or underneath the EPID as shown in previous chapter
4 degrades the EPID imaging performance.
In this study, we proposed an alternate dual detector design which different from our pre-
viously reported design [249]. The main design differences of the alternative dual detector
were: (i) Radiation transparent prototype 2D silicon array (‘Magic Plate’) [250, 251] was
utilised as the dosimeter, (ii) Magic Plate was placed above the EPID (imager). Apart from
being radiation transparent, the Magic Plate also possess several favourable characteristics
to be used as an in vivo dosimeter including; compact design, high temporal resolution (time
resolved dosimetry) and high signal-to-noise ratio. The dose response characterisation of the
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Magic Plate as a 2D transmission detector [250, 252] and as a 2D detector when sandwiched
in solid water for pre-treatment verification [250] had been reported previously. The clinical
application of the dual detector system requires that performance of both the dosimeter and
imager is not significantly degraded due to the presence of either device. In this study we
investigate the clinical feasibility of a new dual detector configuration with a comprehen-
sive experimental assessment. The imaging performance of the EPID and the dose response
characteristics of the Magic Plate in the dual detector configuration as an in vivo dosimeter
were compared against their respective standalone (reference) configurations.
5.2 Methods and Materials
5.2.1 Equipment
The dosimetry equipment used in this study consisted of a prototype 2D silicon diode array
dosimeter with 11 x 11 epitaxial silicon diodes (figure 5.1a) , hereafter referred as Magic
Plate (MP). The silicon detectors are spaced at 10 mm centre-to-centre. The physical size
of each diode in MP is 1.5 x 1.5 x 0.425 mm3 with field of view of 11 x 11 cm2. Details
regarding MP detector construction and data acquisition system are reported in previous
work [250, 252]. The commercial 2D ion chamber array (ICA), I’mRT MatriXX (IBA
Dosimetry, Schwarzenbruck, Germany) was used as the 2D reference dosimeter. This device
has an array of 1020 air-vented plane parallel ionization chambers (with a volume of 0.08
cm3 each) arranged in a 32 × 32 grid of dimensions 24 × 24 cm2. The ionization chambers
are spaced at 7.62 mm centre-to-centre. A solid water slab was used as water equivalent
build-up material (Gammex RMI, Middleton, WI, USA). The imaging detector used was
an a-Si EPID (XRD 1640 AN CS PerkinElmer, Santa Clara, CA) and the imaging data
was collected using XIS software V3.3.1.1 (PerkinElmer, Santa Clara, CA) using a 399 ms
frame period. The EPID consists of a 40 × 40 cm2 a-Si photodiode array and comprises
1024 × 1024 pixels, giving a pixel pitch of approximately 0.4 mm. A QC-3V image quality
phantom and Pips-Pro software (version 3.2.3a, Standard imaging, Inc., Middleton, WI,
USA) were used to assess image quality. All the clinical modulated fields were planned on
the Pinnacle treatment planning system (Philips Radiation Oncology Systems, Fitchburg,
WI Version 9.0).
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Figure 5.1: Schematic illustration for dosimetry measurement setups (a) dual detector con-
figuration and (b) reference dosimetry configuration. For transit geometry measurements,
either the solid water slab or anthropomorphic phantom (interchangeable) was used. For vi-
sualization purpose, only the anthropomorphic phantom image is shown placed at isocenter
5.2.2 Dosimetry experimental setup
Transit dose measurements were performed at an extended 150 cm source-to-detector dis-
tance with a slab of solid water (Gammex RMI, Middleton, WI) or an anthropomorphic
phantom (ATOM® Dosimetry Verification phantoms, CIRS)) positioned on the treatment
couch and centred at the isocenter. The equalization factor to account for detectors sensi-
tivity differences within the MP was obtained by the method proposed by Kwan et al [253]
and applied. The MP was calibrated to dose by cross calibration with the ICA at a 10 × 10
cm2 field size, source to detector distance (SDD) of 150 cm, with no object present in the
beam.
5.2.2.1 Reference dosimetry configuration
The reference dosimetry configuration comprised of a small solid water buildup placed on
the ICA (figure 5.1b) to ensure electronic equilibrium at the detector array. All dosimetry
measurements with the ICA in the reference dosimetry configuration were used to compare
with the dose response of the dual detector configuration. The water equivalence of the ICA
dose response has been validated in both transit and non-transit geometries [155, 206, 238].
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5.2.2.2 Dual detector configuration
The dual detector configuration consisted of an MP (closest to the source), 0.5 cm solid water
slab and EPID. The 0.5 cm of solid water slab between MP and EPID was necessary to fill
the air gap between the two devices (see figure 5.1a). Sections 5.2.3.2 and 5.2.4 describe the
experiments used to compare the dose response of the MP in the dual detector configuration
with the reference dosimetry configuration (described above in Section 5.2.2.1).
5.2.3 Dose response evaluation
5.2.3.1 Estimation of optimal build-up thickness for dosimetry
There is a trade-off between increasing the buildup thickness required for reliable dosimetry
and decreasing the imaging performance due to associated blurring. The optimal buildup
thickness for dosimetry was determined as the minimum build up thickness at which the
measured field size output factor and off-axis response (as described in section 5.2.3.2)
showed the closest agreement between the reference dosimetry configuration and dual de-
tector configuration. Measurements were performed with 3, 5, 10 and 15 mm solid water
build-up for both reference dosimetry configuration and dual detector configuration.
5.2.3.2 Field size output factor and off-axis response
The field size output factor for square field sizes varying from 3 x 3 to 15 x 15 cm2 was
determined from the ratio of the detector response at CAX relative to a 10 x 10 cm2 field.
The measured profiles for field sizes 3 x 3 cm2, 5 x 5 cm2 and 10 x 10 cm2 with both dual
detector configuration and reference dosimetry configuration were compared.
5.2.4 Clinical modulated Fields
Several clinical dosimetry measurements were performed for absolute dose comparison.
Four brain, step and shoot IMRT fields and a VMAT prostate field (single arc plan) were
measured (integrated acquisition mode) using both the dual detector configuration and the
reference dosimetry configuration. Either a 20 cm thick solid water slab or an anthropomor-
phic phantom was placed at isocentre as a transit object. All measurements employed the
optimal build up thickness on the detectors (as described in Sections 5.2.3.1 and 5.2.3.2).
These transit dose measurements were performed at a source-to-detector distance (SDD) of
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150 cm with sheets of solid water or an anthropomorphic phantom positioned on the treat-
ment couch and centered at the isocenter. All experiments were conducted on an Elekta
Synergy linear accelerator (Elekta Oncology Systems, Crawley, UK) with 6 MV photons at
gantry 00 only. The MP plate has a 1 cm2, 2D spatial resolution. For an accurate dose ver-
ification of modulated treatment field, a higher spatial resolution detector is recommended
[109]. To improve the spatial resolution, we delivered the same clinical plans to the MP five
times with the MP shifted relative to the radiation beam by 0.5 cm orthogonally between
measurements (central position, 5 mm in positive X-direction, 5 mm in negative X-direction,
5 mm in positive Y-direction and 5 mm in negative Y-direction from beam axis). Data from
the five measured dose distributions were merged. The gamma evaluation technique [240]
was applied to quantitatively compare the 2D dose maps measured of the dual detector and
reference dosimetry detectors. The gamma criteria used was 3% dose difference (relative to
the maximum dose) and 3 mm distance-to-agreement, with doses below 10% of the maxi-
mum dose excluded from the evaluation.
5.2.5 Imaging experimental setup
The impact from additional build up material and MP used in the dual detector configuration
on the imaging performance of the EPID was evaluated quantitatively and qualitatively.
For both quantitative and qualitative assessment of the dual detector imaging performace,
images were acquired for three different experimental setups: i) MP with no buildup, ii)
MP with 10 mm thick solid water and iii) MP with 15 mm thick solid water. Similar to
the dosimetry evaluation, the EPID’s imaging performance was experimentally evaluated
by comparing the image quality in a reference imaging configuration with the dual detector
configuration. The reference imaging configuration represents the EPID as routinely used in
a clinical setting without the presence of any additional material on the EPID structure. All
the image quality measurements were performed (as discussed in section 5.2.2.2) at a fixed
source to detector (imager) distance of approximately 151.2 cm.
5.2.5.1 Reference imaging configuration
The reference imaging configuration represents the standard EPID as routinely used in a
clinical setting without the presence of any additional material on EPID structure.
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5.2.5.2 Dual detector configuration
The dual detector configuration is the MP with the added solid water slab placed above the
standard EPID as described in section 5.2.2.2
5.2.6 Image quality evaluation
5.2.6.1 QC-3V image quality phantom
The PipsPro QC-3V image quality phantom and software were used to compare the EPID
spatial resolution, noise and contrast-to-noise ratio (CNR) in the dual detector configuration
and reference imaging configuration. The phantom was placed on its side on the treatment
couch and positioned using the external alignment marks at the isocenter. EPID images
of the phantom were acquired using an average of 1 frame (4 MU, or a dose of approxi-
mately 0.6 cGy at the detector plane) in the reference imaging configuration and dual de-
tector configurations. The low dose levels used here are similar to those typically used for
pre-treatment portal imaging. Details on the algorithms used to calculate CNR and MTF
using PipsPro software can be found in the literature [241].
5.2.6.2 Anthropomorphic phantom
Images of an anthropomorphic pelvis phantom were acquired to qualitatively evaluate the
performance of the EPID in the dual detector configuration and reference imaging configu-
ration, when imaging an object representative of human anatomy. With the gantry angle at
00, the pelvis phantom was positioned facing the source on the treatment couch and was cen-
tred at the isocenter. For each EPID configuration, an anterior-posterior (A-P) image of the
phantom was acquired by averaging 1 individual frame (4 MU or a dose of approximately
0.6 cGy cGy at detector plane).
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Figure 5.2: Comparison of (a) measured dual detector field size output factors at build-
up depths 3 mm, 5 mm, 10 mm and 15 mm of solid water with the reference dosimetry
configuration and the dual detector configuration. The relative ratio of field size output
factors between reference dosimetry configuration and dual detector configuration measured
at varying build-up depths is also shown (b)
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5.3 Results and Discussion
5.3.1 Dosimetry evaluation
5.3.1.1 Field size output factor and Off-axis response
Figure 5.2 displays the comparison of field size output factor measured with the dual detector
configuration and reference dosimetry configuration at 3 mm, 5 mm, 10 mm and 15 mm
build-up depths. Field size output factors measured with the dual detector match within
1.5% to those measured with the reference dosimetry configuration at build-up depth 1.5
cm. Figure 5.3 displays the comparison of off axis profiles measured with the dual detector
configuration and reference dosimetry configuration at 3 mm, 5 mm, 10 mm and 15 mm
build-up depths. Off-axis profile measured with the dual detector agreed within 1.0% to that
measured with the reference dosimetry configuration at build-up depth 1.5 cm and is the
closest agreement among build up thicknesses considered here.
5.3.1.2 Clinical IMRT fields
The gamma evaluation results comparing the MP dose map in the dual detector configuration
with reference dosimetry configuration for one prostate and four brain modulated fields with
either anthropomorphic phantoms or 20 cm of solid water slab phantom placed in the beam
are presented in Table 5.1.
Table 5.1: Gamma evaluation results comparing the MP absolute dose map from the dual
detector configuration and reference dosimetry configuration wiht either an anthropomor-






Gamma pass rate 3%/3mm Mean Gamma
Brain 1 IMRT 97.4a 96.1b 0.34a 0.38b
Brain 2 IMRT 96.8a 95.8b 0.39a 0.41b
Brain 3 IMRT 95.5a 94.9b 0.42a 0.46b
Brain 4 IMRT 96.4a 95.7b 0.38a 0.40b
Prostate 1 VMAT 95.8a 95.1b 0.41a 0.44b
aMeasurement with solid water slab phantom in the beam
bMeasurement with anthropomorphic phantom in the beam
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Figure 5.3: Comparison measured dual detector off-axis profiles at build-up depths 3 mm,
5 mm, 10 mm and 15 mm of solid water with the reference dosimetry configuration and the
dual detector configuration for field sizes 3 x 3 cm2, 5 x 5 cm2 and 10 x 10 cm2. The ratio
of profiles between reference detector and dual detector at varying build-up depths for field
size 10 x 10 cm2 is also shown in (e)
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Figure 5.4: The gamma comparison (3% and 3mm) between measurements for one of the
clinical brain IMRT fields, a) Dual detector, b) Reference detector and c) gamma map.
Figure 5.4 displays the gamma agreement of one of the clinical brain IMRT fields. The
gamma pass rates for all clincal modulated fields were greater than 95% indicating a very
close agreement between the two detector configurations in the transit geometry.
The dose response evaluation (figures 5.3 and 5.4, Table 5.1) demonstrates that integrat-
ing the MP with the EPID in the dual detector configuration has no significant impact on
dose response for the five clinical modulated fields investigated here. As the MP can ac-
quire and report data frame by frame in real-time with very high temporal resolution com-
pared to the currently available commercially 2D detector, it could, in principle, be used for
time resolved dose verification during IMRT or volumetric modulated arc therapy (VMAT)
[201, 246] in the dual detector configuration. The dose discrepancy at the field edge may be
due to an error in manual shift of 5 mm performed during the measurement with the dual
detector. Future work is underway to investigate the dose response for a flattening filter free
(FFF) 10 MV and a 18 MV beam. The development of a clinical dosimetry model is beyond
the scope of this work. The majority of previously reported EPID dosimetry approaches
employed a dose in water based model and require additional corrections to convert the
measured EPID signal into a dose in water image. The proposed dual detector configuration
directly provides a water equivalent dose image and hence, removes any of the uncertainty
which could contribute to the modelling dose response of the detector particularly in the case
of standard EPIDs. By eliminating this middle step of dose characterisation of the detector
response, measured dose with dual detector configuration can be directly compared with
predicted the dose image calculated using any of the previously reported EPID dosimetry
models. Therefore, having the dual detector configuration would simplify the implementa-
tion of in vivo treatment verification.
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5.3.2 Image quality evaluation
The spatial resolution determined by the spatial frequency at half the maximum MTF ( f50),
noise and CNR measured using the PipsPro QC-3V image quality phantom and software in
the reference imaging configuration and dual detector configuration are shown in Table 5.2.
Although, the quantitative analysis (Table 5.2) had shown the presence of solid water build
up material and the MP used in the dual detector configuration had impact on both CNR and
resolution. Figure 5.5 shows the images of the QC-3V image quality phantom taken with
the EPID in the reference imaging configuration and dual detector configuration. There is
no appreciable difference in the visual perception of high or low contrast detail between the
two configurations (Figure 5.5).
5.3.2.1 Anthropomorphic phantom
Anterior-posteior projection images of an anthropomorphic pelvis phantom acquired using
the reference imaging configuration and dual detector configuration are shown in Figure 5.6.
Table 5.2: Comparison of resolution, noise and CNR for the dual detector configuration and
reference imaging configuration. The results are quoted as mean ± standard deviation from
three repeat measurements.
EPID configuration Spatial resolution
f50 (lp/mm)
noise CNR
Standard EPID 0.414±1.151x10-3 12.80 ±1.57 643.96±28.85
MP with no buildup 0.412±1.222x10-3 13.1 ±1.37 590.40±26.65
MP with 10mm
buildup
0.405±1.245x10-3 22.80 ±1.47 370.96±31.25
MP with 15mm
buildup
0.402±1.274x10-3 26.80 ±2.07 314.40±32.15
The images from the two configurations show no discernible difference in the visualization
of anatomical details. These qualitative results and the quantitative imaging results reported
above demonstrate that while the presence of the additional MP detector and solid water
build up had a measurable effect on EPID imaging performance (see Table 5.2), the effect
was not visible in qualitative image comparisons (see Figs. 5.5 and 5.6) and is considered
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Figure 5.5: EPID images of the QC-3V image quality phantom taken with the (a) reference
imaging configuration and (b) dual detector configuration (MP with no buildup) (c) dual
detector configuration (MP with 10mm buildup) (d) dual detector configuration (MP with
15 mm buildup)
negligible for clinical purposes.
In this study, we used readily available equipment to demonstrate the feasibility of the dual
detector concept. The proposed dual detector configuration has overcome some limitations
of the previously reported dual detector configuration [249]. The current focus of EPID
technology development is to improve the imaging standards by employing more sensitive
detectors [35, 36]. The success of the previously reported dual detector for dosimetry pur-
poses depends on the overlying EPID imager structure and its composition which should
be materially homogenous perpendicular to the beam. Any structural modification as a part
of a future EPID design development would not impact the dosimetry performance of the
proposed dual detector configuration. Also, the compact design of MP detector used in
the proposed dual detector would resolve the some of the engineering challenges such as
integration of the MP detector inside the EPID structure. Additional considerations not in-
vestigated in this study include the engineering requirements of the mechanical support and
the configuration of electronics and data readout schemes required to implement the pro-
posed dual detector configuration. This study demonstrates a proof-of-concept of a novel
dual detector for radiotherapy treatment verification. Current EPID detectors are optimized
for imaging but are suboptimal for dosimetry. The proposed dual detector concept decouples
the imaging and dosimetry functions so that each can be optimized without compromising
the other, providing more flexibility for future improvements in radiotherapy treatment ver-
ification systems.
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Figure 5.6: Portal image of anthropomorphic pelvis phantom acquired with the (a) reference
imaging configuration and (b) dual detector configuration (MP with no buildup) (c) dual




The proposed dual detector configuration, combining a conventional EPID and a prototype
Magic Plate 2D array dosimeter, can be operated simultaneously as both imager and dosime-
ter without significant compromise in the performance of either device. The prototype tested
requires higher spatial resolution and a larger detection area for clinical implementation.
This is being addressed with a new higher resolution system which is currently in design
phase. This works shows a proof of concept.
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The current trend of radiation therapy (RT) is moving toward increasingly precise and ac-
curate dose delivery, which employs radiation beam intensity-modulation for dose sculpting
and image guidance for target positioning. Modulated beams often contain complex flu-
ence maps with large dose gradients that are tailored to each individual patient and bear
little resemblance to standard fields used for commissioning beam models. Factors that
could lead to differences between the delivered and planned dose distributions include i)
anatomical changes (e.g. changes in tumour size and shape, patient weight and organ mo-
tion [254, 255]), ii) treatment delivery issues (e.g. MLC calibration offsets [256, 257]) and
iii) limitations in TPS beam model accuracy [258]. In response to increasing treatment
complexity, quality assurance (QA) bodies throughout the world acknowledge that patient
treatment verification using in vivo dosimetry is highly desirable for optimal patient safety
during radiation treatment [12, 14, 110].
Commercial a-Si EPIDs have been shown to be suitable for in vivo dosimetry and offer sev-
eral advantages over other common dosimeters [23]. However, the effective use of standard
EPIDs for dosimetry necessitates comprehensive models of both the linac’s treatment beam
and the EPID’s dose response characteristics, both of which vary on a per-patient basis [23].
Regardless of the prediction method used, current portal dosimetry methods are based on
a completely different algorithm or model of linear accelerator than which is used for dose
calculation. Therefore, the strategy of comparing measured dose versus dose estimated at
the EPID plane only verify the machine delivery error and not necessarily verify the TPS
dose model and dose algorithm accuracy. This would potentially undermine the robustness
of the link between EPID dosimetry results and the real agreement in delivered dose versus
prescribed treatment. Considering the complexity of EPID dosimetry algorithms, extensive
commissioning that must be performed in order to optimise EPID utility and minimise the
risk of masking errors as well as patient safety.
The potential of EPIDs for detecting various dose delivery errors has been well demon-
strated in previous studies [119, 200]. Bojechko et al [200] quantified the effectiveness of
EPID- based dosimetry in detecting clinical incidents such as changes in the machine output,
corrupted plans and patient positioning errors occurring during setup. The authors reported
that 74% of 229 high severity incidents reported over a 2.5 year period could be detected by
using in vivo first fraction EPID dosimetry, compared to just 6% when using pre-treatment
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EPID dosimetry. The three most common error modes reported by the authors were wrong
isocenter information, patient misalignment during treatment and error in CT scan data. Ac-
cess to EPID based in vivo dosimetry solutions has improved recently with the introduction
of commercially available systems [259–261]. However, despite the large body of research
dating back to the early 1990s and before, the reported use of clinical EPID based in vivo
dosimetry is still limited to a relatively small number of centres. Nelms et al pointed out
the advantages of using measured EPID images for IMRT QA over predicted portal images
generated independently of the TPS dose calculation algorithm, as the latter approach may
mask TPS modelling errors [262]. Current EPID dosimetry models use various corrections
in both the predicted and measurement derived data that are unrelated to the TPS dose cal-
culation. The reliability and robustness of such systems requires independent validation that
captures the range of clinical scenarios for which it is used, a process that is difficult to
achieve comprehensively without additional specialised tools and resources. The degree to
which these issues may undermine the reliability of EPID dosimetry to ensure patient safety
is not well understood.
One simple EPID dosimetry model that has previously been demonstrated uses the ‘ex-
tended phantom’ concept to calculate a predicted dose image (PDI) at the EPID plane using
the TPS dose in water model [195, 196, 199]. When used with standard EPIDs, this method
still requires a separate EPID model to convert the measured EPID signal into dose in water.
Despite being demonstrated two decades ago, this approach has not been widely adopted
in EPID dosimetry models. More recently, Ortega et al [263] proposed a method to com-
pute PDIs using a clinical dose in water beam model in a commercial TPS. The authors
utilised the actual CT images of a commercial EPID as a quality assurance phantom. Af-
ter calibrating the EPID according to vendor guidelines, the authors demonstrated that the
PDIs computed using the commercial TPS agreed well with measured EPID dose images
(> 95% gamma-index pass rate with 3%/3mm criteria) in a non-transit geometry. Yohannes
et al [264] have written in-house scripts in the Pinnacle3 TPS that can create the structures
and define them as virtual planes. These virtual planes can be generated for any arbitrary
gantry and couch angles, as well as source to planar distance, so that the planar dose maps
at these planes can be computed. Authors verified the planar dose distributions computed
using the scripts for limited clinical fields (three open fields and one IMRT field) with films
and ionisation chamber array and have showed good agreement. Baek et al [175] reported
the feasibility of EPID based transit dosimetry utilising a commercial TPS (Eclipse, Varian
Medical Systems, Salt Lake City, UT, USA). In their work, the EPID was calibrated using
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vendor guidelines. Authors reported that the gamma pass rate (using relative gamma criteria)
for transit dose measurements with clinical modulated fields was lower with an anthropo-
morphic phantom (86.8 ± 3.8%) compared to a homogeneous phantom (94.2 ± 1%) and
concluded that the reduction in gamma pass rate was partially due to the inaccuracy of TPS
calculations for inhomogeneity. Millin et al [265] also reported the feasibility of EPID based
transit dosimetry utilising a commercial TPS (iPLAN ®, BrainLAB, Feldkirchen, Germany
). Their work compared the measured EPID dose, calculated using an analytical model, with
predicted dose calculated by TPS and Monte Carlo (MC) simulations. To facilitate the dose
calculations at the EPID plane, a slab of water equivalent material identical in dimensions to
the EPID was added to the TPS as an RT structure. The authors utilised a separate correction
to account for the differences in TPS-calculated dose to water and the measured dose to the
EPID imager. The authors demonstrated that the MC-simulated dose showed better agree-
ment with the measured EPID dose compared to the TPS-calculated dose when 3%/3mm
relative gamma criteria were used. The dose verification in their study was validated for a
maximum field size of only 5 x 5 cm2 with no intensity modulation. Another issue in this
work is that it used small field sizes that limits the amount of the patient scatter created
and incident on EPID, which will simplify the EPID dosimetry model. Both these studies
[175, 265] recommended that the EPID model refinement is necessary in order to convert
the EPID signal to absorbed dose to water for clinical dosimetry. Standard EPIDs were orig-
inally designed and optimised for imaging applications and therefore employ high density
and high atomic number materials to ensure high detection efficiency of the megavoltage
photon beam.
Alternative EPID designs that are better suited for dosimetry applications relative to standard
a-Si EPIDs include several water equivalent EPIDs (WE-EPID) developed and proposed
by our group [38–40, 206]. In these detectors, the high atomic number materials above
the photodiode array are replaced with water equivalent build up material such as solid
water or segmented plastic scintillator array. A prototype a-Si direct detector dosimeter has
demonstrated dosimetric properties that were more water equivalent than standard EPIDs
[40, 266]. More recently, a standard commercial EPID was modified to operate as a direct
detection dosimeter (direct EPID) and its performance under modulated fields was evaluated
by directly comparing the measured dose with ionisation chamber measurements [38, 39,
206]. However, the demonstrated benefits of a more water-equivalent dose response have
come at a cost of lower sensitivity and reduced overall imaging performance. The direct
EPID exhibits only about 10% of the signal measured with the standard EPID, which means
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that higher doses are needed to achieve comparable image quality. Our group is currently
working to optimise the imaging performance of our plastic scintillator prototype EPID for
this precise reason [267, 268]. In our previous work [40], we characterised the dosimetric
response of a physical plastic scintillator fibre array EPID prototype and demonstrated its
near water-equivalent response in both non-transit and transit configurations using standard
square fields. In this study, we report for the first time the dosimetric characterisation of our
WE-EPID prototype using intensity-modulated fields including dynamic treatments such as
VMAT. This prototype offers improvements in sensitivity compared to the direct detection
EPIDs because of the signal gain introduced when using the scintillator to convert incident
x-rays into optical photons.
The ‘extended phantom’ concept employing in TPS provides water equivalent dose image
at EPID plane and does not requires any additional modelling of the clinical beam or an
independent image prediction algorithm. The main advantage of this method is that por-
tal dose prediction is calculated with the same algorithm and beam model used for patient
dose distribution calculation. Unlike the standard a-Si EPIDs, WE-EPIDs do not require
any additional dose response corrections and therefore the measured WE-EPIDs dose may
be compared directly to TPS dose calculations. The present study combines the WE-EPID
and the ‘extended phantom’ TPS concepts to propose a new model for transit dosimetry
as a means of in vivo dosimetry and demonstrates for the first time the application of the
‘extended phantom’ concept for dosimetry applications using two different WE-EPID con-
figurations. The dosimetric response of both WE-EPIDs was characterised with respect to
a reference ionization chamber array dosimeter using standard open and wedged fields, as
well as intensity-modulated fields (IMRT and VMAT). This new concept removes some of
the limitations of current EPID dosimetry models by allowing for a more direct comparison
of TPS calculated dose with the delivered dose.
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6.2 Methods and Materials
6.2.1 Equipment
6.2.1.1 Water equivalent EPID
The EPID device used was based on a standard a-Si EPID (XRD 1640 AN CS PerkinElmer,
Santa Clara, CA) and the imaging data was collected using XIS software V3.3.1.1 (PerkinElmer,
Santa Clara, CA). The EPID was used in either of two prototype WE-EPID configurations:
novel EPID configuration [40] or the direct EPID configuration [38]. Both configurations
have 3 cm of water equivalent build-up material in place of the copper sheet and gadolinium
oxysulfide phosphor screen components of standard clinical EPIDs (see figure 6.1 a) to c)).
The novel EPID design incorporates a custom-made segmented 2D plastic scintillator array
(PSA) device, which measures 3 cm in thickness and 15 x 15 cm2 in area and has previously
been demonstrated for simultaneous imaging and dosimetry applications in radiotherapy
[40, 266]. The direct EPID configuration uses either 30 x 30 x 3 cm3 (Gammex RMI, Mid-
dleton, WI) or 40 x 40 x 3 cm3 (CIRS, Norfolk, VA, USA) of solid water build-up. Both
configurations have been demonstrated to be water equivalent to within 1.5% [38, 40, 266].
Hereafter, both configurations are referred to as water equivalent EPIDs (WE-EPIDs) unless
stated otherwise. Since the PSA used in the novel EPID configuration is limited to 15 x
15 cm2 in area, the dosimetric validation measurements with this novel EPID configuration
(described in Section 6.2.3) were limited for treatment field dimensions up to 10 x 10 cm2
defined at isocentre. To validate the ‘extended phantom’ concept comprehensively over a
wide range of clinical scenarios, all treatment fields as described in Section 6.2.3 including
those measured with novel EPID configuration were measured with the direct EPID.
6.2.1.2 Reference 2D transit dosimeter
The I’mRT MatriXX two dimensional ionisation chamber array (ICA) and accompanying
OmniPro-I’mRT software (version 1.6, IBA Dosimetry, Schwarzenbruck, Germany) was
used as a reference 2D transit dosimeter (Figure 6.1 d). All the ICA measurements were
performed at 3 cm depth to match the WE-EPID setup.
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Figure 6.1: Experimental setup for transit dose measurements. Two WE-EPID configura-
tions are shown: a) Prototype EPID consisting of a plastic scintillator fibre array (15 cm x
15 cm x 3 cm) directly coupled to the EPID detector, b) Direct EPID consisting of a 30 cm
x 30 cm x 3 cm solid water slab directly coupled to the EPID detector. The EPID was posi-
tioned at 150 cm and wrapped with an opaque black sheet to block any light from reaching
the detector (c). The I’mRT MatriXX ion Chamber Array setup is shown in (d).
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6.2.1.3 Treatment planning system
All radiation fields described in Sections 6.2.3.1, 6.2.3.2 and 6.2.3.3 were planned using a
clinical Pinnacle TPS (Pinnacle, v9.10, Philips Medical Systems, Fitchburg, WI) and cal-
culated using the adaptive convolution/superposition dose algorithm [269]. We adapted a
similar ‘extended phantom’ approach as described in previous studies [195, 196] to modify
the image field of view (FOV) (Figure 6.2). The CT images were processed to extend the
image FOV from 512 x 512 pixels to 1024 x 1024 pixels using in-house software written
in Matlab (version: 7.10.0.499 (R2010a), Mathworks Inc., MA) before importing them into
the TPS. The size of individual pixels was not altered. The padded image pixels were as-
signed CT numbers corresponding to air. Extending the FOV was required to incorporate
the EPID as an RT structure with dimensions 4 x 30 x 30 cm3 at 150 cm source to detector
distance (SDD). The EPID structure was assigned a uniform density of 1.0 g cc-1 to match
that of water (Figure 6.2). This allowed the TPS to perform dose calculations outside of the
scanned CT FOV. The TPS dose at EPID plane was calculated using a dose grid of 2 mm x
2 mm x 2 mm at a depth of 3 cm inside EPID RT structure for all water equivalent detec-
tor configurations. The planner dose calculated at EPID plane was exported using standard
DICOM export option in TPS.
6.2.2 EPID image corrections and dose calibration
All acquired EPID images were dark field and flood field corrected. The flood field correc-
tion removes the variation in pixel-to-pixel sensitivity as well as the beam intensity profile
information from the image. In order to restore the beam profile, a pixel sensitivity map
(PSM) was measured using a multiple field calibration method described previously [270].
The PSM contains only the inherent differences in sensitivity of the individual pixels in the
imaging matrix, specified relative to the central pixel. Each EPID image was processed
using in house MATLAB code to restore beam profile information using a similar method-
ology to that described in a previous study [248]. The corrected WE-EPID pixel values were
calibrated to dose by cross calibration with Farmer chamber. The reference conditions used
for cross calibration were 10 × 10 cm2 field size, 150 cm SDD and 20 cm of solid water
positioned on the treatment couch centred at the isocenter. A pixel-to-dose calibration factor
and PSM was applied to each EPID image to convert it to a dose image. The same principle
of calibration was applied to the ICA, with a dose calibration established from a calibrated
Farmer chamber and a vendor supplied pixel sensitivity map.
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Figure 6.2: Representation of phantom (anthropomorphic pelvis phantom) and virtual EPID
setup in the TPS.
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6.2.3 Dose response evaluation
Basic dose response tests for different field sizes, off axis ratios and transmission factors
were performed. The measured dose response with the both WE-EPIDs and ICA was com-
pared to the TPS-calculated dose at the WE-EPID plane to verify the accuracy of the clinical
TPS beam model under transit dosimetry conditions. For field sizes and transmission factors
dose response analysis of WE-EPIDs, the pixel value averaged over central 10 x 10 pixels
of the exposed field size. In case of an ICA detector the dose value averaged over central
four detectors was used. The TPS model used was a standard clinical model commissioned
according to standard guidelines [271, 272]. We also compared beam profiles for the largest
field size of 25 x 25 cm2 with varying thickness of object in the beam (0, 10, 20, 30 and 40
cm solid water slab). All the field size dimensions reported in this work describe the field
width as defined at the isocentre, unless stated otherwise.
6.2.3.1 Open and Wedged fields with heterogeneous phantoms
Three individual fields were measured: i) a single direct 12 x 12 cm2 open field transit
through an inhomogeneous slab phantom, ii) an open breast tangent field and iii) a wedged
breast tangent field transit through an anthropomorphic phantom (ATOM® Dosimetry Veri-
fication phantoms, CIRS) to mimic the traditional tangential breast treatment setup. Figure
6.3 displays the two heterogeneous phantoms and beam arrangements used for these exper-
iments.
6.2.3.2 IMRT fields
Twenty clinical IMRT cases were measured with either 20 cm or 40 cm thick solid water
slab or an anthropomorphic phantom in the beam. The clinical IMRT cases consisted of four
modulated fields from brain plans and sixteen modulated fields from prostate cases (out of
sixteen clinical fields, seven were from intact prostate plans having low modulation while
nine clinical fields were from prostate plans with involved pelvic nodes covering treatment
areas at least 20 cm in width). All these plans were planned using step and shoot delivery
only.
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Figure 6.3: Two different heterogeneous phantoms: a) an inhomogeneous slab phantom
and b) an anthropomorphic breast phantom. The inhomogeneous slab phantom consists of
stacked bone, lung and water equivalent solid water slab.
6.2.3.3 VMAT field
Three clinical VMAT cases were measured with either 20 cm thick solid water slab or an an-
thropomorphic phantom in the beam. The clinical VMAT cases included one intact prostate
plan (single full arc with low modulation) and two head and neck plans (planned with two
arcs covering a treatment area approximately 23 cm in width).
The measured and calculated doses were evaluated with all control points (CP) collapsed to
gantry zero. To compare time-resolved measurements to predicted dose, the measured dose
was sampled at the correct frequency to match the TPS-calculated dose per control point.
The EPID data was acquired in free running mode unsynchronised with linac gun pulses.
Using a priori knowledge of monitor units and dose rate from the DICOM RTPLAN for each
control point, the number of expected EPID frames per control point can be determined. The
EPID frames were then resampled into integrated CP images. This approach is based on the
method described by Podesta et al [273].
The treatment couch was modelled in the TPS. All experiments were conducted on an Elekta
Synergy linear accelerator (Elekta Oncology Systems, Crawley, UK) with Agility MLC and
6 MV photons at gantry 00 or 900 only. The gamma evaluation technique [240] was applied
to compare the 2D dose maps measured with both WE-EPID detectors and calculated with
the TPS. The gamma criteria used was 3% dose difference (relative to the maximum dose)
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and 2 mm distance-to-agreement, with doses below 10% of the maximum dose excluded
from the evaluation.
6.3 Results
Table 6.1: Comparison of off-axis response measured with WE-EPID, ICA and TPS cal-
culated with solid water thicknesses of 0 cm (i.e. no object), 10, 20, 30 and 40 cm in the
beam, respectively. Data presented constitutes the mean ± standard deviation difference in
the cross-plane profiles normalised at CAX over a 12.5 cm distance from beam axis.
Equipment/
detector
Relative ratio in off-axis response for varying
solid water thickness (cm) placed in beam
0† 10† 20† 30‡ 40‡
WE-EPID vs ICA 0.992±0.007 0.989±0.006 0.988±0.004 0.993±0.004 0.991±0.004
TPS vs ICA 0.999±0.002 1.003±0.004 1.008±0.007 1.008±0.006 1.006±0.007
WE-EPID vs TPS 0.991±0.006 0.987±0.006 0.984±0.007 0.989±0.005 0.988±0.006
† Measurement with 30 x 30 x 3 cm3 solid water build up for 20 x 20 cm2 open field size
‡ Measurement with 40 x 40 x 3 cm3 solid water build up for 25 x 25 cm3 open field size
6.3.1 Dose response evaluation
Figure 6.4 compares the WE-EPID and ICA measured dose response with TPS-calculated
dose response for varying square field sizes and transmission through solid water slabs of
varying thickness. The measured dose response for all tests agreed with the TPS-calculated
dose response to within 2%, suggesting the clinical beam model predicts transit dose accu-
rately at the EPID plane. Figure 6.5 compares the measured beam profiles with 30 cm and
40 cm of solid water thickness for open 25 x 25 cm2 fields with TPS-calculated profiles. The
relative profile agreements are also summarised in Table 6.1. We have presented the data
for prototype WE-EPID configurations with direct EPID only since the novel WE-EPID
configuration results were the same (< 0.5%).
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Figure 6.4: Comparison of dose measured with the WE-EPID and ICA and calculated with
the TPS in the same measurement geometry: a) field size response and b) transmission
factors. Only data for the direct EPID WE-EPID configuration is presented here.
Figure 6.5: Comparison of off-axis response (normalised half profiles) measured with a) 30
cm solid water slab and b) 40 cm solid water slab present in beam. The relative difference in
off-axis response over a distance of 12.5 cm from the beam axis between the TPS-calculated
or WE-EPID-measured dose when compared to the ICA-measured dose is displayed on the
right axis. Only data for the direct EPID WE-EPID configuration is presented here.
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6.3.2 Clinical field
6.3.2.1 Open and Wedged fields with heterogeneous phantoms
The transit dose images measured with the WE-EPID and calculated with the TPS for di-
rect single field (described in Section 6.2.3.1), using an anthropomorphic phantom (open or
wedged) and an inhomogeneous slab phantom (open field) are displayed in Figure 6.6. The
gamma evaluation of the dose images acquired with the WE-EPID versus those measured
with the TPS for all fields showed at least 93.6% agreement with average gamma-index val-
ues between 0.33 and 0.41. Dose profiles in the WE-EPID and TPS-calculated dose images
have also been extracted and compared in Figure 6.6. The measured data presented in Figure
6.6 was acquired with the direct WE-EPID configuration only since measured fields were
larger compared to physical dimensions of the novel WE-EPID detector.
6.3.2.2 IMRT fields
A summary of the gamma-index pass rates for all modulated fields measured with a 20
cm and 40 cm solid water slab (homogeneous phantom) and an anthropomorphic phantom
placed in the beam is shown in Table 6.2. The gamma-index evaluation of the dose images
acquired by the WE-EPID and ICA when compared to those calculated with the TPS for
all clinical IMRT fields showed at least 91% agreement with average gamma-index values
between 0.35 and 0.55.
6.3.2.3 VMAT field
The gamma evaluation of the integrated VMAT dose images acquired by WE-EPID and
ICA versus TPS showed greater than 90% agreement with gamma index < 1. A summary
of the gamma index pass rates for VMAT fields measured with either 20 cm solid water slab
(homogeneous phantom) or an anthropomorphic phantom placed in the beam is shown in
Table 6.3.
Figure 6.7 displays the 2D gamma evaluation between the TPS-calculated and measured
dose images per control point for the first three control points for prostate case. The gamma
pass rate was 95.7 ± 2.4% for all the control points (Table 6.3). The gamma pass rate for
both WE-EPID configuration when compared with ICA and TPS was similar (<0.6%) and
data presented (Table 6.3) was acquired with the novel EPID and direct EPID configura-
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Figure 6.6: The gamma-index comparison (3% and 2mm) between measurement (WE-
EPID) and TPS calculated water-equivalent dose image for a direct beam passing through a)
anthropomorphic phantom (open field) b) anthropomorphic phantom (600 wedge field) and
c) inhomogeneous slab phantom (open field). The dose profiles in the rightmost panes were
extracted from the planes indicated as dotted lines on corresponding EPID dose images.
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Figure 6.7: The gamma comparison between measurement (novel WE-EPID) and calcula-
tion (TPS) for first three control points of a clinical prostate VMAT field in presence of an
anthropomorphic phantom.
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tion for prostate and head and neck cases respectively. Figure 6.7 displays the 2D gamma
evaluation between the TPS-calculated and measured dose for integrated images.
Table 6.2: Gamma-index evaluation when comparing WE-EPID and ICA absolute dose
maps with the TPS absolute IMRT fields using 3%/2 mm criteria. An anthropomorphic or
solid water slab phantom was placed in the beam as a transit object. The range and mean
value has presented for both gamma pass rate and average gamma value.
Prostate\ Prostate# Prostate# Brain Brain




















































































Prostate\-Clinical intact prostate plan
Prostate#-Clinical prostate with pelvic nodes plan
SW†: 40 cm solid water as a transit object in beam
SW‡: 20 cm solid water as a transit object in beam
AP: Anthropomorphic phantom as a transit object in beam
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Table 6.3: Gamma-index evaluation when comparing WE-EPID and ICA measured dose
maps with TPS-calculated VMAT fields using 3%/2 mm criteria (both integrated and control
point by control point). Either an anthropomorphic or solid water slab phantom was placed
in the beam as a transit object.
Percentage and mean gamma pass rate with 3%/2mm criteria
Integrated Control point by
control point





















† Anthropomorphic phantom as a transit object
‡ 20 cm solid water slab as a transit object
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Figure 6.8: The gamma comparison (starting from left in bottom row) between the TPS-
calculated versus WE-EPID measured, TPS versus ICA measured and ICA measured versus
WE-EPID for integrated dose images of a clinical prostate VMAT field in presence of an
anthropomorphic phantom. The integrated dose images are displayed in top row starting
from left, TPS calculated, measured with WE-EPID and ICA measured.
6.4. Discussion 108
6.4 Discussion
A simple model for implementing transit dose verification with a WE-EPID as a means of in
vivo dosimetry has been demonstrated. The dose measured with a WE-EPID can be directly
compared to the dose calculated by the TPS in a clinical treatment plan, replacing the need
for a separate EPID model.
The TPS dose calculated at the EPID plane showed good agreement with the dose measured
by two different dosimetry systems. The gamma-index agreement between measurement
with ICA and both WE-EPIDs for clinical modulated IMRT fields were similar to the pre-
viously reported work [39, 206]. This study reports for the first time VMAT dosimetry
measurement with both WE-EPIDs. Hence, the VMAT dosimetry results presented in this
work cannot be directly be directly compare with previous work. The water equivalence of
both these devices has been demonstrated in several studies [39, 40, 206, 266]. Although,
the previous work [199, 264] presented the approach to calculate dose at EPID plane using
TPS, none of the previous work verified comprehensively the accuracy dose prediction at the
EPID plane against water equivalent dose measurements for wide range of clinical scenario.
This study demonstrates that a TPS model commissioned according to conventional radio-
therapy guidelines [274] may be sufficiently accurate for transit EPID dose calculations for
a wide range of clinical scenarios, including open, wedged, modulated and dynamic beams.
We validated the ability of the Pinnacle TPS using the ‘adaptive convolve’ dose calculation
algorithm, which is based on the collapsed cone convolution [269]. Accurate dose in water
algorithms implemented in other modern radiotherapy treatment planning systems can be
expected to have similar success [275, 276].
The issue of imaging performance with a WE-EPID is not addressed in this study but is
the topic of ongoing studies into optimal detector designs [267, 268]. The focus of this
work was to demonstrate a simple yet powerful approach to in vivo dosimetry that becomes
available with access to a WE-EPID.
Since current TPSs are not designed for the in vivo dosimetry applications presented in this
study there are several limitations to be addressed before the full potential of our system
can be realised. For example we have only included beams at orthogonal gantry angles
similar to proposed by Yohannes et al [264]. Further work is therefore required to develop a
process for extracting TPS-calculated doses at the EPID plane for beams and control points
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at all gantry angles. It would also be possible for a conventional TPS to incorporate a back-
projection dose calculation method to facilitate in vivo dose verification in the future similar
to presented in previous work [198].
The same approach presented in this study could be implemented using a dose in water algo-
rithm on a separate software platform independent of the TPS, similar to currently available
EPID dosimetry systems, but without the need to model the standard EPID dose response.
Any EPID-based dosimetry system that has been proposed using standard EPIDs could be
implemented with a WE-EPID, without the added uncertainty and limitations of modelling
the complex dose response of standard EPIDs. With this increased confidence in dosimetry,
EPID-based dosimetry could maintain tighter tolerances under a wider range of clinical con-
ditions and maintain high levels of confidence in the delivered dose as delivery techniques
become increasingly more complex.
6.5 Conclusion
An approach to transit dose verification is presented utilising a water equivalent EPID and a
commercial TPS. The accuracy of dose calculations at the EPID plane using a commercial
TPS beam model was experimentally confirmed. The model proposed in this study provides
an accurate method to directly verify doses delivered during treatment without the additional
uncertainties inherent in modelling the complex dose response of standard EPIDs.
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High radiation dose delivery to tumours with improved sparing of normal tissues is an ongo-
ing goal of radiotherapy practice. Advanced radiation therapy techniques such as fixed beam
intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT)
and helical tomotherapy (HT) have improved our ability to achieve this goal [277]. How-
ever, these techniques are also more complex to deliver. As such, an understanding of
delivery uncertainties within these advanced planning and delivery techniques is required
to ensure the potential for improved effectiveness from these techniques is actually being
achieved. Margalit et al.[278] outlined the different errors associated with either IMRT or
3D/conventional treatment techniques and highlighted how the occurrence of error types
differs between treatment techniques. The dosimetric impact of multileaf collimator (MLC)
leaf position errors has been thoroughly studied and reported [41–46] for IMRT and VMAT
delivery. Further, Tatsumi et al.[279] demonstrated that the sensitivity to MLC errors de-
pends upon the treatment planning system (TPS) type, implementation of inverse optimiza-
tion, and MLC segmentation algorithm within the TPS. The dosimetric impact from sim-
ulated delivery errors from other mechanical parameters such as gantry angle, collimator
angle and table position in IMRT and VMAT delivery has also been studied [42, 280, 281].
Betzel et al.[133] reported that RapidArc™ (Varian Medical Systems, Palo Alto, CA) deliv-
eries were found to be more tolerant to variations in dose rate, gantry position, and MLC leaf
position compared to IMRT delivery. All of the above reported studies on the sensitivity to
treatment delivery errors were based on a C-arm gantry linac. The information is therefore
not relevant to HT machines as the mechanics of HT treatment delivery are different from
other forms of external beam RT. As opposed to the work discussed above for IMRT and
VMAT, few researchers have conducted a similar analysis for HT plan delivery. Fenwick
et al [282] studied the link between machine characteristics and the delivered dose for HT
by modelling the dose distribution delivered to an on-axis target with a cylindrical phan-
tom aligned co-axially using a simple unmodulated beam. They characterised the impact on
the on-axis target dose distribution from the angular variation in gantry rotation speed and
output per linac pulses.
Most of the recommended HT QA procedures and tolerances in AAPM Task Group 148 [47]
were adopted from the collective experience of the task group members, vendor designed
QA tests and from previously published reports [48–50]. It is unclear whether suggested QA
tolerances have any clinical significance. This is the first study to demonstrate the potential
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clinical impact of variation in delivery parameters on actual HT clinical plans. The goal of
this study was to simulate several potential HT delivery errors associated with the mechani-
cal system, considering nasopharynx plans with common plan parameters and to understand
the impact of these errors on patient dosimetry. We assessed the errors resulting in clinical
impact against the current machine interlock values. This work provides a framework to
establish QA tolerances that are clinically significant for specific anatomical sites and for
relevant planning techniques.
7.2 Methods and Materials
7.2.1 Patient selection and treatment planning
Table 7.1: Description of the range of complexity among ten clinical HT plans presented in















1 Bilateral Partial overlap
with both parotid
11 22.6 273.8
2 Ipsilateral RT Partial
and Brainstem
10.5 22.5 271.7
2 Bilateral Partial overlap
with both parotid
12 23.5 394.1
4 Ipsilateral LT Partial
and Brainstem
12.3 25.3 305.6
5 Ipsilateral RT parotid 10.9 23.3 346.7
6 Bilateral Brainstem 13.3 25.1 373.6
7 Ipsilateral Both parotid 9.5 24.7 275.8
8 Bilateral None 11.4 20 220
9 Ipsilateral Both parotid
and Brainstem
10.6 24.6 408.7
10 Ipsilateral Both parotid 10.5 21.6 260.8
† Maximum distance of any pixel within PTV56 or parotid from the bore centre.
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Ten retrospective clinical nasopharynx HT plans with varying complexity (Table 7.1) were
selected randomly for this study. All ten clinical plans were optimised using a fixed 2.5 cm
jaw width, 0.287 or 0.403 pitch and 2.2-2.4 modulation factor with the clinical TomoTherapy
TPS version 4.2, hereafter referred as the clinical TPS. The approved dose distributions were
used as a baseline for dosimetry comparison. It was decided to use a single plan type for
this study to focus the investigation on planning methods and error introduction.
7.2.2 Simulation of delivery errors
All dose calculations were performed using a TomoTherapy version 5.0 standalone GPU
dose calculator; hereafter referred as the research TPS. Use of the research TPS was nec-
essary for two reasons: i) this version of software is capable of interpolating between the
jaw penumbra data at different jaw positions, essential for simulating the jaw errors and ii)
introducing the error and then recalculating dose without re-optimization is not possible in
the clinical TPS. Figure 7.1 is a schematic describing the multiple steps involved in simu-
lating HT delivery errors, error plan dose re-calculations and plan metric, and calculations
using Comp Plan [283] which is an in-house software application to extract the dose vol-
ume histogram (DVH) from DICOM RT dose and RT structure files and calculate various
radiobiological plan metrics. Simulated error plans were generated by converting the opti-
mized clinical plan into an XML-defined calibration procedure and then modifying either
the XML or binary MLC sinogram to introduce simulated errors. Five key mechanical er-
rors were simulated: couch speed (CS), gantry start position (GSP), gantry period (GP), jaw
width (JW) and MLC leaf open time (MLC LOT).
Each error type was simulated independently for a range of magnitudes as described in table
7.2 The JW error in this study is the error in individual jaw position (either front or back
jaws). In the case of MLC LOT errors, the optimized clinical plan sinogram was edited using
MATLAB (version: 7.10.0.499 (R2010a), Mathworks Inc., MA). Three different MLC LOT
errors were simulated: (1) leaf 32, 42 or 52 stuck open, (2) random errors using a normal
distribution with a mean and standard deviation of -2% and then with a mean and standard
deviation of -4%. The leaf open times greater than 100% are not possible to deliver, so were
truncated and (3) a normal distribution with mean of 0% and standard deviation ranging
1-10%. As demonstrated in previous work, the MLC LOT random error with mean and
standard deviation of -2% can occurs when suboptimal pitch is used during plan optimisation
[284].
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Figure 7.1: Schematic describing the processes involved in creating the simulated error
plans, dose recalculations for simulated error plans and the calculation of plan metrics for
dosimetry comparison
Table 7.2: Five key simulated errors and the associated magnitudes simulated. All error
magnitudes are defined relative to the reference clinical plan value
Machine delivery parameter Number of simu-
lated error plans
Magnitude of simulated error
Couch speed† (cm per sec) 24 ±0.1, ±0.3, ±0.5, ±1, ±1.5, ±2, ±2.5, ±3,
±3.5, ±4, ±4.5 and ±5
Gantry Start Position‡ (deg) 24 ±0.1, ±0.3, ±0.5, ±1, ±1.5, ±2, ±2.5, ±3,
±3.5, ±4, ±4.5 and ±5
Gantry period‡ (sec) 24 ±0.1,±0.2, ±0.4,±0.5,±0.6,±0.8, ±1, ±1.5,
±2, ±2.5, ±3,±4
Jaw width‡ (mm) 12 ±0.1,±0.3, ±0.5, ±1, ±1.5, ±2
MLC LOT 3 Leaf 32 stuck open, Leaf 42 stuck open Leaf
52 stuck open
2 †Mean random error of -2% and -4%
2 † standard deviation of error of 1-10%
† Percentage difference relative to planned value
‡ absolute difference relative to planned value
7.2.3 Plan evaluation
The plan metrics considered for quantitative analysis were D95 for PTV70 and PTV56, D1cc
for spinal cord, D1cc for brainstem and mean dose for parotid similar to those used by a
previous study [285]. The percentage dose difference was calculated using equation 7.1
similar to work [285]. It has been suggested that a percentage dose difference of 3–5% can
affect the tumour response and outcome of treatment [286, 287].
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In this paper, we used a percentage dose difference of 5% as a clinical tolerance for D95 of
PTV70 and D95 PTV56, D1cc of the spinal cord and D1cc of the brainstem [285]. Hunter
et al [288] demonstrated that a mean parotid dose difference of less than 3.6 Gy was not
clinically important as radiobiological models do not change below this difference. For the
parotid gland, a percentage dose difference of 10% in the mean dose to the parotid was
used as the clinical tolerance; however, if a difference of greater than 3.6 Gy in the mean
dose to parotid was seen this was also noted for comparison as suggested in previous studies
[285, 288].







7.3.1 Evaluation of plan metrics
Figure 7.2 displays the average percentage dose difference over ten patients in D95 of PTV70,
D95 of PTV56, D1cc for spinal cord, D1cc for brainstem and the mean dose to the parotid (for
parotid that was spared during optimisation) for simulated JW, CS, GP and GSP errors. The
overall impact on the dose distribution from each error type varies both with the magnitude
and direction of the errors from the planned values as well as between patients as indicated
by error bars (Figure 7.2). The patient dose distribution was compromised either by under
dose to the target or overdose to the OAR based on the set clinical tolerance when simulated
delivery errors of JW ≥ 1mm, CS ≥ 2.5% cm per sec and GP ≥ ±2 sec were reached. A
difference of greater than 3.6 Gy in the mean dose to parotid was seen in 5 patients out of
10 for simulated errors of JW of 1.5 mm, CS of -3% cm per sec, GP of -3 sec and MLC42
stuck open. For the JW, CS and GP systematic errors, noticeable dosimetric variations from
the clinical reference plan DVH are seen in figure 7.3 for one representative patient dataset.
Overall, the impact of GSP error up to 40 on patient dosimetry particularly PTV70 was
small, as demonstrated by only small changes in percentage dose difference (figure 7.2) and
by small shifts in the dose volume histograms (DVHs) for all structures (figure 7.3).
Figure 7.4 displays the distribution of the ten patient datasets for which the dose variation
are within the set clinical tolerance. From the patient cohort data considered here to ensure
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Figure 7.2: The average percentage dose difference compared to the clinical reference (no
error) plans over the ten patients for a) D95 of PTV70, b) D95 of PTV56 c) D1cc for spinal
cord, d) D1cc for brainstem and e) mean dose to the parotid. The error bars represents one
standard deviation in plan metrics from the ten patients. The red dotted line represents the
set clinical tolerance
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Figure 7.3: DVH graphs for a representative patient data set comparing the clinical reference
plan with the following simulated errors a) Jaw width b) Couch speed c) Gantry period and
d) Gantry start position. Other patient datasets demonstrated similar variation
dose variation is within the set clinical tolerance, the machine QA tolerance should be set to
JW 0.5 mm, CS 1.5% cm per sec, GP 1 sec and GSP 20.
The average percentage dose difference with simulated MLC LOT errors is presented in
figure 7.5. For the MLC LOT error with MLC stuck open and a MLC LOT random reduction
of 4%, noticeable dosimetric variations from the clinical reference plan DVH are seen (figure
7.6). The MLC LOT random error up to 10% with mean MLC LOT error of 0% did not
display any effect on the dose distribution.
Figure 7.7, 7.8 and 7.9 shows example of degradation in the dose distribution from four
different simulated delivery error types for a same patient with error magnitudes that were
found to be clinically relevant.
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Figure 7.4: Histogram distribution of the treatment plans from the ten patient cohort that are
within the set clinical tolerances (both PTV and OAR) for varying magnitude of errors in
a) Jaw width (JW) b) Couch speed (CS) c) Gantry period (GP) and d) Gantry start position
(GSP). The red dashed bar shown above represents the machine interlock threshold for each
error type. The jaw error has 2 levels of interlocks while the couch speed does not have a
specific interlock since the couch position is monitored instead of the couch speed
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Figure 7.5: The average percentage dose difference compared to the clinical reference (no
error) plans over the ten patients for a) D95 of PTV70, b) D95 of PTV56, c) D1cc for spinal
cord and c) D1cc for brainstem and d) mean dose to the parotid with simulated MLC LOT
errors. Two random MLC LOT errors were considered: i) The reduction was randomly
applied across all open leaves such that the mean reduction was 2% or 4% and ii) The MLC
LOT random modification applies a normal random distribution to all open projections with
a given standard deviation (1-10%) and a mean of 0%. The error bars represent one standard
deviation in plan metrics from the ten patients. The red dotted line represents the set clinical
tolerance
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Figure 7.6: DVH graphs for a representative patient data set comparing the clinical reference
plan with the following simulated MLC LOT errors: leaf 32 stuck open, leaf 42 stuck open
and MLC LOT reduced by 2% and 4% and standard deviation of 5% and 10% with mean
MLC LOT error of 0% as described in the methodology. Other patient datasets demonstrated
similar variation
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Figure 7.7: Isodose distribution comparison between the reference clinical plan and each
of the four simulated delivery error plans a) transverse view cutting through isocentre. The
dose distribution example is from one selected patient dataset and shows the worst impact
on the dose distribution. The simulated error magnitude were for JW was +1 mm, CS +2.5%
cm per sec, GP +3sec and GSP +40. The magnitude for each error type displayed here was
such that the set clinical tolerance was exceeded.
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Figure 7.8: Isodose distribution comparison between the reference clinical plan and each
of the four simulated delivery error plans coronal view cutting through isocentre. The dose
distribution example is from one selected patient dataset and shows the worst impact on the
dose distribution. The simulated error magnitude were for JW was +1 mm, CS +2.5% cm
per sec, GP +3sec and GSP +40. The magnitude for each error type displayed here was such
that the set clinical tolerance was exceeded.
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Figure 7.9: Isodose distribution comparison between the reference clinical plan and each
of the four simulated delivery error plans sagittal view cutting through isocentre. The dose
distribution example is from one selected patient dataset and shows the worst impact on the
dose distribution. The simulated error magnitude were for JW was +1 mm, CS +2.5% cm
per sec, GP +3sec and GSP +40. The magnitude for each error type displayed here was such
that the set clinical tolerance was exceeded.
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7.4 Discussion
In this study, we present a framework to simulate several HT mechanical errors and assess
the clinical impact on HT plans typical of nasopharynx treatments in our clinic. Further-
more, we demonstrate how clinically meaningful HT QA tolerances can be developed and
provide examples of how to evaluate the sensitivity to errors of several delivery parameters
for individual treatment sites. We also assess the effectiveness of the machine interlock set-
tings in preventing the simulated parameter errors that were found to be clinically relevant.
The dose variation due to simulated errors exceeds the set clinical tolerance in patient co-
horts for the following simulated errors: in JW ± 0.5 mm, CS ranges between -1% cm per
sec to 1.5% cm per sec, GP ranges ± 1sec, GSP ranges between -1.50 to 20 and MLC LOT
random error up to 2% from the planned value. The sensitivity of all the simulated delivery
errors reported in this study are applicable to nasopharynx treatments planned with similar
planning parameters used and dose fractionation (2-2.4 Gy). As seen in Table 7.3 and fig-
ure 7.4, for the plans considered the current machine interlocks will prevent delivery errors
resulting in a clinical impact with a few exceptions. In the case that the primary interlock
for JW fails, the secondary interlock of 1.25 mm may not prevent clinical impact as this
work demonstrated that a JW error > 1mm would affect the patient dosimetry. A tighter
tolerance on this interlock should be considered for 2.5 cm JW. The suggested QA tolerance
by AAPM Task Group 148 [47, 50] for JW is FWHM within 1% (i.e. 0.25 mm for 2.5 cm
JW) and GSP within 10.
In addition, our study demonstrates that MLC LOT and GP errors can lead to unaccept-
able dose distribution. While the MLC LOT and GP performance is stringently monitored
during treatment, no specific recommended QA test frequency and tolerance to monitor the
performance for MLC LOT and GP is suggested in the AAPM TG-148 report [47]. We
recommend that routine QA tests be implemented to monitor MLC and GP performance.
Although couch speed itself is not monitored, a matrix of couch position versus time based
on pitch is created by planning system and the interlock will trigger when the instantaneous
position of the couch deviates by more than 1 mm during couch travel at specific time. We
created a similar matrix of table position versus time for the first five gantry rotations using
a pitch value and jaw width for the planned couch speed as well as for simulated errors in
couch speed of ±2% cm per sec, ±3% cm per sec and ±5% cm per sec to determine the
interlock threshold for couch speed. As shown in figure 7.10, even couch speed errors of
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2% cm per sec and 5% cm per sec from planned values which is demonstrated as clinically
relevant would be undetected by machine interlocks for an initial couch travel of 50 mm
and 22 mm respectively. This suggests that the couch position should be monitored with
improved precision. Fortunately, an internal review of patient logs files from actual patient
treatments at our centre suggest that the average error value in couch position was observed
to be 0.20 ± 0.05 mm from the expected position.
Table 7.3: Summary of machine interlock, recommended machine QA tolerance and estab-
lished using dosimetric based simulation
Machine
parameter




Dosimetric based QA toler-
ance
Jaw width Primary interlock 500 microns
Secondary interlock 1.25mm
1% of JW ( 0.25
mm for 2.5 cm
JW)
0.5 mm for 2.5 cm JW
Couch speed Couch position at any point of
delivery is differing by 1mm
from
the planned value
2% < 1.5% from planned value
Gantry period 2% of planned value No specific toler-
ance
< 1 sec of planned value
Gantry
position
± 0.10 from planned value
(Tomo-Direct capable machine)
10 1.50
MLC LOT Leaf does not begin to move in
about 40ms from the time when
a leaf does not reach its des-
tination in about 70ms when a
leaf moves past its intended des-
tination Leaf reaches its desti-
nation in the allotted time, but
then transitions back to the tran-




Random error 2and mechan-
ical fault ( individual stuck
open or closed)
A simulated error in GSP, similar to patient rotation setup error (roll), up to±30 did not show
any clinical impact on the planned dose distribution (in 8 out of 10 patients) indicating that
this error is less sensitive compared to other delivery errors simulated in this study. Although
not directly comparable, simulated GSP error < 30 also did not show any clinical impact
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Figure 7.10: Comparing the expected couch position calculated based on planning parame-
ter against the predicted couch position for simulated couch speed delivery error of±2% cm
per sec, ±3% cm per sec and ±5% cm per sec from planned value. The dotted red lines are
the machine interlock threshold when the couch position is different from expected planned
value (±1 mm)
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for c-arm linac based treatments such as RapidArc™[43] and IMRT delivery [133, 281]
demonstrating GSP error is insensitive for linac based treatment as well. The JW and CS
simulated errors were uniformly applied to all planned projections leading to a threading
effect (refer to figure 7.8 coronal view), as both effectively change the pitch. The dose
variation pattern that manifest as a ‘ripple’ (peak-to-trough relative to the average dose).
This ripple in dose distribution is called threading effect. A detailed explanation about the
threading effect can be found in previously reported studies [289, 290].
The threading effect has been shown to be dependent on the pitch value used, off-axis dis-
tance of the RT structures, and beam divergence [290]. The average off-axis distance of the
farthest pixel in PTV56 was 11 cm. For GP and GSP errors the angles of radiation incidence
are changed. This can lead to beams with high fluence through OARs or partially missing
an off-axis located target e.g. PTV56 (figure 7.11). Because the spatial relationship of PTV
to the parotid glands (i.e. overlap or clearance) varies from one patient to another (see fig-
ure 7.12), the effect of GP and GSP error is patient and plan specific and nonlinear. For
GP errors, the angular offset in delivered projections from the planned position increases
as a function of beam-on time. As demonstrated in figure 7.2, the gantry offset due to GP
error had a major impact on an elongated and off-axis located PTV56. In (Appendix B), we
studied the clinical impact of intentional HT delivery errors on lung SABR cases (i.e. long
duration treatments) using the same framework proposed in this chapter and demonstrated
that GP error have higher clinical impact on patient dosimetry compared to conventional
fractionation treatment studied in this work. This suggest GP error will have a detrimen-
tal impact on long duration treatments such as total marrow/body irradiation (TMI/TBI) or
located far off-axis structures or lung SABR cases (Appendix B). and therefore the impact
from GP error could be much higher than what is presented here for these clinical scenarios.
One of the limitations of this work is the limited patient sample size. However, this frame-
work can be used as an ongoing machine learning process. One approach would be for the
process to be applied to an individual patient dataset to determine the plan specific deliv-
ery error threshold as well as validate plan robustness for a given machine QA tolerance.
Another approach would be to evaluate the QA tolerance by considering the appropriate
sample size for given treatment sites. There is growing interest to use the log file-based QA
approach [291–293]. It is still not certain whether the log file-based QA approach offers the
same confidence as real dosimetric measurements. Independent commissioning and robust
routine QA of the sensors reported in the log files may be also required. Unfortunately, the
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Figure 7.11: Illustration of dosimetric impact due to the gantry related delivery error i.e.
gantry start position (GSP) and gantry period (GP). Error in GP or GSP will systematically
offset the projection from the planned position (left) such that high fluence projections are
rotated from their intended angles, affecting the delivered dose distribution
Figure 7.12: The transverse CT images for 3 different patients showing the spatial variation
of the PTV70 contour (red colour) relative to parotid (cyan-right and purple-left side). The
green contour is PTV56.
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TomoTherapy log file is missing MLC information, which is one of the major uncertainties
of treatment delivery. Instead, the log files report only the average error value between the
planned and actual couch position. It should also be noted that we did not investigate the
effect of combinations of errors. Therefore, our work has studied the clinical effects where
only a single interlock might fail. That said the framework we have developed could be
extended to study combinations of errors and is a potential topic of future work.
7.5 Conclusion
Dose variation in the considered nasopharynx dataset was within set tolerances for simu-
lated errors in JW up to 0.5 mm, CS up to 1% cm per sec, GP up to 0.5 sec, GSP up to
20 and MLC LOT random error up to 2% from the planned value for HT plans with jaw
width of 2.5 cm, pitch of 0.287 or 0.403 and dose per fractionation of 2-2.4 Gy. Most of
the clinically relevant errors are prevented by machine interlocks except the couch position
and the secondary interlock for jaw position. Our study highlights that the system inter-
lock thresholds for jaw position and couch position should be tighter and monitored with
improved precision than monitored currently to avoid any clinically relevant delivery errors.
This work has established a method to characterize HT machine delivery errors and estimate
their clinical significance. We demonstrated that the effect of these delivery errors could be
plan technique/site specific (particularly gantry speed errors). This work can be extended to
additional error modes and other treatment techniques/anatomical sites in the future. Using
this approach, a HT QA program can be strengthened by consideration of treatment sites,
institution-specific planning methods, and clinical tolerances.
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Inaccurate radiotherapy can result in ineffective treatment or serious harm to the patient [14].
Advanced radiotherapy technologies and methods such as intensity modulated radiotherapy
(IMRT), volumetric modulated arc therapy (VMAT) and helical tomotherapy (HT) are com-
plex and are less tolerant to poor implementation than are standard techniques [294]. HT is a
dynamic delivery that relies on synchronisation of the gantry, treatment couch, and multileaf
collimator(MLC) leaf movement with the radiation beam during treatment [49]. For these
treatments, an optimised treatment plan (i.e. inverse planning) is tailored to each individual
patient. The beam apertures generated during optimisation are highly complex and bear little
resemblance to treatment beam fields used during TomoTherapy commissioning. Therefore,
stringent delivery quality assurance (DQA) methods are recommended to ensure the correct
treatment delivery for each patient [90], which should be conducted for each clinically ap-
proved plan prior to delivering the first treatment fraction to detect possible errors (both the
dose calculation accuracy of the treatment planning system (TPS) and accuracy of treatment
delivery). A wide variety of instrumentation and experimental methods are in clinical use for
pre-treatment verification. Historically, HT DQA was performed with film or ion chamber
point dose measurements [47]. The complexity and inefficiency of film dosimetry proce-
dures has led to the development of systems that provide real-time measurements. In recent
years a number of (2D, semi 3D and 3D) commercial detector arrays have become available
including the Delta4 (ScandiDos AB, Uppsala, Sweden), ArcCHECK/MapCHECK (Sun
Nuclear Corp., Melbourne, FL), MatriXX (IBA Dosimetry GmbH, Schwarzenbruck, Ger-
many), and 2D-ARRAY seven29 (PTW, Freiburg, Germany) for pre-treatment verification
that provides real-time measurements [51, 153, 156, 208, 295, 296]. Most clinics have now
routinely adapted these commercially available dosimeters to perform HT DQA [297–301].
The gamma evaluation technique has become the current standard to provide a quantitative
comparison [109]. However, there is limited evidence in the literature about the ability of
such dosimetry systems to detect delivery errors for HT treatment deliveries.
Several studies (summarised in Table 8.1 have assessed the sensitivity of different detectors
to IMRT and/or VMAT simulated errors. Fredh et al. [58] investigated a number of mea-
suring devices and the response of these devices to MLC bank positional errors, dosimetric
errors and collimator errors introduced into patient plans. Their study concluded that the
different detectors were able to detect particular errors; however they did not quantify the
sensitivities in detecting these errors. Arumugam et al [54] evaluated the sensitivity of Arc-
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CHECK dosimeter to VMAT delivery associated with MLC and dose output errors. Their
study inferred that ArcCHECK was able to detect a minimum of 3 mm MLC error, and 3%
output errors. Detector sensitivity for error detection also depends on plan complexity.
Table 8.1: Summary of previous reported studies on detector sensitivity for commercial
detectors.
Detector Treatment Error type Treatment sites Key reference
type (number of plans)




Masi et al [52]
Rapid Arc MLC position and
Dose error
Prostate (not specified) Carver et al [302]
Rapid Arc MLC, dose and
collimator error
Prostate,head and neck and
brain(4 plans)
Fredh et al [58]
ArcCHECK IMRT(SW) Gantry rotation,
MLC position








VMAT Dose error, MLC
error













MapCHECK IMRT (S&S) MLC error Head and Neck(8 plans) Yan et al [46]
IMRT (S&S) MLC error Head and Neck(1 plan) Le´tourneau et al
[55]
MatriXX IMRT(S&S) MLC position and
collimator error










Masi et al [52]
Rapid Arc MLC, dose and
collimator error
Prostate,head and neck and
brain(4 plans)






plans) and test pattern(one)
Hussein et al [57]
SW=Sliding Window; S&S= Step and Shoot
Feygelman et al [51] have demonstrated that the larger gantry spacing between the CPs and
narrow field width results in larger errors in dose calculation, especially in the ArcCHECK
measurement plane compared to Delta4 detector [51]. This is mainly due to the discretisation
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of the gantry angle aperture shapes in the TPS dose calculation. Masi et al [52] measured
clinical VMAT plans using four different dosimetetr systems. Authors reported slightly
lower gamma pass-rate for plans from one of the considered planning systems which was
attributed to a higher level of complexity of the optimised plans. The detector sensitivity
to intentional 3 mm translation shifts and to gantry angle offset was shown to be strongly
plan and partially detector dependent. Bawazeer et al [56] demonstrated the MatriXXEvolution
(IBA Dosimetry, Germany) 2D detector was able to detect MLC position errors of 1 mm and
collimator rotation errors of 20 for step and shoot IMRT delivery. All of the above detector
sensitivity studies focused on the MLC positional accuracy, collimator or gantry rotation
and dose errors for C-arm linac based treatment and may therefore may not be relevant to
the different delivery mechanism of HT machines.
The only study on detector sensitivity to detect HT delivery error using the ArcCHECK
dosimeter was reported by Templeton et al [59]. They measured a total of nine clinical
plans: three head and neck, three prostate with pelvis nodes, and three prostate only. The
ArcCHECK sensitivity was assessed to detect intentionally introduced delivery errors in
couch speed, gantry start position and MLC leaf open time. No specific details about plan-
ning parameters were provided for clinical plans used in their study. Author reported the
error size required to degrade the gamma pass rate to 90% or below (using 3% and 3 mm
gamma criteria) was on average a 3% change in couch speed, 50 change in gantry synchro-
nisation ( i.e. gantry start position), or a 5 ms change in leaf closing speed.
Our previous work [303, 304] (as described in chapter 7) evaluated the clinical impact of HT
delivery error in couch speed, jaw width and MLC leaf open time errors for ten nasopharynx
clinical plans. In this work, we have compared the sensitivity of two commercial dosime-
ters MatriXXEvolution and ArcCHECK to detect clinically relevant errors in couch speed, jaw
width and MLC leaf open time errors for the same sets of ten clinical nasopharynx HT plans
considered in Chapter 7. The focus of the present work was to determine how the intention-
ally introduced delivery error would be manifested in QA dosimetry system measurements.
The threshold was determined at which these dosimeters are sensitive to particular delivery
errors. For each of the dosimeters, two parameters were evaluated i) the minimum error
magnitude that the detector systems can detect (i.e. threshold) and ii) how the sensitivity to
the errors varies between detector systems (i.e. sensitivity to a particular error).
In this work, we have compared the sensitivity of two commercially available dosimeters
8.2. Methods and Materials 134
MatriXXEvolution and ArcCHECK to detect intentionally introduced delivery errors in jaw
width, couch speed and MLC LOT using gamma criteria of 3% and 3 mm for ten clinical
nasopharynx HT plans. The focus of the present work was to determine how the intention-
ally introduced delivery errors would be manifest in QA dosimetry system measurements,
given the fact that there is marked deviation from patient geometry. The threshold was deter-
mined at which these dosimeters are sensitive to particular delivery errors. Two hypotheses
were tested i) the minimum error magnitude that the detector systems can detect (i.e. thresh-
old) and ii) that how the sensitivity to errors varies between detector systems (i.e. sensitivity
to a particular error).
8.2 Methods and Materials
8.2.1 Patient selection and treatment planning
Ten retrospective clinical nasopharynx HT plans with varying complexity were selected for
this study used in previous work [304] and previous chapter 7 . All ten clinical plans were
optimised using a fixed 2.5 cm jaw width, 0.287 or 0.403 pitch and 2.2-2.4 modulation factor
with the clinical TomoTherapy (Accuray Incorporated, Sunnyvale CA) TPS version 4.2.2,
to meet planning goals outlined in the RTOG 0615 protocol [305].
8.2.2 Dosimetry system
Two commercial dosimetry systems were considered. The construction details and addi-
tional corrections required to convert the measured signal to dose for each dosimeter system
are described in following sections
8.2.2.1 MatriXXEvolution dosimetry system
The MatriXXEvolution system consists of a MatriXX device (a two dimensional array of ion-
ization chambers), a MULTICube Lite (IBA Dosimetry) phantom, and OmniPro-I’mRT
software (IBA Dosimetry, Germany). This array has 1020 air-vented plane parallel ion-
ization chambers (with a volume of 0.08 cm3 each) arranged in a 32 × 32 grid providing a
maximum field of view of 24 × 24 cm2. The ionization chambers are spaced at 7.62 mm
centre-to-centre. The MatriXXEvolution measurements were made in the movie mode with a
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sampling rate of 500 ms/snap (i.e. 500 ms/image). The MatriXXEvolution device was inserted
into the MULTICube Lite phantom. The MULTICube Lite is made of plastic water with
dimensions 31.4 cm long, 22 cm high and 34 cm wide. The MULTICube Lite phantom
is positioned on HT couch. The absolute dose calibration procedure recommended by the
manufacturer was followed to calibrate the device. Only chamber sensitivity correction and
calibration correction were applied to the measured signal. In the HT setting, the angular
correction cannot be applied as the dosimetry system relies on inclinometer input for obtain-
ing the instantaneous gantry position information and the inclinometer cannot be attached
to a HT unit due to the gantry head access.
8.2.2.2 ArcCHECK dosimetry system
ArcCHECK is a cylindrical phantom that consists of 1386 diode detectors arranged in a
helical grid pattern with 10 mm detector spacing. The helical grid detector array has di-
mensions of 20.8 cm diameter and 21 cm length with detectors at a depth of 2.9 cm from
the surface of the phantom [51]. The dose measured by each detector is corrected for back-
ground, heterogeneity and diode angular response and field size sensitivity. The ArcCHECK
dosimeter used in this study included the central cylindrical insert and all measurements
were performed with the cylindrical insert in place. The absolute dose calibration procedure
recommended by the manufacturer was followed to calibrate the device.
8.2.2.3 DQA Plans
DQA plans were recalculated by superimposing the clinical plan dose on phantom CT
images. The scanned MatriXXEvolution images were imported as a QA phantom for the
MatriXXEvolution dosimetry system. In the case of the ArcCHECK dosimetry system, a
pseudo CT dataset (supplied by manufacturer) representing the ArcCHECK geometry was
imported as a QA phantom. A uniform density of 1.15 g/cm3 was assigned to the Arc-
CHECK geometry as per manufacturer guidelines as well as used in previous work [63, 306].
The ArcCHECK was positioned such that the diodes passed through the high dose region
of the plan, which resulted in an off-centred location of the QA phantom. The planned dose
corresponding to the measured dose was extracted by the SNC Patient Dose Analysis soft-
ware (version 6.6, Sun Nuclear Corporation, Melbourne, Florida, USA) from the DICOM
3D dose cubes calculated on the ArcCHECK phantom geometry [51]. In the case of the
MatriXXEvolution , the planar dose was directly extracted from the TPS at the detector plane.
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8.2.2.4 Delivery errors and measurements
A HT delivery plan is defined by the following parameters; jaw width, gantry period, gantry
start position and a sinogram (a matrix which defines the fraction of MLC LOT for each
projection). In Chapter 7, we simulated all the above mentioned delivery errors to evaluate
their clinical impact on patient dosimetry for a range of error magnitudes. In this work, we
investigated the sensitivity of two detectors for delivery errors in jaw width, couch speed
and MLC LOT only for error magnitude that was demonstrated to be clinically relevant
i.e. compromise the patient dosimetry. For each patient, error plans were created by inde-
pendently introducing systematic offsets in: a) jaw width error ±1, ±1.5 and ±2 mm, b)
couch speed error ±2%, ±2.5, ±3% and ±4%, and c) MLC leaf open time (MLC LOT)
errors. Three scenarios for MLC errors considered were: leaf 32 stuck open during deliv-
ery, leaf 42 stuck open during delivery (these leaves are commonly used to treat central and
off-centered targets for head and neck cases) and 4% random reductions in MLC LOT from
planned values. In the case of MLC LOT errors, the optimized clinical plan sinogram was
edited using MATLAB (version: 7.10.0.499 (R2010a), Mathworks Inc., MA). The random
error was simulated by using a normal distribution with a standard deviation of 4% and leaf
open times greater than 100% are not possible to deliver, so were truncated. All intentional
error plans along with the ‘no error’ plan for each patient were measured using both dosime-
try systems in the same session to minimize any machine output or experimental variations.
Prior to each measurement session, daily output and a cross plane profile were measured us-
ing TomoDOSE (Sun Nuclear Corporation, Melbourne, Florida, USA) as a constancy check
to monitor machine behaviour. The gamma evaluation (global) technique (3%/3 mm) was
applied to quantitatively compare the measured dose from the two dosimeters against the
TPS. The 90% gamma pass rate is an action level at approximately the mean pass rate of
previously treated plans for similar complexity in our clinic minus two standard deviations,
as proposed in previous studies [59, 307]. The phantom set up accuracy was verified by
on-board megavoltage CT (MVCT) image guidance prior to each measurement session.
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8.2.3 Detector sensitivity
The sensitivity of both detectors to delivery errors was studied by calculating the gradient
of the global γ pass rate (equation 8.1) for each error scenario.
5γ = 4γ pass rate
4 introduced error
(8.1)
Where, (4γ pass rate) is the change in γ pass rate and (4 introduced error) is the unit
change in introduced error. The 5γ for a given error scenario was calculated by fitting
the γ pass rate for the studied error range using a linear least square fit. The gamma pass
rate and Wilcoxon Signed–Rank significance (P < 0.05) test were used to decide whether
an intentional introduced error can be detected by the dosimetry systems. The number of
dose measurements points used for gamma computation are different for MatriXX and Arc-
CHECK dosimeters due to difference in detector geometry and detector spacing. Therefore,
the absolute gamma pass rate when measured for same clinical plan using both dosimeters
would not be directly comparable. To compare sensitivity in detecting intentional errors for
each dosimeter as a measure of change in gamma pass rate, first, the gamma pass rate with
no error plan is normalised to 100% and then, the gamma pass rate for each intentional error
plans were scaled to no error plan.
8.2.4 Criteria for minimum error detection
In the presence of varying complexity in clinical plans, the gamma pass rate for these plans
are expected to exhibit a considerable spread for both intentional error and no error plans. In
order to detect the error confidently in studied plans, a clear separation between the no error
and intentional error delivery was defined by incorporating the standard deviation of the γ
pass rate for both no error and intentional delivered error plans. As described in a previous
study [54], an error in the simulated plan was considered detected when the criterion given
in equation 8.2 is met.
(mean γ pass rate+ σ of γ pass rate) for error delivery <
(mean γ pass rate− σ of γ pass rate) for no delivery error
(8.2)
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Where, σ is the standard deviation of the pass rate of the respective no-error and intentional
delivery error plans.
The quantity on the right hand side of equation 8.2 represents the minimum pass rate (lower
limit) observed in the no error delivery. Subtracting the σ of the no error plans from the
mean pass rate of the no error plans allows the difference in level of complexity between
plans to be considered. The quantity on the left hand side of the equation represents the
maximum pass rate (upper limit) observed with the detected error. Adding the σ defines the
upper limit of pass rate again considering plan complexity variation.
8.3 Results
8.3.1 Detector sensitivity
The mean (γ) global gamma pass rate for intentional error plans measured with both dosime-
ter systems is shown in figure 8.1. The global γ pass rate for the 3%/3 mm tolerance criteria
decreased linearly with increase in error magnitude for both dosimeters. The error mag-
nitude change required to degrade the gamma pass rate for each error type as well as the
detector sensitivity determined using equation 8.1 for each error type is summarised is Ta-
ble 8.2.
Table 8.2: Magnitude of change required to degrade mean gamma pass rate to below 90%
with 3%/3mm gamma criteria and detector sensitivity as determined from equation 8.1 for
both dosimeters. A linear fit of mean gamma pass rate versus error magnitude was used to
obtain both error magnitude to degrade gamma pass rate below 90% and detector sensitivity
Error type Error direction Error magnitude to degrade the Detector sensitivity5γ
/details mean gamma pass rate ≤ 90%
MatriXX ArcCHECK MatriXX ArcCHECK
Jaw width Negative 0.4 mm 0.8 mm 18.2 12.4
Positive 0.2 mm 0.3 mm 32.9 30.3
Couch speed Negative 0.7% 0.8% 10.3 9.8
Positive 2.1% 2.2% 4.3 3.8
The gamma pass rate for intentional introduced errors in JW and CS are dependent on the
error direction (see figure 8.1 and Table 8.3; -2% and +2% differ for couch speed and -1 mm
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Figure 8.1: Comparison of mean gamma pass rate measured for intentional error plans in
jaw width, couch speed and MLC LOT measured with ArcCHECK and MatriXXEvolution
dosimeters. The error bar shows maximum and minimum pass rate for a given error magni-
tude. The dotted red line represents 90% gamma pass rate used as an action level. The mean
pass rate for no error plan for both dosimeter is normalised to 100% and gamma pass rate
for each plan is then scaled to no error plan
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and +1 mm for jaw width).
8.3.2 Error detection by dosimeter systems
Table 8.3 summarises the mean and mean-σ of γ pass rate for no error plans with 3% and 3
mm global gamma tolerance criteria along with mean+σ of γ pass rate for couch speed and
jaw width error plans. The Wilcoxon Signed–Rank test indicated a similarity in gamma
pass rate metrics between the two dosimetry systems (p > 0.05). Although the overall
mean gamma pass rates for both dosimeters is comparable, the error detection magnitude is
slightly superior for MatriXXEvolution compared to ArCHECK (Table 8.3).
Table 8.3: Summary of gamma pass rate with 3%/3mm tolerance criteria and error detected.
The statistical Wilcoxon Signed–Rank test was used to evaluate difference in sensitivity
between two dosimetry systems for detecting the delivery error
Error Error Mean of γ pass rate (Mean-σ) of γ pass rate (Mean+σ) of γ pass rate p-value
type magnitude (95%
CI)
AC MAT AC MAT AC MAT
No error 0 97.5 95.7 95.1 92.8
Couch -4 58.7 62.5 72.1 78.5 0.374
speed -2.5 73.5 74.1 86.7 87.1 0.678
(%) 2.5 89.6 86.7 95.8 89.8 0.508
4 80.7 75.5 88.7 87.6 0.173
Jaw -2 72.7 57.4 85.8 69.7 0.096
width -1.5 81.3 72.5 95.8 85.9 0.186
(mm) 1.5 63.9 59.9 64.2 71.7 0.441
2.0 34.1 34 48.1 51.1 0.515
MLC MLC 32 stuck 24.8 29.3 55.2 53.8 0.443
LOT MLC 42 stuck 21.8 36.7 50.8 68.9 0.172
Random 4% 36.3 46.7 71.1 80.3 0.612
AC=ArcCHECK; MAT= MatriXXEvolution
8.4 Discussion
The approach we used in this work was to introduce errors that can occur based on machine
malfunction or calibration errors. The effect on clinical dosimetry from the same intentional
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introduced errors for the same sets of clinical plans in a patient geometry was quantified in
our previous work [303, 304] and is presented in Chapter 7. All the errors introduced in this
study to evaluate the detector sensitivity were demonstrated to be compromised the patient
dosimetry and hence considered clinically relevant [303, 304]. We did not assess the detector
sensitivity for gantry related errors. We demonstrated the gantry start position (GSP) error
was least sensitive among all the delivery simulated in our previous work [303, 304]. More-
over, the sensitivity for GSP error for ArcCHECK was investigated in previous work [59]
and hence did not consider the GSP error in this work. Regarding the other gantry related
error i.e. gantry period (GP), there was a physical limitations on the machine to maintain the
same treatment time to that of reference plan, when the GP from the patient calibration pro-
cedure is edited. Any change in gantry period error from the patient calibration procedure
leads to change in treatment time which is proportional to the magnitude of change in gantry
period. Therefore, we could not able to measure the GP delivery error. In this work, we have
compared the sensitivity of two commercially available dosimeters MatriXXEvolution and Ar-
cCHECK to detect intentionally introduced clinically relevant delivery errors in jaw width,
couch speed and MLC LOT for ten clinical nasopharynx HT treatment plans. The threshold
was determined at which these dosimeters are sensitive to particular delivery errors.
Intentional delivery errors in couch speed or jaw width had an impact on overall dose distri-
bution. The resultant dose discrepancy was spread uniformly over the entire treated volume
but worse at the superior and inferior ends of the treatment volume. The MatriXXEvolution
shows slightly higher sensitivity to both these delivery errors compared to the ArcCHECK
(Table 8.2 and 8.3). This could be due to the relatively coarse detector resolution of Arc-
CHECK (10 mm) compared to MatriXXEvolution (7.62 mm) in the superior-inferior direction.
Templeton et al [59] also studied the detector sensitivity of ArcCHECK for intentional de-
livery errors in couch speed and demonstrated an intentional error of 2.8% in couch speed
led to a gamma pass rate ≤ 90% for head and neck cases. Our work found this threshold to
be -2.0% to +0.8% determined using linear interpolation from linear fit of the mean gamma
pass rate vs error magnitude (R2 ≥ 0.95).
Templeton et al [59] did not provide details about complexity and planning parameters used
for the head and neck plans used in their study. Therefore it is difficult to compare our
results directly with Templeton et al [59]. Templeton et al [59] also reported the increase
and decrease of a given parameter of the same magnitude yields similar passing rates. Our
results for couch speed and jaw width introduced errors showed the increase and decrease
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of a given parameter of the same magnitude yields different gamma pass rates (Table 8.3).
Similar trends were observed in the relative change in dose volume histogram metrics in our
previous dosimetric simulation work [303]. There were variations in plan complexity within
the cohort of clinical plans used in this study even though they were from the same clinical
site. This may have contributed to the large variations in gamma pass rates for the same error
magnitude (figure 8.1). The factors that determine the clinical plan complexity are treatment
plan length, targets off-centred from the machine rotational axis [58, 59], spatial separation
between target and organ at risk, institute specific planning protocols. Therefore, it is im-
portant that each clinic should evaluate carefully detector sensitivity in detecting delivery
errors and understand the limitations of dosimetry systems for their clinical applications
and planning protocols. Table 8.4 compares the minimum magnitude of detected error (i.e.
threshold) between the two dosimetry systems to the error magnitude that was demonstrated
in Chapter 7 to be clinically relevant [303] and the set machine interlock tolerance.
Table 8.4: Comparison of minimum error detection by dosimeters, clinically relevant error
magnitude based on dosimetric simulations and machine interlock
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about 40ms from the time ii) when
a leaf does not reach its destination
in about 70 ms when a leaf moves
past its intended destination
Both of the detectors show similar sensitivity to all the MLC LOT errors that were clinically
relevant. A recent study by Fredh et al [58] measured the intentional delivery error plans
for RapidArc (Varian Medical Systems, Palo Alto CA) plans. They demonstrated a wide
variation of ability to detect the delivery errors when measured with the same error plans
and different dosimetry systems. The variation in the ability to detect the delivery errors
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between the two dosimetry systems for intentional errors simulated in this study could be
associated with a number of factors, including the detector resolution, implementation of
gamma reporting within different dosimetry systems, variation in data processing to con-
vert the measured signal to dose, variation in plan complexity and the way the QA plan is
prepared. Neilson [299] demonstrated a higher gamma pass rate (by about 3.3%) for the
same clinical plan when measured by aligning the high dose volume with the detector plane
compared to the QA plan with high dose situated at the centre of the phantom. In this work,
we aligned the high dose with the detector plane for consistency while preparing a DQA
plan with both dosimetry systems. We also monitored the machine behaviour prior to each
measurement session, which was found to be stable and consistent (i.e. machine output
was within 0.25% and profile shape measured with a TomoDose detector array was indis-
tinguishable). As illustrated in Table 8.2 and figure 8.1, the sensitivity of error detection
for given magnitude error was different when varied in opposite direction (e.g. JW +1mm
and JW -1mm). Our previous work [304] had shown the resultant dosimetric impact from
intentional JW and CS error for a given magnitude when varied in opposite direction was
different for same clinical plans. This is reflected in sensitivity variation of error detection
(Table 8.2 and figure 8.1). Typically, the phantom based QA measurements are performed
by aligning the detector to high dose region (i.e. high dose PTV). As shown in our previous
work [304], the impact on PTV dose variation is not of same magnitude when delivery error
of similar magnitude introduced in opposite direction. Therefore, the gamma pass rate and
hence the sensitivity of detector would not be similar to same error magnitude when varied
in opposite direction.
An ideal dosimeter is one which can detect inconsistencies between planned and delivered
dose distributions with a high level of confidence. The type of metric used for the dosimetry
system sensitivity analysis has an important role [308]. In this study, the sensitivity of
MatriXXEvolution and ArcCHECK was assessed using the gamma analysis method which is
widely used in clinical practice to compare the measured and planned dose distributions. In
a real situation, the dose measured by a dosimetry system consists of inherent uncertainties
from the treatment delivery as well as from inherent limitations of dosimeters [109, 309,
310] (i.e. detector spacing, angular response etc.). In addition to this, the dose calculated by
the TPS has its own uncertainties due to limitations in the modelling of the treatment beam
[311] and dose computation methods in complex treatment techniques. The combination of
these uncertainties that are difficult to isolate. These uncertainties plays an important role in
the minimum error that can be detected by the system with sufficient confidence in addition
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to plan complexity and robustness to the delivery errors.
8.5 Conclusion
In this work the sensitivity of the MatriXXEvolution and ArcCHECK dosimetry systems in
detecting delivery errors that arise from jaw width, couch speed and MLC LOT for clini-
cal nasopharynx plans has been systematically studied. No statistically significant differ-
ences (p>0.05 95% CI) were found in detecting the simulated delivery errors between the
MatriXXEvolution and ArcCheck dosimeter systems as indicated by the Wilcoxon Signed–Rank
test. Both dosimeters used in the study were able to pick up clinically relevant delivery er-
rors except the ArcCHECK with couch speed up to 2.5% and jaw width up to -1 mm. The
evaluation of both detector’s sensitivity for different clinical sites will be studied in future
work.
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Intensity Modulated Radiation Therapy (IMRT) patient-specific Quality Assurance (QA)
is an important component of any IMRT clinical implementation [90], including helical
tomotherapy (HT) (Accuray Incorporated, Sunnyvale, CA) [47]. Stringent QA methods
are required now more than ever to be confident that the treatment is delivered accurately
for each patient due the associated complexity in treatment delivery and dose distribution
in modern radiotherapy treatments. Methods to perform IMRT patient-specific QA for HT,
also referred to as Delivery Quality Assurance (DQA), commonly include film, ion chamber,
and single planar/multi-planar/cylindrical ion chamber or diode arrays [53, 312–314]. The
underlying limitations of phantom-based IMRT QA process are i) they are time consuming,
ii) their measurement length is limited to approximately 27 cm or below to prevent the
exposure of detector electronics, and iii) the phantoms are very heavy to handle. Also,
all these detectors exhibit angular response. Some systems rely on inclinometer input for
obtaining the instantaneous gantry position information to account the angular response;
which cannot be attached to a HT unit due to the lack of gantry head access. This can
cause additional measurement uncertainty since the angular response cannot be corrected.
Phantom position can also cause measurement variability. Neilson [299] demonstrated a
lower gamma pass (about 3.5%) rate reporting for the same clinical plan when measured by
aligning the high dose volume with detector plane compared to the QA plan with high dose
situated at centre of the phantom in case of ArcCHECK dosimetry system.
HT is a unique delivery method, often tasked with treating long or otherwise large fields such
as cranio-spinal irradiation (CSI) [315–318] and total body/marrow/lymphatic irradiations
[319, 320]. When performing DQA for long treatment fields using phantoms, the mea-
surement device must be re-positioned multiple times to sample the entire treatment field.
Alternatively, multiple films can be used with a custom large phantom [321]. As suggested
by European Society for Radiotherapy and Oncology (ESTRO) [322], patient verification
should be kept as simple as possible, because QA efforts are proportional to the number of
patients. On the other hand, they should be extensive enough to be able to detect errors and
problems.
Previous studies demonstrated the lack of correlation between conventional IMRT QA per-
formance metrics (Gamma criteria) and dose errors in anatomic regions-of-interests [262,
323]. Hence, the interpretation of phantom-based QA results based on widely used gamma
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criteria alone is difficult and challenging to link between QA results and their clinical signifi-
cance. Now, few commercial dosimetry QA systems have implemented the dose reconstruc-
tion algorithm. These systems utilised the measured dose with conventional verification QA
tool and reconstructs the dose inside patient to assess the clinical impact. However, the dose
reconstruction algorithms contain significant approximations and their limitations have been
demonstrated by recent studies [62, 63].
HT is a dedicated IMRT system with on-board MVCT imaging capability. The on board
detector (OBD) consists of an arc-shaped CT xenon detector array located opposite the lin-
ear accelerator on a rotating slip-ring gantry. For the purpose of treatment planning dose
calculation and optimisation, each rotation is divided into discrete 51 sections called pro-
jections. For each projection, each MLC leaf has a unique opening time. Each MLC event
during each projection is stored as a sinogram (as delivery instruction). Sinogram is a bi-
nary file that that contains the data for each projection (fluence or MLC data). The OBD
measured flucene data is stored as binary file and can be extracted from the patient archive.
Methods for the verification of Multi-Leaf Collimator Leaf Open Time (MLC LOTs) have
been reported using the OBD to perform in vivo dose calculation based on dose recon-
struction [215, 216, 218, 324]. Some researchers [64, 65] have proposed a DQA procedure
that involves applying a simple method to verify the MLC performance as a pre-treatment
verification tool using OBD. Pisaturo et al [64] developed a convolution based calculation
model to link the leaf control sinogram from the TPS (treatment planning system) to the
data acquired by the OBD during a static couch procedure. Dose reconstruction approach
using OBD data was demonstrated by Handsfield et al [291] for in vivo dose verification,
but used Monte Carlo (MC) based secondary dose calculations which required more com-
puting resource or a longer calculation time as well as extensive validation/benchmarking of
the MC model accuracy against previously proven dosimeters prior to implement clinically.
Also, Chen et al [218] highlighted challenges with extracting the uncompressed raw projec-
tion data as it can take several minutes to transfer the raw data from the HT machine and
requires proprietary knowledge of accessing the detector files. None of the previously re-
ported studies, on HT pre-treatment verification [64, 65] utilising OBD did not implemented
dose reconstruction.
This work reports on the development of an in-house exit detector based dose reconstruction
DQA tool for HT pre-treatment plan verification which is simple, efficient and yet compre-
hensive to identify MLC LOT errors. Comprehensive validation of this tool for clinical
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implementation purposes is presented. This includes: i) sensitivity to intentional MLC LOT
error ii) dose reconstruction accuracy iii) Gamma analysis metrics comparison of the exit
detector DQA tool versus clinical ArcCHEK DQA methods and iv) an efficiency assessment
of the tool compared to the existing clinical DQA method.
9.2 Theory
The OBD response (R) for a given MLC leaf is modelled as a convolution of two compo-
nents, namely the expected fluence (decomposed into the expected fluence (F) plus a leaf
fluence error (E) resulting from the delivery error if any multiplied by an OBD sensitivity
S (calibration factor) and a Leaf Spread Function (LSF), plus a background signal (B) as
shown in equation 9.1:
R = S(F + E)⊗ LSF +B (9.1)
The LSF is used to model the MLC penumbra. If the LSF is assumed to be independent
of the MLC leaf, the convolution can be reduced to the multiplication of discrete Fourier
transforms according to the convolution theorem, as shown in equation 9.2:




∗ FT (LSF ) (9.2)












The parameters S, B and LSF can be determined using the vendor-supplied TomoTherapy
Quality Assurance (TQA)® daily QA module. The advantage of using this procedure is that
it is already delivered every day as part of morning QA. Figure 9.1 displays the measured
OBD response for the TQA daily QA module.
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Figure 9.1: Exit detector response from TQA daily QA module. TQA daily QA module
comprises of dynamic MLC procedure with varying MLC pattern. Each of the MLC pattern
is sequenced to specific projection interval. The exit detector sensitivity (S), leaf to OBD
channel, background signals (B), and leaf spread function (LSF) were determined from
specific projections interval as shown.
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Figure 9.2: Resultant superimposed even and odd leaf detector response from Daily TQA
module. For projections between 5400-5699 (only the odd MLC leaves are open) and be-
tween projections 5700-5999 (only even leaves are open). This data used to define a map of
MLC leaf to the OBD channel that yields the maximum signal
Following sections described how each of these parameters (S, B and LSF) were determined
using daily TQA procedure.
9.2.1 OBD Sensitivity (S)
Up through projection 2399 (Figure 9.1, all MLC leaves are open and the jaws are open
(-2.4 cm, +2.4 cm), also referred to as J48. By extracting the exit detector channel response
between projections 1000-2000 and dividing by the expected fluence distribution for the
same field size, the OBD sensitivity (S) can be determined as shown in Figure 9.2
9.2.2 MLC leaf Map
The projections between 5400-5699, only the odd MLC leaves are open, and between pro-
jections 5700-5999, only even leaves are open. Figure 9.3a shows the superimposed even
and odd leaf profiles as a function of OBD channel number. The maximum signal is used as
it is the detector channel most closely aligned to the center the MLC leaf, therefore making
its response most strongly correlated to leaf open and closing. Thus, by mapping the exit de-
tector channel that yields the maximum signal i.e. profile peak which corresponds to known
MLC leaf number which held open, a MLC leaf map to OBD channel can be established as
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Figure 9.3: Resultant superimposed even and odd leaf detector response from Daily TQA
module. For projections between 5400-5699 (only the odd MLC leaves are open) and be-
tween projections 5700-5999 (only even leaves are open). The MLC leaf map (b) was es-
tablished by mapping the OBD channel that yields the maximum signal which corresponds
to the known MLC leaf number(i.e. leaf held open).
shown in figure 9.3b. Because the Daily QA procedure includes gantry rotation, this map-
ping can also be determined as a function of gantry position. However, for simplicity only
the mean channel is used in the proposed algorithm. Once a leaf channel map is determined,
the signal for each leaf can be extracted from the exit-detector response R.
9.2.3 LSF and background signal (B)
The projection 6000 through 6599, banks are sequentially opened with different amounts
of modulation. The modulation was achieved by changing the amount of time each binary
leaf held open and the process is iterated for consecutive banks of eight leaves. The LSF
is measured by recording the OBD signal for channel corresponding to leaf 26 (which is
open), then the OBD signal for channels corresponding to adjacent leaves 10 through 25
(which are closed). The relative signal at each closed leaf is then computed by dividing the
OBD signal for each closed leaf by the open leaf. Figure 9.4 shows the measured response
for ten adjacent closed leaves. The LSF is considered to be symmetric. Therefore prior to
calculating the discrete Fourier Transform, the LSF is mirrored and zero-padded to 64 leaves
such that it is the same length as the number of MLC leaves in the measured exit-detector
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Figure 9.4: Leaf Spread Function (left) was derived using discrete Fourier Transform (right).
response R.
Finally, the background signal B can be determined using the same projections interval as
used for LSF determination by measuring the exit detector signal under the closed leaves
further away (i.e., greater than ten leaves) from an open leaf. The background signal is
comprised of electronics leakage (dark current), radiation leakage through the MLC leaves,
and scatter from other parts of the TomoTherapy system.
9.2.4 Planned Fluence Retrieval
Once the TQA Daily QA module exit-detector data has been parsed, the next step is to
extract the expected fluence F for the patient plan from the patient archive. The patient
archive uses eXtensible Markup Language (XML) to reference all treatment plan data and
associated binaries. For each approved treatment plan, there are several variations of the
MLC delivery pattern.
The machine agnostic and specific delivery plans are created when the optimized treatment
plan is fractionated and approved for delivery on the destination treatment system. As its
name suggests, the machine agnostic delivery plan represents the “ideal” fluence after the
effects of fractionation, but before MLC-specific corrections are applied, such as leaf la-
tency. The machine specific delivery plan, alternatively, is the set of delivery instructions
for a TomoTherapy treatment system, which when delivered, would deliver the expected
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fluence contained in the machine agnostic plan. Therefore, for purposes of this analysis the
machine agnostic delivery plan is extracted.
The XPath JavaTM API library (javax.xml.xpath) is leveraged to read the patient XML into
MATLAB. The XPath expression //fullDeliveryPlanDataArray/fullDeliveryPlanDataArray
is used to identify all delivery plans; subsequently, (Appendix C, Table C.4), lists the XPath
sub-expressions and parameters extracted for each delivery plan. Using the above parame-
ters, the binary file of leaf events can be read and converted into a 2D array of relative leaf
open times for each MLC leaf and plan projection. The binary file stores each projection as
a pair of leaf events; the first event is the time (in tau units, where one tau equals one projec-
tion) when the leaf opens, and the second is the time when the leaf closes. Subtracting these
two values yields the fraction of a projection that the leaf is planned to be open, while the
magnitude of the values (rounded down to an integer) is the projection that the event occurs
in.
9.3 Methods and Materials
The TQA daily QA procedure and a static couch DQA of the patient’s DQA plan were deliv-
ered on the treatment machine with the couch static and out of the bore. There is nothing in
the beam path when delivering TQA and DQA. Based on these inputs, a simplified workflow
was defined in few steps and illustrated in figure 9.5
The exit detector DQA tool was designed around two commonly available methods for
exporting data from the HT system: patient archives and DICOM transit dose export. The
latter data export method is not a default option and only available on licence purchase. The
tool was developed in MATLAB (MathWorks Incorporated, Natick, MA) and was organized
into four modules: i) extraction of OBD data from the static couch DQA procedure and
TQA daily QA procedure to de-convolve the OBD signal into a ‘measured sinogram’ ii)
extraction of the planned sinogram from the patient archive and comparison to the measured
sinogram to determine differences in each leaf event (projection), iii) application of the
differences from each leaf event to the optimized sinogram and recalculation of the dose
using the TomoTherapy version 5.0 standalone dose calculator and finally, iv) 3D gamma
dose evaluation and dose volume histogram comparison between planned and measured
dose. This is discussed in details in following section.
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Figure 9.5: Illustration of clinical Workflow for performing exit detector DQA tool using
two commonly available methods for exporting data from the HT system. The planned
fluence for the analysis was machine agnostic delivery plan which was extracted from the
patient archive. The static couch DQA procedure is standard clinical DQA plan executed on
treatment machine with couch retracted ouside bore and couch remains static while beam is
on
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9.3.1 Exit detector DQA tool
A brief description about each module’s function is outlined in following sections.
9.3.1.1 Sinogram analysis
Once the TQA Daily QA module OBD data is parsed to the exit detector DQA tool, the next
step is to retrieve the expected fluence (F) from the patient archive as described in section
9.2.4.
In order to calculate the de-convolved measured fluence, first, the OBD signal for each of
the 64 leaves at a given projection is extracted from the sinogram. The OBD signal is then
corrected by subtracting the background (B) and channel sensitivity (S). Finally, the de-
convolution is calculated (as shown in equation 9.2) by computing the Fourier transform of
the corrected OBD signal, dividing that by the Fourier transform of the LSF, then computing
the inverse Fourier transform. This is repeated for each projection.
Following this, the fluence error E is computed using equation 9.3. As described in section
9.2.4, the binary file containing planned fluence information stores each projection as a pair
of leaf events, by comparing the planned fluence with the measured fluence projection by
projection, the difference from each leaf event can be determined.
9.3.1.2 Dose reconstruction
Following the sinogram analysis, the dose reconstruction step is performed using the To-
moTherapy version 5.0 standalone dose calculator (Accuray Incorporated, Sunnyvale, CA).
The beam model in clinical planning system is different from the beam model used in stan-
dalone dose calculator. To mitigate any potential systematic error in dose computation in
measured plan from approved clinical plan, the dose calculation is actually performed twice,
first without any changes made to the delivery plan leaf events, and subsequently with the
fluence error (E) applied to the planned fluence. The former recalculated dose is referred
as the ‘original planned dose’ while the latter is referred as ‘adjusted planned dose’. A 3-
D dose evaluation is then conducted using 2%/2 mm Gamma index (global) [240] criteria
above a dose threshold of 10% for dose comparison. Dose volume histogram is calculated
and evaluated from both original planned dose and adjusted planned dose to assess the clin-
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ical impact.
9.3.2 Clinical validation
Comprehensive validation of this tool for clinical implementation purposes is presented.
Several tests were designed to validate the accuracy and robustness of the exit detector DQA
tool. The accuracy of each module of exit detector DQA tool was verified independently as
described in following sections.
9.3.2.1 Sinogram analysis accuracy and sensitivity
The vendor supplied plans (‘TomoPhant’) designed to treat on-axis and off-axis cylindrical
targets generated for each commissioned jaw width size on the ‘cheese phantom’ were used.
The ‘TomoPhant’ treatment plans (1, 3, and 5) with no modification (unmodified) and with
intentionally introduced MLC LOT error (modified) plans were used to assess the accuracy
and sensitivity of this tool. Four MLC LOT intentional error scenarios were tested: (i) leaf
32 was ‘stuck open’ (modified to have a leaf open time of 100% for each projection), (ii) leaf
42 was ‘stuck open’, (iii) all leaves were randomly closed by 2%, and finally (iv) all leaves
were randomly closed by 4%. The random MLC LOT errors are introduced using a normal
distribution with a mean and standard deviation of -2% and then with a mean and standard
deviation of -4%. The leaf open times greater than 100% are not possible to deliver, so
were truncated. Each intentional error was introduced independently. A static couch DQA
was then run five times, first with the original optimized delivery plan, then once with each
intentional modification. The OBD data was extracted for each run and analysed by the tool.
First, the original optimised delivery plan was compared with original machine agnostic
delivery plan, and next the original optimised plans with the known modification applied
(known intentional MLC LOT error) to compare with corresponding modified DQA plans.
The original clinical plan recalculated for a given known plan modification (intentional MLC
LOT errors) is referred as the ‘a priori’ planned dose.
9.3.2.2 Reconstructed dose accuracy
Following the sinogram analysis (for both unmodified and modified ‘TomoPhant’ as de-
scribed in section 9.3.2.1), the dose for original clinical plan, the original plan with each
‘a priori’ modification and adjusted planned dose from measured static couch DQA was
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recalculated using standalone Tomotherapy dose calculator as described in section 9.3.1.2).
The accuracy of the adjusted planned dose calculations (dose reconstruction) on the cheese
phantom for each plan were verified with ion chamber measurements (Standard Imaging
A1SL, Middleton, WI) both in high and low gradient regions. This is equivalent to validate
the reconstructed dose inside patient anatomy.
9.3.2.3 Clinical assessment of Exit detector DQA tool versus existing clinical Arc-
CHECK DQA method
Table 9.1: Summary of clinical plans with varying treatment characteristics for comparing
two QA systems.
Clinical site Number of clini-
cal plans
Percentage MLC LOT time (Mean
± SD)
Head and Neck 47 49.4 ± 5.7
Brain 19 48.1 ± 6.1
Pelvis 29 48.6 ± 7.1
GI 14 48.1 ± 4.8
Brain SRS 5 60.2 ± 12.6
CSI 3 47.2 ± 8.3
Lymphoma (Hypo-fractionated) 5 47.9 ± 8.7
Prior to implementing the Exit detector DQA tool, ArcCHECK dosimetry system (Sun Nu-
clear Corp., Melbourne, FL) was pre-treatment DQA tool to verify clinical plan. Both the
proposed exit detector DQA system and ArcCHECK dosimetry system used common 3D
dose evaluation metrics (gamma criteria). To demonstrate both QA systems produce a com-
parable statistics, a similar analysis metrics (2%/2mm global gamma with dose threshold
10%) was used. Table 9.1 summarised the clinical plans having wide range of dosimetric
and treatment characteristics were used for comparison. The treatment verification of three
CSI plans was not possible with ArcCHECK dosimeter alone due to limited measurement
length of dosimeter. In addition, the time taken to perform HT DQA for both methods was
also compared to assess the efficiency. The similarity of Gamma pass rate and the efficiency
between two DQA methods was tested using Wilcoxon Signed–Rank test.
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9.3.2.4 DVH metrics calculation accuracy
To assess the accuracy of reported DVH metrics by exit detector DQA tool, five clinical
plans were used. The clinically relevant DVH metrics for five different structures from each
clinical plan were independently calculated using in-house Comp Plan tool and compared
them to the reported DVH metrics by exit detector DQA tool. The DVH reconstruction
code implemented in exit detector DQA tool was different from the in-house code Comp
Plan [283] tool.
9.4 Results
9.4.1 Sinogram analysis sensitivity and accuracy
Table 9.2 summarises the sinogram analysis evaluation. The mean MLC LOT error across
all leaf events (projection) for both unmodified and modified ‘TomoPhant’ plans are given.
The smaller mean MLC LOT error in sinogram analysis evaluation for all unmodified plans
validated the ability of the tool to measure the original plan. Similarly lower mean MLC
LOT error for the sinogram analysis evaluation for modified plans validates the tool correctly
identify the MLC LOT error. In addition, a graphical comparison for the leaf 42 staying open
(intentional error) is provided in figure 9.6 demonstrating that the tool correctly identified
that leaf was opened and pick up MLC LOT error.
Table 9.2: Mean MLC LOT error ± standard deviation across all leaf events (projection)
determined via sinogram analysis for both unmodified and modified ‘Tomophant’ plan. In
the first column, the unmodified plan de-convolved fluence was compared to the planned
sinogram. In each remaining column, the de-convolved fluence for each modification was
compared to ‘a priori’ known modification to the planned fluence.
Plan Unmodified Leaf 32 Open Leaf 42 Open Random -2% Random -4%
1 0.24% ± 1.11 -0.09% ± 1.03 0.07% ± 1.64 0.36% ± 2.46 -0.81% ± 2.61%
2 -0.26% ± 1.33 0.10% ± 1.69 0.34% ± 2.17 -0.59% ± 3.31 -0.84% ± 2.85%
3 -0.60% ± 1.96 -0.51% ± 1.45 -0.42% ± 2.72 -0.60% ± 2.61 -1.13% ± 2.41%
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Figure 9.6: Graphical illustration of sinogram (top) extracted from original clinical plan,
sinogram (middle) for the original optimised plans with ‘a priori’ known modification ap-
plied (leaf 42 stuck open) and static couch QA de-convolved measured fluence (bottom) of
modified plan with leaf 42 stuck open.
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9.4.2 Reconstructed dose accuracy
Table 9.3 presents the gamma pass rate for both unmodified (first column) and modified
‘TomoPhant’ plans (remaining columns). In case of modified plans (a priori planned dose
versus measured) have shown high gamma pass rate (>95% with 2%/2 mm) indicating that
this tool able to track the MLC LOT errors. Table 9.4 summarise the difference between the
adjusted planned dose calculated by the exit detector DQA tool with ion chamber measure-
ment for each unmodified ‘TomoPhant’ plan. The close agreement between the independent
ion-chamber measured dose and dose calculated by the exit detector DQA tool (<2%) plus
gamma pass rate > 95% (with stringent 2%/2mm gamma criteria) for all three unmodi-
fied ‘Tomophant’ demonstrates the accurate dose reconstruction of this tool inside patient
anatomy.
Table 9.3: Gamma evaluation (2%/2mm) of original planned dose (planned) and adjusted
planned dose (measured) computed from both unmodified and modified plans. In the first
column, the unmodified adjusted planned dose is compared to the original planned dose.
In each remaining column, the adjusted planned dose for each modification is compared to
the original planned dose recalculated for the known plan modification (‘a priori’ planned
dose).
Plan Unmodified Leaf 32 Open Leaf 42 Open Random -2% Random -4%
1 99.8% 99.1% 99.1 98.9% 97.3%
2 99.7% 98.7% 97.2 98.1% 96.6%
3 99.9% 99.2% 98.6 97.6% 96.8%
Table 9.4: Difference between the adjusted planned dose calculated by the tool and ion
chamber measurement at various IEC-x positions along the cheese phantom. Measurement
location X= -10.5 cm and X= -1.5 cm are in a low dose gradient region while other positions
are in higher dose gradients. Each column represents different ion chamber measurement
positions at different IEC-x positions along the mid-plane of the cheese phantom.
Plan Dose difference between measured (ion chamber) and adjusted dose by tool at various IEC-x
positions (cm)
X=-10.5 cm X=-1.5 cm X=2.0 cm X=6 cm X=10.5 cm X=12 cm
1 -1.49% 0.61% 1.13% 0.16% 1.24% 1.90%
2 -1.50% 0.80% 1.83% 1.67% 1.20% 1.52%
3 -0.81% 1.49% 1.23% 1.26% 0.21% 0.41%
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Figure 9.7: Transverse planar doses through the target for Tomophant (plan 1) with leaf 42
held open: a) original planned dose recalculated given known plan modification (‘a priori’
planned dose), b) modified OBD based adjusted dose (‘a posteriori’ adjusted dose) by tool
and c) gamma map (2% and 2mm).
Figure 9.7 displays the transverse planar doses through the target for ‘TomoPhant’ (plan 1)
with leaf 42 held open, and the corresponding gamma map. In comparing (a) to (b) in Figure
9.7, there is a slight increase in the penumbra around the target area. This causes the gamma
index to be higher in this region between two targets as shown in figure 9.7(c).
9.4.3 Clinical assessment of Exit detector DQA tool versus ArcCHECK
DQA method
The average gamma pass rate (2%/2mm) from 119 clinical plans DQA measurements was
94.9 ± 1.5 and 91.9 ± 3.3 for exit detector DQA tool and ArcCHECK phantom based
measurements respectively. The Wilcoxon Signed–Rank test indicated a lack of significant
difference in gamma pass rate metrics between the two DQA systems (p=0.868). It should
be noted that the exit detector-based comparison is comparing all voxels greater than set dose
threshold (10% of maximum dose), while the ArcCHECK is only comparing the difference
at each diode. Therefore, although the differences are not directly comparable, both DQA
methods yield similar QA results if a common analysis metrics is used demonstrated similar
accuracy.
The time required for performing with exit detector QA tool for 119 conventional clinical
plans was 24.7 ± 3.5 minutes compared to 39.5 ± 4.5 minutes (treatment length < 30 cm)
for ArcCHECK phantom-based measurements. In particular, the time required to perform
DQA with exit detector QA tool for the 3 CSI treatments was 35± 3.5 minutes compared to
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Figure 9.8: The planning target volume (PTV) D95 dose error as a function of the mean
MLC LOT error (%).
90 ± 5.2 minutes for phantom (film and point dose measurement) based measurement. The
exit detector DQA tool demonstrated a significant improvement in efficiency compared to
the phantom based DQA method (p= 0.001, 95% confidence level). The exit detector DQA
tool showed significant efficiency gain for all three CSI treatment verification.
Out of 119 clinical plans measured, ArcCHECK phantom based measurements for seven
clinical plans indicated a large drop in gamma pass rate when the gamma evaluation criteria
was changed from 3%/3mm to 2%/2 mm (92.4 %± 2.5% to 75.5%± 4.5%). Following the
investigation using exit detector DQA tool sinogram analysis module indicated that larger
mean LOT error with lower mean MLC LOT in all these clinical plans. Previous work [284]
demonstrated the lower mean LOT yields larger point dose differences between planned and
measured dose. The reconstructed dose with our tool also showed larger dose difference in
terms of drop in D95 of PTV > 5% which is clinically relevant (figure 9.8) and consistent
to previous work [284]. This demonstrates the sensitivity of the tool tracking the planning
issues as well as MLC LOT errors that are clinically relevant in addition to time gain to
perform patient treatment verification.
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9.4.4 DVH metrics calculation accuracy
Table 9.5 illustrates the reported DVH metric accuracy reported by exit detector QA tool
when compared with to those calculated independently in-house Comp Plan [283] tool from
five clinical plans.
Table 9.5: Comparing the clinically relevant DVH parameter from five clinical reported by
exit detector based DQA tool with in-house Comp plan tool. The difference is presented as
mean ± standard deviation (from five clinical plans)
Structure DVH metrics Difference in reported dose (Proposed tool vs
in-house tool)
PTV D95 0.84 ± 0.9
Spinal cord D1cc 1.1 ± 0.6
Parotid Mean dosse 0.79 ± 0.9
Mandible D1cc 1.3 ± 0.9
Brainstem D1cc 1.1 ± 0.9
9.5 Discussion
This work presents a comprehensive clinical validation of an in-house exit detector-based
dose reconstruction tool for HT DQA. We have demonstrated that the algorithm presented
here is straightforward and comprehensive to identify the planning issues as well as MLC
LOT errors. We also demonstrated that the exit detector based dose reconstruction offers
powerful advantages over conventional QA methods to link the DQA results to their clinical
significance, particularly for long treatments. In all tests, the tool was able to easily load in
the measured data and patient archives and conduct the analysis including dose reconstruc-
tions without interruption of clinical workflow as shown in Figure 9.5. The relatively short
time needed for this (5-7 minutes), demonstrates the tool is practical for routine clinical
use. The static couch DQA is captured by the treatment staff and analysis is performed by
physics. Both these tasks can be done in normal working hours, which reduces the physics
staff burden of preforming after hours pre-treatment QA measurements.
In addition, we demonstrated that the sinogram analysis module accurately identifies several
types of MLC LOT errors (Table 9.2). The dose reconstruction accuracy of the algorithm
was validated (Table 9.3 and 9.4 ) with direct measurement for baseline ‘TomoPhant’ plans
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by independent ion chamber measurements (absolute dose) as well as 3D gamma criteria
comparing planned versus measured (spatially). We noticed the higher gamma index (figure
9.7(c)) in the small gap between the targets, as the low dose in the gap disappears. The
added penumbra is caused by the de-convolution’s inability to completely remove the effect
of leaf scatter. It is a limitation of the currently implemented LSF approximation evaluation
method. This effect was exacerbated by the leaf remaining open for all projection, which
is an extreme example and unlikely to be of clinical relevance. There is a scope to further
improve accuracy in determining the LSF as a subject to future work.
Note that the exit detector DQA tool focuses mainly on MLC leaf differences and their
effects on patient dose, and that there are numerous other mechanisms for plan delivery
failure. For instance, couch motion and couch/gantry synchronicity are important during
HT. However, the authors of TG-148 recommended checking these components quarterly
with no expectation that IMRT QA would be sensitive enough to detect issues at the spec-
ifications reported in TG-148 for these tests. It is unclear that current DQA system with
3%/3mm gamma criteria, for routine clinical sites such as prostate, lung, or head and neck
are sensitive enough to be considered an appropriate mitigation for these issues. The MLC
LOT remains the most variable and patient-specific component of an HT treatment plan
delivery [284, 324]. Moreover, MLC performance is not recommended as a routine test
in AAPM TG-148 and other previous work HT QA [48, 50]. Many centres do not have
an access to TQA packages to verify MLC performance hence is not performed routinely
by most of the centres. We believe that the improved QA tools (i.e. TQA) available on
modern TomoTherapy systems provide efficient and highly effective modules for measuring
couch uniformity, jaw motion, and gantry speed, and synchronicity, making it feasible to
increase the frequency of testing these components, rather than quarterly as recommended
by TG-148.
The Exit detector DQA tool offers a great advantage for treatment verification, especially
when the treatments lengths exceed the size of existing commercial QA dosimetry systems.
Most phantom-based QA devices that are currently available measured dose to only a few
points or on a finite 2D surface (flat or cylindrical) at a coarse resolution. If machine deliv-
ery errors result in dose errors beyond the measurement surface, those phantom-based QA
methods may not be able to detect them. The OBD measured fluence with higher resolution
and therefore increase detection sensitivity to MLC errors compared to external planar or
cylindrical detectors arrays. This tool provides comprehensive MLC performance evaluation
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of individual leaf differences on a per-plan basis and supplemented with dose distribution.
As shown in figure 9.8, exit detector based DQA tool able to detect delivery issues related
to MLC LOT and also helps to identify sources of errors such as planning issues (e.g. sub-
optimal use of planning parameter). Unfortunately, there is no parameter that can be used
during HT plan optimisation to restrict low MLC LOT. These errors or dose discrepancy (as
shown in figure 9.8) would not have picked up by phantom-based measurements in case the
commonly used 3%/3mm gamma criteria used. This demonstrated sensitivity of this tool
over conventional QA methods. The performance of this tool was validated for all possi-
ble clinical scenario summarised in Table 9.1 by conducting the serial measurement with
ArcCHECK (2%/2mm criteria). The similarity in gamma pass rate reported by these two
QA systems indicates that the exit detector based DQA system maintains similar accuracy
to that of phantom-based measurements.
There are several inputs that are obtained from a daily QA measurement. In addition to
run the daily TQA procedure, an independent daily output measurement is performed using
TomoDOSE®(R) (Sun Nuclear Corp. of Melbourne, FL) which has been demonstrated to
pick up machine performance degradation such as energy or output [325]. Also, as a safe-
guard, the exit detector QA is run on baseline ‘Tomophant’ immediately after the fortnight
output constancy measurement with A1SL chamber is performed. This independent QA de-
signed and implemented specifically to monitor the performance of the exit detector based
QA tool on a fornight basis. We also perform image guidance and registration tests as a part
of the daily QA which checked the couch movement accuracy. Finally, we presented the
clinical results for static jaw procedure only. The proposed tool is also capable for verifying
the plans with dynamic jaw procedure; its validation is the subject of future work.
9.5.1 Conclusion
The exit detector tool demonstrated an improved efficiency and sensitivity relative to a con-
ventional phantom-based QA method for HT treatment plan verification. This tool provides
comprehensive MLC performance evaluation of individual leaf differences on a per-plan
basis and provides an additional insight into the plan by showing the clinical impact of ob-
served discrepancies. This functionality provides a better understanding to assess the DQA
failure and the clinical relevance of QA results.
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The recent rapid pace of development in radiotherapy techniques and the significant increase
in the associated complexities, have introduced considerable new challenges to verify treat-
ment accuracy and ensure patient safety. The development of novel detectors for treatment
verification still remains an active area of research.
While the EPID’s potential as a dosimeter has been well demonstrated [23], there are some
technical challenges that still remain unresolved: e.g. i) inconsistent interpretations of stan-
dard EPID dose response from previous literature [28, 181–183] ii) challenges of clinical
implementation of EPID based in vivo dosimetry in routine clinical practice.
The dose response linearity of standard a-Si EPIDs was evaluated for different combinations
of linac, image acquisition settings and imaging data processing methods was investigated
and a simple pixel-to-dose calibration method was described and validated in Chapter 3 for
step and shoot IMRT delivery. This work contributes to a more consistent understanding
and implementation of pixel-to-dose calibration methods for EPID-based IMRT dosimetry.
Ensuring patient safety and treatment accuracy for advanced techniques requires verifying
both the target location (i.e. geometry) and the dose delivered to patient. Standard EPID
design optimised for imaging applications is problematic for dosimetry due to non-linear
energy dependence [25–27, 189, 248]. Previous work on novel EPID design was focused
specifically to act as dosimeters rather than imagers [27, 37–39, 326]. In both cases, pro-
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posed detectors have not been suitable for applications in both imaging and dosimetry.
Novel, dual-purpose prototypes developed to optimise the EPID detectors for radiotherapy
applications were introduced and characterised in Chapters 4 and 5. The dual-purpose proto-
types were designed to simultaneously verify both anatomical location and quantity the dose
delivered during treatment on conventional linacs. These dual-purpose prototypes maintains
water-equivalent dose response. A simple model for transit dosimetry based on a treatment
planning system and a water equivalent EPID is presented in chapter 6. WE-EPID does
not require a separate EPID model to correct for the complex dose response and hence, pro-
vides directly water-equivalent dose image transiting through patient. Clinical TPS provides
a water-equivalent dose image at EPID plane (PDI) to compare against the measured tran-
sit dose image. Therefore, neither a separate EPID model to correct for the complex dose
response nor an independent image prediction algorithm is necessary. The main advantage
of this method is that PDI is calculated with the same beam model used for patient dose
distribution calculation. Therefore, the model proposed in Chapter 6 provides a simpler and
more direct method of performing accurate EPID-based in vivo dosimetry.
The HT system has a unique mechanism to deliver dose to patient. Therefore, a specific
understanding is required of the effects of delivery uncertainties to enable the optimisation
of methods for resilience to their presence (treatment robustness). Chapter 7 outlined a
framework to characterize HT machine delivery errors and their clinical significance. This
framework could be applied to any patient dataset to determine a given institution’s plan
specific delivery error threshold as well as validate plan robustness for a given machine QA
tolerance or determine clinically relevant HT QA tolerances.
Treatment verification of HT clinical plans currently relies on phantom-based measurement
QA. Different measurement systems have varying ability to reliably identify errors [58].
Chapter 8 outlined a systematic comparative assessment of commercial dosimetry systems
sensitivity to detect clinically relevant HT delivery errors. This assessment provides a crucial
understanding of the strengths and weaknesses of commercial dosimetry systems.
More efficient QA methods are needed to verify treatments to reduce the increased burden
on physics resources due to the additional patient specific QA [60, 61]. The underlying lim-
itations of phantom-based measurement QA are: i) Interpretations of QA results and their
clinical relevance and ii) verification of treatment plans larger than the phantom physical
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dimensions. Chapter 9 discussed the development and clinical implementation of exit de-
tector DQA tool for HT pre-treatment verification. This tool offered an improved efficiency
and sensitivity relative to a conventional phantom-based QA method for HT treatment plan
verification. This tool also provides a comprehensive MLC performance evaluation of in-
dividual leaf differences on a per-plan basis and offers an advantage to assess the clinical
impact of observed discrepancies. This functionality provides a better understanding to as-
sess the DQA failure and the clinical relevance of QA results.
This thesis represents a body of work investigating two different components of treatment
verification firstly for a conventional linac and secondly for HT based treatment delivery as
outlined in chapter 1:
(i). Dose characterisation and development of novel EPID based prototypes for treatment
verification of a conventional linac system
(ii). Assessment of current dosimetry systems and development of an on board exit detector
based tool for efficient pre-treatment verification for HT delivery
10.1.1 Dose characterisation and development of novel prototype hy-
brid EPID based dosimeters for treatment verification for a con-
ventional linac system
Research questions:
What are the underlying causes for EPID dose under response at smaller moni-
tor units?
The key reviews [28, 181–185] regarding EPID dose response summarized in
chapters 2 and 3, highlighted the inconsistent interpretation of EPID dose re-
sponse characteristics. Chapter 3 investigated the EPID dose linearity under dif-
ferent combinations of linac, EPID design and acquisition system to understand
the underlying causes of EPID under response to dose at small MU.
The measured EPID under response to dose showed good agreement between
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static and segmented delivery and persists in both deliveries. This validates
previously reported methods of applying the EPID under response to dose cor-
rection determined from open static beam exposures on a segment-by-segment
basis for IMRT dosimetry [28, 181]. This work also demonstrated the gain
ghosting as the dominant cause of EPID non-linear dose response, and how this
effect impacts EPID dosimetry of segmental IMRT.
A method of simultaneous measurements with an ICA and EPID was demon-
strated to reliably separate out the EPID dose response from beam delivery char-
acteristics. This methodology demonstrated an irregularity in the Siemens ac-
quisition readout scheme, which resulted in poor measurement reproducibility
of IMRT fields at small MU per segment. Podesta et al. [221] modelled the
discrepancies in Siemens clinical EPID dose response and confirmed that these
variation are associated with a problem in the acquisition readout scheme (i.e.
missing frames) consistent with the finding of work presented in Chapter 3.
Previous work [28, 181] implemented the ghosting/image lag correction on a
pixel by pixel basis in their EPID dosimetry model. A pixel-to-dose calibration
method described in Chapter 3 does not require this correction hence simplifying
the EPID dosimetry model. This work (Chapter 3) resolves some of the incon-
sistencies in the literature regarding EPID dose response and proposes a simple
yet accurate pixel-to-dose calibration method for EPID-based IMRT dosimetry.
Dose linearity for dynamic MLC and VMAT delivery was not investigated, and
further work is required to determine the applicability of these results to these
dynamic deliveries.
Research questions:
Can the standard EPID design be improved on to provide a superior system for
simultaneous geometric and dosimetric treatment verification?
Standard EPIDs are optimised for anatomical imaging but are suboptimal for
dosimetry due to non-linear energy dependence [25–27, 189, 248]. Despite the
potential, the clinical implementation of EPID dosimetry is still limited to a
relatively small number of centres. Several groups have developed the methods
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to account for energy response either with complex algorithms or Monte Carlo
computations [25, 28–34] to utilise standard EPIDs as a dosimeter. Current
research in EPID technology is focused on developing more efficient detectors
for imaging using very high density scintillators [35, 247] which are likely to
be even more problematic for dosimetry. The previously reported ‘direct EPID’
[27, 37–39, 326] designs demonstrated accurate patient dosimetry but suffered
from decreased x-ray detection efficiency thus inhibiting their use for imaging
and dosimetry.
Chapters 4 and 5 described development and characterisation of a novel dual
detector configuration for treatment verification on a conventional linac. The
novel dual detector configurations were modified with the specific goal of im-
proving the dosimetry performance without compromising the imaging perfor-
mance. Both dual detector configurations combined a conventional EPID (im-
ager) and a 2D array dosimeter.
Excellent agreement in measured dose response (<1.5%) and gamma pass rate
(> 94%) for all clinical modulated fields was achieved for each of the prototype
detectors compared to reference dosimeters in the transit geometry. The wa-
ter equivalent dose response achieved with each novel prototype detector over-
comes a limitation of implementing in vivo dosimetry with current EPIDs.
The imaging performance of both dual detector designs discussed in chapter 4
and 5 was approximately the same as the standard EPID. This demonstrates the
dual detector configuration can be operated simultaneously as both imager and
dosimeter without significant compromise in the performance of either device.
The dual detector design decouples the imaging and dosimetry functions so that
each can be optimized without significantly compromising the other, providing
more flexibility for future improvements in radiotherapy treatment verification
systems.
As a proof-of-concept, both novel prototypes demonstrated simultaneous geo-
metric and dosimetric treatment verification. To utilise these prototypes as a
clinical system requires additional engineering considerations, further optimisa-
tion, and therefore further research.
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Research questions:
Can a water equivalent EPID overcome the current limitations of implementing
a-Si EPID based dosimetry in the clinic?
The 2D dosimeter (chapter 4 and 5) within each novel prototype hybrid EPID
based systems was demonstrated to maintain water equivalent dose response.
Hence, no additional model is required to correct the complex dose response
unlike a-Si EPID based dosimetry. A simple model for implementing compre-
hensive transit dosimetry as a means of in vivo dose verification with a novel
prototypes and a conventional TPS was investigated in chapter 6. Excellent
agreement was achieved in measured dose response when compared with TPS-
calculated portal dose images.
This approach would overcome two complicated steps involved in standard EPID
dosimetry models i) modeling the complex dose response [25–27, 189, 248]
and ii) calculating the predicted dose image at the EPID plane [23]. The water
equivalence of the novel prototype provides a means of directly comparing the
measurement to the TPS calculated image dose, for individual patient treatment
plans. No additional EPID modelling is required, thereby removing the uncer-
tainty in modelling the complex dose response of standard EPIDs. This would
simplify the implementation of EPID based dosimetry in the clinic.
Accurate dose in water algorithms implemented in other commercial TPSs (other
than Pinnacle, the one studied here) are likely to have similar success, but would
need comprehensive validation. Further development of a back-projection dose
calculation method is warranted to facilitate in vivo dose verification in the fu-
ture.
10.1.2 Assessment of current dosimetry systems and development of
an on board exit detector based tool for efficient pre-treatment
verification for HT delivery
Research questions:
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What magnitude of changes to helical tomotherapy delivery parameters will
have a clinical impact on the resulting dose distribution?
Many studies investigated the clinical impact due to changes in delivery parame-
ters for conventional linacs as discussed in Chapter 7. However, the information
from these studies cannot be directly translated to HT due to the different deliv-
ery mechanism of HT machines. Chapter 7 provides a framework to quantify
clinically relevant HT delivery errors.
The work presented in Chapter 7 is the first study investigating the clinical
impact due to changes in delivery parameters for HT delivery and provides a
framework how clinically meaningful HT QA tolerances can be developed. The
recommended AAPM Task Group 148 QA [47] tolerances and machine inter-
locks were also compared with clinically relevant errors. This framework was
also tested on lung SABR plans (since they have different complexity compared
to nasopharynx plans) and is presented in Appendix B. The dosimetric QA tol-
erance derived for both clinical sites were similar except for the gantry related
delivery error. This demonstrates the effect of these delivery errors was tech-
nique/site specific (Table B.1). The recommended QA tolerances (AAPM Task
Group 148) for HT machine were demonstrated to be adequate to prevent clin-
ically relevant HT delivery errors for both lung SABR and nasopharynx plans.
This validates the use of a generic HT QA tolerance table as outlined in AAPM
Task Group 148 rather than separate plan complexity specific QA tolerance ta-
bles as the case for a conventional linac. Most of the clinically relevant errors are
prevented by machine interlocks except the couch position and the secondary in-
terlock for jaw position for nasopharynx clinical cases and should be monitored
with improved precision.
This work has established a framework to characterize HT machine delivery er-
rors and their clinical significance. This framework could be applied to any pa-
tient dataset to determine a given institutions plan specific delivery error thresh-
old as well as validate plan robustness for a given machine QA tolerance or
determine clinically relevant HT QA tolerances. This work can be extended to
additional error modes and other treatment techniques/anatomical sites in the
future.
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Research questions:
Are the available commercial dosimeters sensitive to clinically relevant delivery
errors for helical tomotherapy?
The systematic comparative assessment of sensitivity for MatriXXEvolution and
ArcCHECK to detect clinically relevant HT delivery errors were assessed and
discussed in chapter 8. By altering the jaw width, couch speed and MLC LOT
delivery parameters, failure modes were simulated and tested independently for
the same ten nasopharynx clinical plans used for dosimetric simulation in chap-
ter 7.
Templeton et al [59] also studied the detector sensitivity of ArcCHECK for in-
tentional delivery errors in couch speed and demonstrated an intentional error
up to 2.8% in couch speed led to a decrease in gamma pass rate to < 90% for
head and neck cases. This threshold was -1.5% to +2.5% for couch speed er-
ror. However, Templeton et al [59] did not provide details about complexity and
planning parameters used for the head and neck plans in their study, therefore it
is difficult to compare our results directly.
Templeton et al [59] also reported that the increase or decrease of a given pa-
rameter by the same magnitude yields similar passing rates. On the contrary,
our results for couch speed and jaw width introduced errors showed the increase
or decrease of a given parameter by the same magnitude yields different gamma
pass rates. Similar trends were observed in the relative change in dose volume
histogram metrics reported in previous dosimetric simulation work [303] and
discussed in Chapter 7, consistent with measurements for both dosimetry sys-
tems investigated here.
The Wilcoxon signed rank test indicated that no statistically significant differ-
ences were found in detecting the simulated delivery errors between these two
dosimetry systems (p»0.05, 95% confidence level). Both dosimeters were able
to pick up clinically relevant delivery errors except the ArcCHECK with couch
speed up to 2.5% and jaw width up to -1 mm. The MatriXXEvolution showed
slightly higher sensitivity to couch speed and jaw width delivery errors com-
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pared to the ArcCHECK. This could be due to the relatively coarse detector
resolution of ArcCHECK (10 mm) compared to MatriXXEvolution (7.62 mm) in
the superior-inferior direction.
This work evaluates the two commercial dosimetry system’s sensitivity to detect
clinically relevant delivery errors as well as their inherent limitations for a clini-
cal site. This work provides a framework to evaluate the sensitivity of a detector
to identify the delivery errors for HT treatment. The evaluation of the sensitiv-
ity of these commercial detectors for different clinical sites for HT treatments
warrants future work.
Research questions:
Can the on board exit detector system achieve equivalent or improved sensitiv-
ity, robustness and efficiency compared to the current standard phantom based
measurement for HT pre-treatment verification?
An in-house exit detector DQA tool was developed to analyse HT treatment
plans and perform dose reconstruction to compare to the optimized patient dose.
The comprehensive clinical implementation and validation of the tool is dis-
cussed in chapter 9. Excellent agreement was found in the gamma pass rate
> 95% between the planned and reconstructed dose using this tool. The close
agreement of measured ion chamber (<1.5%) to reconstructed dose computed
by the exit detector DQA tool on the ‘cheese phantom’ validated the accuracy
of dose reconstruction inside the patient. The mean time for performing DQA
on the 119 clinical plans was 24.7± 3.5 minutes and 39.5± 4.5 minutes for the
exit detector DQA tool demonstrated efficiency. The sensitivity to detect MLC
errors was demonstrated.
The exit detector DQA tool offers a direct and comprehensive solution with
the opportunity to visualize the clinical significance of MLC delivery errors.
This tool offers powerful advantages for supplementing existing patient spe-
cific DQA with specific advantages for patient cases where the field delivery
geometry exceed the size of the commercial dosimetry measurement systems.
The development of this tool has addressed some of the limitations of phantom-
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based measurement QA. The significant gain in efficiency of performing HT QA
reduced the additional burden on physics resources in our local implementation.
10.2 Implementation of this work within a clinical environ-
ment
Some of the research presented in this dissertation has been adopted in local
clinical practice. Positive clinical outcomes include:
(i) The pixel-to-dose calibration at 20 MU method discussed in chapter 3 has
been implemented locally at the Liverpool Hospital-Cancer Therapy Centre as
an EPID dosimetry model since 2013 [327].
(ii) The clinically relevant HT QA tolerance derived from framework discussed
in Chapter 7 were adopted as clinical QA tolerances in department’s QA proto-
col since June 2014.
(iii) The in-house exit DQA tool discussed in Chapter 9 for HT pre-treatment
verification has been implemented locally at the Liverpool Hospital-Cancer Ther-
apy Centre since August 2015.
To implement this work in routine clinical practice involves extensive documen-
tation and staff training. Additional QA checks to assess the performance of this
tool also requires additional QA time.
10.3 Future work
From the topics presented in this thesis there are a number of issues that justify
further investigation, including:
(i) Further optimisation of novel prototype hybrid EPID based dosimeters
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(ii) Clinical implementation of the novel prototype hybrid EPID based dosime-
ters for in vivo dosimetry.
(iii) Assessment of the clinical impact due to changes in HT delivery parameters
for additional clinical sites and plan techniques
(iv) Develop the HT exit detector DQA tool for generalised use
10.3.1 Optimisation of novel prototype hybrid EPID based dosimeters
Novel prototypes discussed in chapter 4 and 5 demonstrated their capability
of performing two measures of treatment verification, imaging (geometric) and
dosimetry (dosimetric) as a single system.
a) Novel prototype (EPID and ICA configuration)
For the dual detector design discussed in chapter 4, the following issues warrant
further investigation
The engineering requirements of the mechanical support and the configuration
of electronics and data readout schemes for both dual detector configuration
discussed in chapter 4, the following issues warrant further investigation:
(i) Develop a larger detection area (40 x 40 cm2) and smaller detector spacing
(≤ 5mm) for higher resolution dosimetry in modulated fields
(ii) A higher signal to noise ratio for the ICA detector would also be desirable
for use in the transit dosimetry setting
(iii) Investigate the dose response characterisation of the next generation of MV
imagers (when available)
(iv) Optimisation of backscatter thickness
b) Novel prototype (EPID and MP configuration)
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For the dual detector design discussed in Chapter 5, the following issues warrant
further investigation
(i) Develop a larger detection area (40 x 40 cm2) and smaller detector spacing (≤
5mm) on the dose detector (MP) for higher resolution dosimetry in modulated
fields
(ii) Investigate the optimal build up for dosimetry for beam energies > 6 MV
without compromising the imaging performance.
(iii) The use of novel prototypes under clinical applications such as moving
target dosimetry, FFF beams; MLC/couch tracking needs further research.
10.3.2 Clinical implementation of EPID based prototype for in vivo
dosimetry.
The framework for the clinical implementation of in vivo dose verification pre-
sented in chapter 6 utilising EPID based prototypes and a commercial TPS in-
volves a number of steps. These steps should be integrated and automated to
make this tool efficient and user friendly. The framework was validated for the
Pinnacle treatment planning system only. The accuracy of the dose algorithm to
calculate dose at the EPID plane for other planning systems needs further eval-
uation. The framework was validated with beams at orthogonal gantry angles
only. Further work is therefore required to develop a process for extracting TPS-
calculated doses at the EPID plane for beams and control points at all gantry an-
gles similar to presented in previous work [264]. Similar to previously reported
investigations [30, 198], the dose calculation algorithm should be implemented
in order to calculate the dose inside the patient from the measured EPID dose
on the planned CT data or treatment verification cone beam data. This approach
provides the direct link between the treatment verification QA results and the
clinical impact.
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10.3.3 Assess the clinical impact due to changes in HT delivery param-
eter for additional clinical sites and planning techniques
The dosimetric simulation framework presented in chapter 8 can be extended
to additional error modes and other treatment techniques/anatomical sites. To
improve the efficiency for simulating the errors, all steps should be automated.
The flexibility to incorporate the actual delivery parameter (such as actual de-
livery parameter from log files or from routine QA data base) needs further
research to verify the robustness of the clinical plan or on newly implemented
techniques. The sensitivity of all dosimetry systems to detect the clinically rel-
evant delivery errors for specific treatment site/techniques should be assessed
to gain confidence on pre-treatment QA. Such evaluation on sensitivity of dif-
ferent dosimetry systems provides an improved understanding of their strengths
and limitations for individual clinical situations. Such an understanding also
provides useful guidelines for the choice of the most appropriate dosimetry sys-
tem to implement complex treatment techniques safer.
10.3.4 Develop the HT exit detector DQA tool for generalised use
The dose calculation on patient CT data requires a standalone tomotherapy re-
search planning system. To generalise the utility of the tool, further development
on a separate dose calculation engine [328] is warranted. Currently this tool cal-
culates the dose on planned CT data. Further refinement of this tool is warranted
to accommodate the dose calculations on MVCT images with other delivery pa-
rameters such as jaw width, couch speed etc ( derived from log file) to assess
overall impact on patient dosimetry.
10.4 Summary
This thesis dissertation investigated treatment verification for two different ra-
diotherapy delivery systems. The first part of the thesis focused on improving
EPID dosimetry on conventional linacs. This included improving the under-
standing of EPID dose response characteristics, and the development of novel
prototypes that featured separate imaging systems for anatomical imaging and
10.4. Summary 180
dosimetric imaging.
The systematic investigation of standard EPID dose response demonstrated the
gain ghosting as the dominant cause of EPID non-linear dose response, and how
this effect impacts EPID dosimetry of segmental IMRT. The ghosting/image
lag correction suggested in previous studies is complex to implement accurately
on a pixel-by-pixel basis for EPID dosimetry. A much simpler pixel-to-dose
calibration method was described and validated in chapter 3. This work also
contributes to a more consistent understanding and implementation of pixel-to-
dose calibration methods for EPID-based IMRT dosimetry.
Novel prototypes were introduced and characterised. These novel prototypes
demonstrated for the first time the capability to simultaneously verify both loca-
tion and quantity of the dose delivered during treatment on conventional linacs.
No reduction in patient throughput is expected as the integration of EPIDs and
daily imaging is already routine. The clinical implementation of the new pro-
totypes promises to be highly cost-effective. The novel dual detector concept
which decouples the imaging and dosimetry functions so that each can be opti-
mised without significantly compromising the other, potentially provides more
flexibility for future improvements in radiotherapy treatment verification sys-
tems (chapters 4 and 5). The water equivalent dose response of prototypes pro-
vides an accurate method to directly verify doses delivered during treatment
without the additional uncertainties inherent in modelling the complex dose re-
sponse of standard EPIDs. An approach to transit dose verification was pre-
sented in chapter 6 utilising a water equivalent EPID and a commercial TPS dose
in water model. This approach would overcome two complicated steps involved
in standard EPID dosimetry model i) modeling the complex dose response and
ii) calculating the predicted dose image at the EPID plane and thereby simplify
the implementation of EPID based dosimetry as routine practice across the wider
community and clinics. The novel prototypes will benefits radiotherapy patients
by reducing the risk of mistreatments and ensuring the accuracy of treatment
with a new level of precision and confidence.
The second part of the thesis focused on treatment verification of the HT treat-
ment delivery system. A framework to quantify clinically relevant HT delivery
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errors was developed and described. Understanding the effect of delivery un-
certainty enables the optimisation of planning protocols and validates planning
protocol robustness for a given machine parameter QA tolerance.
The systematic comparative assessment of sensitivity for two commercial dosime-
ters to detect clinically relevant HT errors was presented. This assessment pro-
vides a crucial understanding of the strengths and weaknesses of commercial
dosimetry systems and provides guidelines for choice of the most appropriate
dosimeter for individual clinical situations. It will also inform future direction
for improvement to next generation novel detector developments.
An in-house on board exit dosimetry DQA tool for HT pre-treatment QA was
developed and demonstrated to be accurate and efficient. The ability of dose
reconstructions provides an opportunity to understand the clinical relevance of
QA results which helps the physicist and radiation oncologist to make well in-
formed decisions. This tool significantly reduce the normally increased burden
on physics resources for performing patient QA and overcomes limitations of
current commercial dosimeters for verifying field delivery geometries exceeding
the size of the commercial dosimetry measurement systems. This tool provides
in depth analysis on a leaf-by-leaf basis which improves the understanding and
interpretations of QA failure results for complex HT delivery.
It is hoped this project will benefit radiotherapy patients by reducing the risk of
mistreatments and ensuring the accuracy of treatment with a new level of preci-
sion and confidence. The improved level of treatment verification will facilitate
a safer and more efficient implementation of other new techniques.
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Appendix A
LSF and MTF measurement
To assess the impact on imaging performance due to the presence of 2D dosime-
ter in dual detector configuration, the MTF was determined using an angled slit
technique as described in chapter 4. A purpose built LSF apparatus with slit
angle set to 40 was used for MV image quality experiments. Two 2D dosime-
ter (ICA and MP) were used. Three different configurations of dual detector
were investigated i) MP placed beneath the EPID ii) MP placed above the EPID
and iii) ICA placed above the EPID. EPID images of the slit for both reference
imaging configuration i.e. standard EPID and dual detector configuration were
acquired. The calculated MTF and LSF for reference imaging configuration was




Figure A.1: Comarison of measured modulation transfer function (MTF) for the reference
imaging configuration versus dual detector configuration (MP placed beneath EPID) on
left, reference imaging configuration versus dual detector configuration (MP placed above
EPID) in middle and reference imaging configuration versus dual detector configuration
(ICA placed above EPID) on right.
Figure A.2: Comarison of measured line spread function (LSF) for the reference imaging
configuration versus dual detector configuration (MP placed beneath EPID) on left, refer-
ence imaging configuration versus dual detector configuration (MP placed above EPID) in
middle and reference imaging configuration versus dual detector configuration (ICA placed
above EPID) on right.
Appendix B
Tomotherapy error simulation for lung
SABR
The clinical impact due to changes in delivery parameter for lung SABR plans
was assessed via dosimetric simulation. We used same framework and simi-
lar delivery errors discussed in chapter 7. Ten clinical lung SABR (HT) plans
were selected for this study. All clinical plans were optimised using a fixed 2.5
cm jaw width, 0.286 pitch and 1.6-1.8 modulation factor with the clinical HT
planning system. Each plan was edited using the TomoTherapy version 5.0 stan-
dalone GPU dose calculator (Research planning system) to introduce systematic
errors in jaw width (JW), couch speed (CS), gantry period (GP), gantry start po-
sition (GSP), multi leaf collimator leaf open time (MLC LOT) errors with an
individual MLC leaf (either 32, 42 or 52) stuck open. For the case of MLC
LOT, the random errors in MLC LOT with standard deviation of 1-10% with a
mean MLC LOT error of zero were investigated. Each error type was simulated
independently for a range of magnitudes. Dose metrics and associate clinical
thresholds were assessed for the following structures: (D98% = prescription
dose and D99%≥ 90% of prescription dose and conformity index), (lung-PTV)
mean dose< 4Gy), heart (D1cc < 27Gy) and oesophagus (D1cc < 28.5Gy) and
maximum point dose to spinal cord < 25 Gy and great vessels < 45Gy ) were
assessed [329, 330]. The magnitude for each of the errors where the clinical tol-
erance values was exceeded for any treatment plan was determined. The errors
where the clinical tolerance was exceeded were compared against both the cur-
rent machine interlock thresholds and quality assurance (QA) tolerance values
‡Part of work presented in ICCR 2016 conference, London UK
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Figure B.1: Histogram distribution of the treatment plans meeting the set clinical tolerances
(both PTV and OAR) for varying magnitude of errors in a) jaw width (JW) b) couch speed
(CS) c) gantry period (GP) and d) gantry start position (GSP). The red dashed bar shown
above represents the machine interlock threshold for each error type. The green line shown
above represents the machine QA thresholds as specified by TG-148 report.
as outlined in AAPM report 148 [47]. The dosimetric QA tolerance derived for
nasopharynx cases were compared to assess whether generic QA tolerance can
be used for all HT plan techniques.
Most of the clinically relevant errors are prevented by machine interlocks except
the couch position and the secondary interlock for jaw position and gantry pe-
riod. This work highlights that the interlock thresholds for jaw position, gantry
period and couch position should be monitored more precisely than monitored
currently to avoid any clinically relevant delivery errors. Clinically significant
machine tolerances were similar between lung SABR and previous Head and
Neck clinical cases (7) for JW and CS and different for gantry related error.
However, If the clinical HT machine QA tolerance are maintained within the
specifications outlined in AAPM TG 148 recommendation, all the clinically rel-
evant errors derived for both clinical cases having varying complexity would
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be prevented. This validates the AAPM TG-148 recommendations to have a
generic QA tolerance table irrespective to the complexity of treatment tech-
niques unlike for conventional C-arm Linac (TG-142).
Table B.1: Comparing the dosimetrically derived QA tolerences for lung SABR, nasophar-
ynx cases with AAPM TG-148 recommended machine QA tolerance. The nasophynx data









AAPM TG-148 QA tol-
erance
Jaw width > 0.5mm > 0.5mm 1% of JW (0.25 mm for
2.5cm JW)
Couch speed > 1.5% > 1.5% < 2%




MLC LOT Relatively insensitive for
both systematic error and
random error
MLC LOT systematic er-
ror (MLC stuck open)
No specific tolerance and
test
Appendix C
Description of values retrieved from the
patient XML in exit dosimetry DQA tool
The XPath Java ™TM API library (javax.xml.xpath) is leveraged to read the
patient XML into MATLAB. The XPath expression //fullDeliveryPlanDataAr-
ray/fullDeliveryPlanDataArray is used to identify all delivery plans; Table C.4
lists the XPath sub-expressions and parameters extracted for each delivery plan.
Table C.1: Values retrieved from the patient XML for determination of the planned fluence
XPath Expression Description
deliveryPlan/purpose Delivery plan purpose (fluence, machine spe-
cific/agnostic)




deliveryPlan/totalTau Number of leaf events
deliveryPlan/states/states/lowerLeafIndex Leaf number of the first leaf in the delivery
plan binary array
deliveryPlan/states/states/numberOfProjections Number of projections in binary array
deliveryPlan/states/states/numberOfLeaves Number of leaves in binary array
deliveryPlan/states/states/synchronizeActions/
synchronizeActions/jawVelocity/
List of front and back jaw velocity changes
during plan
binaryFileNameArray/binaryFileNameArray File name of binary array containing leaf
events
Dose re-calculation is performed using the TomoTherapy version 5.0 standalone
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dose calculator, provided with a research treatment planning workstation through
a collaboration agreement with Accuray Incorporated. The standalone dose cal-
culator accepts a series of input files listed in Table C.2.
Table C.2: Files required for execution of the standalone dose calculator
Input File Description
dcom.header Text file containing beam model information specific to the commissioned
TomoTherapy Treatment System. Additional binary files (below) are refer-
enced by this file.
cone.img Binary file containing the transverse profile. Also used to determine the
expected open field fluence
penumbra.img Binary file containing the longitudinal/jaw profiles for various field sizes.
lft.img Binary file containing the MLC leaf penumbra profiles.
fat.img Binary file containing the Collapsed Cone Fluence Attenuation Table.
kernel.img Binary file containing the Collapsed Cone Convolution kernel.
ct.header Text file containing information about the size, location, and dimensions of
the CT image, as well as the CT to density table.
ct_0.img Binary file containing the CT image.
plan.header Text file containing information about the treatment plan, including all syn-
chronized and unsynchronized events (jaw velocities, gantry velocity, start
angle, starting jaw positions, etc.), as well as the number of MLC leaf
events stored in the plan.img binary file.
plan.img Binary file containing the timing of each MLC leaf open and close event
during plan delivery.
dose.cfg Text file containing information about the size, location, and dimensions of
the resulting dose calculation image.
The CT files (ct.header and ct_0.img) are generated by searching the patient
XML using the XPath expression //fullPlanDataArray/fullPlanDataArray to load
all delivery plans in the patient XML, then plan/briefPlan/approvedPlanTrialUID
to find which approved plan is associated with the selected machine agnostic de-
livery plan (using the plan trial UID), then searching for the associated KVCT
image using the expression fullImageDataArray/fullImageDataArray/image. Un-
der this node, Table C.3 lists the XPath expressions used to extract the necessary
CT specifications.
Next, the expression plan/fullDoseIVDT is used to determine the CT to density
table associated with the fluence delivery plan identified above. A copy of the
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imaging equipment archives are stored within each patient archive; by searching
through the imaging equipment XML files, the CT to density table referenced
by plan/fullDoseIVDT can be determined, and the table extracted.
Table C.3: Values retrieved from the patient XML for determination of the planning CT
XPath Expression Description
imageType Type of fullImageData. Should be KVCT.
arrayHeader/binaryFileName File name of binary data containing the CT im-
age.
arrayHeader/dimensions Dimensions (x,y,z) of the CT image.
arrayHeader/start Starting coordinate (x,y,z) of the first voxel.
arrayHeader/elementSize Size (x,y,z) of each voxel.
This data, along with the CT data, is then written to the text file ct.header. The
binary file of the CT image is written to ct_0.img. The same dimensions, coor-
dinates, and voxel sizes are used to define the dose.cfg text file, such that dose
is calculated for each CT voxel (also referred to as Fine calculation).
The plan.header file is generated by searching the patient XML for all treatment
delivery parameters of the fluence delivery plan associated with the machine
agnostic plan. This is accomplished by using the XPath expression //fullPlan-
DataArray/fullPlanDataArray to load all delivery plans in the patient XML, then
deliveryPlan/dbInfo/databaseParent to find which fluence delivery plan is asso-
ciated with the selected machine agnostic delivery plan (using the parent UID).
Table C.3 lists the sub-expressions used to extract each delivery parameter re-
quired.
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Table C.4: Values retrieved from the patient XML for determination of the delivery param-
eters
XPath Expression Description
deliveryPlan/purpose Delivery plan purpose (fluence, machine spe-
cific/agnostic)




deliveryPlan/totalTau Number of leaf events
deliveryPlan/states/states/lowerLeafIndex Leaf number of the first leaf in the delivery
plan binary array
deliveryPlan/states/states/numberOfProjections Number of projections in binary array































dosed = dosed ∗ max(A1 ( : ) ) ; %scale dosed as a percent of the maximum
dose
G=zeros ( size1 ) ; %this will be the output
Ga=zeros ( size1 ) ;
if size1 == size2
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for i = 1 : size1( 1 )
for j = 1 : size1( 2 )
for k = 1 : size1( 1 )
for l = 1 : size1( 2 )
r2 = ( i - k )2 + (j - l)2; %distance (radius) squared
d2 = ( A1( i , j ) - A2( k , l ) )2 ; %difference squared
Ga( k , l ) = sqrt(r2 / (DTA)2 + d2/ (dosed)2;
end
end













figure, imagesc(G,[0 1.2]), axis(’image’), colorbar;
D.2 Codes for MTF and LSF calculations
To calculate MTF for an angled slit image, need 2 images: one with the open
slit measurement, and another with the slit shielded to give you a background
reading, which we subtract from the open slit image.
Read the open-slit .his image file and shielded-slit image using following codes.
function image = readHISfile_Sam()
% First need to load the data...
[FileName, PathName, FilterIndex] = uigetfile(’./∗.his’,’Select .his file to ana-
lyze’,’MultiSelect’,’off’);
numFiles = 1;
% Create an empty array to store the integrated image
image = double(zeros(1024,1024,numFiles));
file_id = fopen(FileName);
if file_id == -1
warning(’File could not be opened’);
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image = -1;
else
FileType = fread(file_id,1,’uint16’)’; %2 bytes
HeaderSize = fread(file_id,1,’uint16’)’; %2 bytes
HeaderVersion = fread(file_id,1,’uint16’)’; %2 bytes
FileSize = fread(file_id,1,’uint32’)’; %4 bytes
ImageHeaderSize = fread(file_id,1,’uint16’)’; %2 bytes
ULX = fread(file_id,1,’uint16’)’; %2 bytes
ULY = fread(file_id,1,’uint16’)’; %2 bytes
BRX = fread(file_id,1,’uint16’)’; %2 bytes
BRY = fread(file_id,1,’uint16’)’; %2 bytes
NumFrames = fread(file_id,1,’uint16’)’; %2 bytes
Correction = fread(file_id,1,’uint16’)’; %2 bytes
IntTime_us = fread(file_id,1,’double’)’; %8 bytes
Extra = fread(file_id,18,’uint16’)’; %36 bytes - = 68 bytes
ImageHeader = fread(file_id,16,’uint16’)’; %32 bytes - = 32 bytes
Header = struct(’FileType’,FileType, ...
’HeaderSize’,HeaderSize, ...













Or, if one wishes to simply read the header as a single data type of uint16, com-
ment out the above, uncomment the next 3 lines, and comment out the following
lines 90 and 93: % Header = fread(file_id,50,’uint16’)’; % dim = Header(9:10);
% numFrames = Header(11);
% Parse the header for data (the image dimensions - 1024x1024)
dim = [Header.BottomRightX Header.BottomRightY];
% Parse the header for data (the number of frames)
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numFrames = Header.NumFrames;
% Write a for-loop to read through all frames, 1 at a time, to create an integrated
(summed) image.





Run the same code to read in the shielded-slit image.
Open the script ConstructLSF·m and edit the filenames at the beginning of the
function (lines 21 and 22) to match the names of the files you saved above
function LSF = ConstructLSF()
raw = load(’filename_open.2Dlsf’);
bg = load(’filename_shielded.2Dlsf’);
cor = raw - bg;
cor(cor<0) = 0;
% Make all dead pixels away from the slit 0:
%bins = -74.8:0.4:74.8; % For simulated data (375 x 0.4mm bins)
bins = -204.8:0.4:204.8; % For simulated data (1025 x 0.4mm bins)
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% To re-align the offset source position for each point along the slit to the CAX,
must shift the
% x-values. To do this, we first need to know the angle of the slit wrt vertical.
% Now let’s find the peaks - start with the max value in each column and save
them in the vector "PEAKS"
maxValue = max(max(corRoi));
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n = 1;
for i = 1:size(corRoi,2)
for j = 1:size(corRoi,1)








% Plot the defined region of the slit with the peaks superimposed:












% Now we need to take the (x,y) values from PEAKS to determine the slit
% angle. Perhaps find the line of best fit, then calculate the
% angle from the fit’s endpoints:
p = polyfit(peaks(:,1),peaks(:,2),1);
% p returns 2 coefficients fitting r = a_1 ∗ x + a_2
r = p(1) .∗ peaks(:,1) + p(2); % compute a new vector r that has matching data-
points in x
scatter(peaks(:,1),r,40,’+b’,’MarkerFaceColor’,’b’);
delta_x = peaks(length(peaks),1) - peaks(1,1);
delta_y = r(length(r)) - r(1);
theta = atan(delta_x / delta_y); %angle in radians
radtodeg(theta)
% OK, now that we know the slit angle, we can begin to reconstruct the sub-
sampled LSF. %Each row of the SLIT image should be shifted by an amount
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ShiftedX = Ytan(theta):
for i = 1:length(roiPositionIndexY)
ShiftedX(i,:) = bins(roiPositionIndexX(:)) - (bins(roiPositionIndexY(i))∗tan(theta));
end
% Now we need to combine each of the above LSFs to create a single, sub-
sampled LSF.












% Now we just need to average together those bins that have the same x value





for i = 2:length(LSF_cat)
if LSF_cat(i,1) == LSF_cat(i-1,1)
% if this x-value is (almost) the same as the one before it
TEMP_x = LSF_cat(i,1);
TEMP_y = TEMP_y + LSF_cat(i,2);
n_y = n_y + 1;
% index for calculating average y-value
else
% if this is a new x-value
j = j + 1;
% index for adding newly average entries to final LSF
LSF(j,1) = TEMP_x;
LSF(j,2) = TEMP_y/n_y;
% reset the variables







% Try instead to normalize to the area under the LSF
LSF(:,2) = LSF(:,2) ./ sum(LSF(:,2));
Now, simply run the command » [lsf, mtf] = ConstructMTF(); and you will be
shown the open-slit image in colorscale. To calculate the MTF, you need to use
the mouse to select a rectangular region encompassing part of the slit. Feel free
to experiment with which region you choose and see if/how it affects the final
MTF.
function [LSF, MTF] = ConstructMTF()
% First need to construct the LSF:
LSF = ConstructLSF();
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Fs = 1/T; % Sampling frequency (in mm-̂1)
x = LSF(:,1);
y = LSF(:,2);
L = length(x);% number of elements in the LSF









% To speed up FFT algorithm, specify the transform length as a power of 2.
%NFFT = 2n̂extpow2(L); % Next power of 2 from length of x (equals 512) %Y
= fft(y,NFFT); %Y = fftshift(y)/L;
%Create a vector of linearly spaced numbers from 0 to 1:
%Z = linspace(0,1,NFFT/2+1);
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% Now make the vector run from 0 to 1.25 mm-1
%X = Fs/2∗Z;
%MTF(:,1) = X; %MTF(:,2) = abs(Y(1:NFFT/2+1)); % example does 2∗abs(...)










D.3 Codes for CT FOV manupulation
function image = readDICOMImages(path)
% Descriptiton: readDICOMImages read all CT images from a given directory
% into a matlab structure called image.
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% Input: path-the directory where all patient CT images sit.
% Output: image- matlat structure with following field. % image.data-the 3D
matrix containing the CT data. % image.patientID % .......other head informa-
tion.
% useage:
% Below is an example of how this function is used:
% path = ’/path/to/files/’;
% image = LoadDICOMImages(path);
% Author: Dr.Aitang Xing and Shrikant Deshpande
% list all the dicom file in director into cell array
file_list=getFileList(path);
names=listDicomFile(file_list);
% Execute in try/catch statement try
% If a valid screen size is returned (MATLAB was run without -nodisplay)
if usejava(’jvm’) && feature(’ShowFigureWindows’)
% Start waitbar
progress = waitbar(0, ’Loading DICOM images’); end
% Initialize empty variables for the UIDs, patient demographics, and image %
dimensions image.classUID = ”;











% Initialize empty 3D array for images and vector of slice locations % (the data




% Loop through each file in names list
for i = 1:length(names)
% Update waitbar
if exist(’progress’, ’var’) && ishandle(progress)
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waitbar(i/(length(names)+2), progress);
end
% Attempt to load each file using dicominfo
try





% If this is the first DICOM image (and the class UID % have not yet been set
if strcmp(image.classUID,”)





















image.width(3) = info.SliceThickness / 10;
% Otherwise, if this file’s study UID does not match the others, % multiple
DICOM studies may be present in the same folder (not % currently supported)
elseif strcmp(image.studyUID, info.StudyInstanceUID)
% Otherwise, if this file’s series UID does not match the others, % multiple
DICOM series may be present in the same folder (not % currently supported)
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elseif strcmp(image.seriesUID,info.SeriesInstanceUID)
% Otherwise, if this file’s slice thickness in cm is different than % the others,
throw an error (variable slice thickness is not % currently supported)
elseif image.width(3) ~= info.SliceThickness / 10
end
% Append this slice’s instance UID image.instanceUIDslength(image.instanceUIDs)+1
= info.SOPInstanceUID;
% Append this slice’s location to the sliceLocations vector sliceLocations(length(sliceLocations)+1)
= ... info.ImagePositionPatient(3);
% Append this slice’s image data to the images array images(size(images,1)+1,:,:)
= dicomread(info);
end




% Set image type based on series description (for MVCTs) or DICOM
% header modality tag (for everything else)
if strcmp(info.SeriesDescription, ’CTrue Image Set’)
image.type = ’MVCT’;




% Retrieve start voxel coordinate from DICOM header, in cm image.start(1) =
info.ImagePositionPatient(1) / 10;
% Adjust IEC-Y to inverted value, in cm image.start(2) = -(info.ImagePositionPatient(2)
+ info.PixelSpacing(2) ∗ ... (size(images, 2) - 1)) / 10;
% Retrieve x/y voxel widths from DICOM header, in cm
image.width(1) = info.PixelSpacing(1) / 10;
image.width(2) = info.PixelSpacing(2) / 10;
% If patient is Head First
if isequal(info.ImageOrientationPatient, [1;0;0;0;1;0]) ‖ ... isequal(info.ImageOrientationPatient,
[-1;0;0;0;-1;0])
if info.ImageOrientationPatient(5) == 1 image.position = ’HFS’;
elseif info.ImageOrientationPatient(5) == -1 image.position = ’HFP’;
end
[~, indices] = sort(sliceLocations, ’descend’);
image.start(3) = -max(sliceLocations) / 10;
elseif isequal(info.ImageOrientationPatient, [-1;0;0;0;1;0]) | ... isequal(info.ImageOrientationPatient,
[1;0;0;0;-1;0])
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if info.ImageOrientationPatient(5) == 1 image.position = ’FFS’;
elseif info.ImageOrientationPatient(5) == -1 image.position = ’FFP’;
end
[~,indices] = sort(sliceLocations, ’ascend’);
image.start(3) = min(sliceLocations) / 10; end
image.data = single(zeros(size(images, 3), size(images, 2), ... size(images, 1)));
if exist(’Event’, ’file’) == 2 Event(’Sorting DICOM images’); end
for i = 1:length(sliceLocations)
image.data(:, :, i) = ... single(rot90(permute(images(indices(i), :, :), [2 3 1])));
end
image.data = max(image.data, 0);
image.data = flip(image.data, 1);
image.dimensions = size(image.data);
if exist(’progress’, ’var’) && ishandle(progress) waitbar(1.0, progress, ’Image
loading completed’); end
if exist(’progress’, ’var’) && ishandle(progress) close(progress); end
clear i images info sliceLocations indices progress;
catch err
if exist(’progress’, ’var’) && ishandle(progress), delete(progress); end
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end
end
% run this script for changing FOV and rewrite dicom
path2=’define path’;
file_list=getFileList(path2);
cell=listDicomFile(file_list);
for k=1:length(cell)
tmp1=cellk;
I3=dicomread(tmp1);
info3=dicominfo(tmp1);
X3=padarray(I3,[256 256],0);
tmp5=strcat(num2str(k),’.dcm’)
X4=dicomwrite(X3,tmp5,info3,’CreateMode’,’copy’);
end
